

Statistical Analysis Plan

Sol-Gel Technologies Ltd. SGT-65-05

Version: 2

Date: 26 NOV 2019

STATISTICAL ANALYSIS PLAN

Protocol Number:	SGT-65-05
Study Title:	A Phase 3 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study of S6G5T-3 in the Treatment of Acne Vulgaris
Development Phase of Study:	3
Sponsor:	Sol-Gel Technologies Ltd.
Sponsor Contact:	
Statistical Analysis Plan based on Protocol Version:	2.0
Statistical Analysis Plan Date:	26NOV2019
Statistical Analysis Plan Version:	V2

SAP Approval

Authored by:

SIGNATURE: _____

DATE: 02 DEC 2019

QST Consultations, Ltd.

Reviewed by:

SIGNATURE: _____

DATE: 02 DEC 2019

QST Consultations, Ltd.

Approved by:

SIGNATURE: _____

DATE: _____

Sol-Gel Technologies Ltd.

Revisions to the Statistical Analysis Plan described herein must be approved through a formal written amendment with the exception of minor editorial changes to tables, figures, or listing shells, and any necessary textual clarifications for programmers that do not affect the stated analysis variables, study endpoints, or statistical methods.

SAP Change History

Version	Date	Summary of Changes	Author
1	02MAY2019	Original document	
2	26NOV2019	<p>In Section 8.1.11 an age grouping (9-11, 12-17 and 18-30, 31 and up) was added.</p> <p>In Section 8.7 the text was revised so that the secondary efficacy analysis is also being performed on the Per-Protocol population.</p> <p>In the table mocks the treatment header was updated to E-BPO/E-ATRA 3%/0.1% Cream for the active arm.</p> <p>In Section 8.4.4 the text ws updated to properly reflect the intended Week 12 window of +/- 4 days.</p>	

TABLE OF CONTENTS

1.	LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS.....	7
2.	PREFACE	8
3.	RESPONSIBILITIES	9
4.	INTRODUCTION.....	9
5.	STUDY OBJECTIVES.....	10
5.1	Primary Objectives	10
5.2	Secondary Objective	11
5.3	Supportive Objective	11
5.4	Safety Objective.....	11
6.	STUDY DESIGN	11
6.1	Overall Study Design.....	11
6.1.1	Schedule of Visits and Assessments	12
6.1.2	Method of Assigning Subjects to Treatment Groups	12
6.1.3	Blinding	13
7.	EFFICACY AND SAFETY ENDPOINTS	14
7.1	Efficacy Endpoints.....	14
7.1.1	Primary Efficacy Endpoints	14
7.1.2	Secondary Efficacy Endpoints	14
7.1.3	Supportive Efficacy Endpoints.....	14
7.1.4	Exploratory Endpoints.....	15
7.2	Safety Endpoints	15
8.	STATISTICAL AND ANALYTICAL PLANS	15
8.1	General Methodology	15
8.1.1	Statistical Analysis	16
8.1.2	Baseline Definition.....	16
8.1.3	Visit Windowing	16
8.1.4	Adjustments for Covariates	17
8.1.5	Handling of Dropouts or Missing Data	17
8.1.5.1	Lesion Count Variable Missing Data Imputation	18
8.1.5.2	IGA Missing Data Imputation	19

8.1.5.3	PRE-FACE Missing Data Imputation.....	20
8.1.5.4	Medication Date Imputation	21
8.1.6	Interim Analyses and Data Monitoring	21
8.1.7	Multicenter Studies.....	21
8.1.8	Multiple Comparisons/Multiplicity	24
8.1.9	Use of an Efficacy Subset of Subjects.....	24
8.1.10	Active-Control Studies Intended to Show Equivalence	25
8.1.11	Examination of Subgroups	25
8.2	Disposition of Subjects	26
8.3	Protocol Deviations.....	26
8.4	Data Sets Analyzed	26
8.4.1	Randomized Population	26
8.4.2	Intent-to-Treat (ITT) Population	27
8.4.3	Safety Population	27
8.4.4	Per-Protocol (PP) Population	27
8.5	Demographic and Other Baseline Characteristics	28
8.6	Prior and Concomitant Medications	28
8.7	Analysis of Efficacy.....	29
8.7.1	Primary Efficacy Analysis.....	29
8.7.1.1	Lesion Counts	29
8.7.1.2	Investigator Global Assessment (IGA).....	31
8.7.2	Sensitivity Efficacy Analysis	31
8.7.2.1	Sensitivity Analyses for Absolute Change in Lesion Count.....	31
8.7.2.1.1	Repeated Measures	31
8.7.2.1.2	Model Based Multiple Imputation.....	31
8.7.2.1.3	Tipping Point	32
8.7.2.2	Sensitivity Analyses for IGA	32
8.7.2.2.1	Repeated Measures	32
8.7.2.2.2	Model Based Multiple Imputation.....	33
8.7.2.2.3	Tipping Point	33
8.7.3	Secondary Efficacy Analysis.....	34
8.7.4	Supportive Efficacy Analysis	34
8.7.5	Exploratory Endpoint Analysis	34
8.8	Safety Evaluation	35
8.8.1	Extent of Exposure	35

8.8.2	Adverse Events (AEs)	36
8.8.1	Clinical Laboratory Evaluation	37
8.8.1	Other Observations Related to Safety	37
8.8.1.1	Cutaneous Safety Assessments	37
8.8.1.2	Local Tolerability Assessments	37
8.8.1.3	Vital Signs.....	37
8.8.1.4	Physical Examination.....	38
9.	DETERMINATION OF SAMPLE SIZE	38
10.	CHANGES IN THE PLANNED ANALYSES.....	39
11.	REFERENCES.....	40
12.	INDEX OF PLANNED TABLES	41
13.	INDEX OF PLANNED FIGURES	172
14.	INDEX OF PLANNED LISTINGS	174

1. LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS

Acne-QoL	Acne Quality-of-Life Questionnaire
AE(s)	adverse event(s)
AID	Acne impact domain
ANCOVA	analysis of covariance
ANOVA	analysis of variance
ATC	Anatomical Therapeutic Chemical
ASD	acne sign and symptom domain
BMI	body mass index
C	Celsius
cm	centimeters
CRF(s)	case report form(s)
eCRF(s)	electronic case report form(s)
E-BPO	encapsulated benzoyl peroxide
FDA	Food and Drug Administration
GCP	good clinical practice
IGA	Investigator Global Assessment
ITT	Intent-to-Treat
IWRS	Interactive Web Response System
kg	kilograms
LOCF	last observation carried forward
LSMean or LSM	least square mean
max	maximum
MCMC	Markov Chain Monte Carlo
MedDRA	Medical Dictionary for Regulatory Activities
mg	milligram
min	minimum
n	number of observations
N	number of subjects (sample size)
PRO	Patient Reported Outcome
PRE-FACE	Patient-Reported Evaluation of Facial Acne
PGI-C	Patient Global Impression of Change

PGI-S	Patient Global Impression of Symptom Severity
PGI-SE	Patient Global Impression of Treatments Side Effects
PGI-TS	Patient Global Impression of Treatments Satisfaction
PP	per-protocol
PT	preferred term
QST	QST Consultations, Ltd.
SAE(s)	serious adverse event(s)
SAS®	Statistical Analysis System (SAS® Institute Inc., Cary, NC)
SD	standard deviation
SOC	system organ class
TEAE(s)	treatment-emergent adverse event(s)
WHO	World Health Organization

2. PREFACE

This Statistical Analysis Plan (SAP) describes the statistical analyses as it is foreseen before breaking the blind. The SAP will serve as a compliment to the study protocol and supersedes it in case of differences. In case of major differences between the study protocol and SAP, e.g. changes in the analysis related to the primary endpoint, a protocol amendment will be considered. The SAP may be updated during the study conduct and will be finalized before breaking the blind.

The following documents were reviewed in preparation of this SAP:

- Clinical Study Protocol SGT-65-05
 - Version 1.0 issued on 10OCT2018,
 - Version 2.0 issued on 01NOV2018,
- Case report form (CRF) for SGT-65-05.
- ICH E9 Guidance on Statistical Principles for Clinical Trials.
- ICH E3 Structure and Content of Clinical Study Reports (CSRs)

The reader of this SAP is encouraged to also read the clinical protocol for details on the conduct of this study, and the operational aspects of clinical assessments and timing for completing a patient in this study.

3. RESPONSIBILITIES

The study statistician will be responsible for the statistical analysis planning. QST Consultations, Ltd. (QST), a Contract Research Organization (CRO) selected by Sol-Gel, will be responsible for the execution of all statistical programming deliverables. The statistical programming work will be supervised by the study statistician.

4. INTRODUCTION

Acne vulgaris is a common condition of the pilosebaceous units of the skin (hair follicles and oil glands). Acne is the most common skin disorder in the United States, affecting 40-50 million Americans. Acne usually begins in puberty, but the condition is not restricted to any age group.

Approximately 85% of people between the ages of 12 and 24 experience at least minor, most often on the face, chest, and back [1]. Acne is caused by four major factors:

1. Production of oil by enlarged oil glands in the skin.
2. Blockage of the hair follicles that release oil.
3. Growth of bacteria, called *Propionibacterium acnes*, within the hair follicles.
4. Inflammatory/immune response to *P. acnes*.

The pathophysiologic features of acne suggest that combination therapy should be utilized as early as possible to simultaneously attack the multiple pathogenic factors of the condition [2]. Antimicrobials have been a mainstay of acne treatment for many years, having multiple mechanisms of action. The most important may be the ability of antibiotics to decrease the number of *P. acnes* in and around the follicle. They have a bacteriostatic effect on *P. acnes*, which prevents the bacteria from producing pro-inflammatory molecules [3].

In June 2017, Sol Gel completed a double blind, randomized, dose ranging Phase 2 trial for S6G5T-3 involving 726 adult Patients at thirty-six centers in the United States (SGT-65-02: A Phase 2, Randomized, Double Blind, Active and Vehicle Controlled, 12-Week Study Evaluating the Efficacy, Safety, and Tolerability of S6G5T-3 and S6G5T-1 for the Treatment of Acne Vulgaris). The Phase 2 trial had two co primary endpoints: success in Investigator Global Assessment (IGA) namely, a two-grade reduction in IGA on a scale of 0 to 4 (“clear”, “almost clear”, “mild”, “moderate”, “severe”) with “clear” or “almost clear” at Week 12; and a reduction in the mean inflammatory and non-inflammatory lesion count at Week 12 (end of trial). All Patients were 9 years of age or older with IGA of 3 or 4, 20 or more inflammatory lesions and 25 non-inflammatory lesions at enrollment. Patients were randomly divided into six groups of 119 to 122 Patients each and received a once daily dose, with one group receiving S6G5T-3 encapsulated benzoyl peroxide/encapsulated ATRA (E-BPO/E-ATRA 3%/0.1%), S6G5T-1

(E-BPO/E-ATRA (3%/0.05%), E-ATRA 0.1%, E-ATRA 0.05%, E-BPO 3% and Vehicle Cream alone. S6G5T-3 demonstrated numerical superiority to the active component E-BPO 3% and vehicle for the co-primary endpoints (treatment success and lesion counts inflammatory) at the Week 12 visit but only matched efficacy for non-inflammatory lesions for E-ATRA 0.1%. The success rate for at Least 2-Grade Improvement and Clear or Almost Clear was 12.27%, 22.10%, 31.72% and 39.68% for Vehicle Cream, E-BPO 3%, E-ATRA 0.1% and S6G5T-3, respectively. The mean inflammatory change from Baseline was -11.5, -13.8, -14.9 and -16.9. for Vehicle Cream, E-BPO 3%, E-ATRA 0.1% and S6G5T-3, respectively. The mean non-inflammatory change from Baseline was -13.7, -16.2, -23.8 and -23.6 for Vehicle Cream, E-BPO 3%, E-ATRA 0.1% and S6G5T-3, respectively. S6G5T-3 each demonstrated statistical superiority ($p=0.006$ or less) to vehicle for the co-primary endpoints (treatment success, lesion counts both inflammatory and non-inflammatory) at the Week 12 visit.

In addition, S6G5T-3 were safe and well tolerated. The most common treatment-emergent adverse events (TEAEs) ($\geq 5\%$ incidence in any treatment group) were application site dryness, exfoliation and pain as well as upper respiratory infection. Cutaneous safety and tolerability assessment (erythema, scaling, pigmentation, itching, burning and stinging) by the Investigator showed that the proportion of Patients with these complaints tended to remain unchanged from Baseline over 12 weeks. On the other hand, based on self-assessments, a slightly greater proportion of Patients in the S6G5T-3 treatment groups had at least one higher post-baseline assessment of scaling, burning and stinging (mild) compared to vehicle. There were no apparent differences in mean changes from Baseline in any of the hematological and clinical chemistry test results in all treatment groups at Weeks 8 and 12. Most urinalysis test results were normal at Baseline and at Weeks 8 and 12. There were no clinically significant abnormalities in ECGs in the study.

In conclusion, both S6G5T-1 and S6G5T-3 demonstrate efficacy and safety in the treatment of acne vulgaris, however, S6G5T-3 showed additional benefit in achieving a greater proportion of treatment IGA success. Therefore, S6G5T-3 was selected as the “to be marketed formulation” and the active arm in this study.

5. STUDY OBJECTIVES

5.1 Primary Objectives

The primary objectives of this pivotal study are:

- To assess the efficacy of S6G5T-3 compared to its Vehicle when applied once daily for 12 weeks in Patients with acne vulgaris.

- To assess the safety of S6G5T-3 when applied once daily for 12 weeks in Patients with acne vulgaris.

5.2 Secondary Objective

The secondary objective of this pivotal study is:

- To demonstrate statistical superiority in efficacy of Products S6G5T-3 as compared to the vehicle regarding percent change from Baseline.

5.3 Supportive Objective

The supportive objective of this pivotal study is:

- To determine the time required to observe improvement in the efficacy parameters associated with clearance of acne for Products S6G5T-3 compared to vehicle.

5.4 Safety Objective

The safety objectives of this pivotal study are:

- To determine the nature, severity and frequency of the adverse event (AE) rate and the local cutaneous reaction and tolerability of Products S6G5T-3 compared to the vehicle.

6. STUDY DESIGN

6.1 Overall Study Design

This study will be a randomized, double-blind, multicenter, parallel group, active- and vehicle-controlled pivotal study to assess efficacy, and safety of Products S6G5T-3 and its vehicle for the treatment of acne vulgaris for 12 weeks. Approximately 420 Patients with moderate to severe acne vulgaris (rated 3 or 4 on the 5-point IGA) will be enrolled at up to 31 sites. Patients in this randomized, double-blind, vehicle-controlled, parallel-group multi-center study will be randomly assigned in a 2:1 ratio to Encapsulated Benzoyl Peroxide 3%/Encapsulated All-Trans-Retinoic Acids 0.1% (E-BPO/E-ATRA) Cream or Vehicle Cream respectively. Patients with severe acne vulgaris who are appropriate for systemic treatment need to be counseled regarding their treatment options by the Principal Investigator (PI).

The overall schedule of study visits includes:

- Visit 1/Screening
- Visit 2/Baseline, Day 1

- Visit 3/Week 2, Day 15 (± 3 Days)
- Visit 4/Week 4, Day 29 (± 3 Days)
- Visit 5/Week 8, Day 57 (± 3 Days)
- Visit 6/Week 12, Day 85 (± 4 Days) / End of Study or Early Termination

Treatment efficacy will be evaluated using both clinician reported outcome (ClinRO) and Patient-reported outcome (PRO) questionnaires. Clinician reported efficacy assessments will include facial inflammatory and non-inflammatory lesion counts and an IGA which asks assessors to rate Patient's acne from 0 (Clear) to 4 (Severe). Patient reported efficacy assessments include the Patient-Reported Evaluation of Facial Acne (PRE-FACE), the Patient Global Impression of Symptom Severity (PGI-S), the Patient Global Impression of Change (PGI-C), and the Patient Global Impression of Treatments Satisfaction (PGI-TS).

Safety will be assessed at all visits and will include monitoring local and systemic AEs; the Investigator Cutaneous Safety Assessment rating of pigmentation, erythema, dryness and scaling on a scale ranging from 0 (None) to 3 (Severe) and the Patient assessment of Local Tolerability Assessment rating itching, burning and stinging on a scale ranging from 0 (None) to 3 (Severe). A Patient Global Impression of Treatment Side Effects (PGI-SE) will also be administered as part of the study design.

Clinician reported outcomes will be collected at study Visit 1, 2, 3, 4, 5 and 6. Patient-reported outcomes will be collected at study visit 2, 3, 4, 5, and 6 (with the exception of the PGI-C, PGI-TS and PGI-SE) which are not collected at Visit 1 or Visit 2). AEs and concomitant medications will be assessed throughout the treatment period. A urine pregnancy test is required at Visit 1, 2, 3, 4, 5 and 6 for all females of child-bearing potential and premenarchal.

6.1.1 Schedule of Visits and Assessments

The schedule of assessments can be found in Section 12.10 of the protocol.

6.1.2 Method of Assigning Subjects to Treatment Groups

It is planned that approximately 420 Patients, who meet the inclusion/exclusion criteria, will be enrolled in this study at up to 31 U.S. study sites. Patients will be at least 9 years of age and older, of either gender.

The study products will be administered in a double-blinded fashion (i.e., the treatment assignment will not be known to the Patient or to study personnel including Sol-Gel and its representatives). Patients will be instructed not to discuss the study product with the study personnel. Patients will be randomly assigned, in a 2:1 ratio, as follows:

- E-BPO/E-ATRA 3%/0.1% Cream (Product S6G5T-3) (280 Patients)
- Vehicle Cream (Product S6G5T-8) (140 Patients)

Each Patient who signs an informed consent, meets inclusion/exclusion criteria, and successfully completes the screening procedures will be enrolled in the study. The Patient randomization schedule will be a permuted block design stratified by investigational site. Blocks will be composed of 3 treatment assignments in a ratio of 2:1 study product and vehicle respectively. Complete blocks from the randomization schedule will be allocated to investigational sites as they randomize Patients. Patients will be randomized through the IWRS and assigned a unique randomization ID assigning treatment group. The study product supplies will be packed in kits containing 4-pumps and will be numbered in a scrambled randomized method. The kits will be dispensed by the IWRS according to the Baseline assigned randomized treatment group.

6.1.3 Blinding

The staff involved in data management and statistical evaluation will remain blinded until identification of the analysis populations is completed and the database is locked.

The randomization schedule and treatment code will not be revealed to the Patients, study personnel, Sol-Gel or its representatives until after the database lock, except to the Medical Monitor or PI in the case of an emergency unblinding. Access to the randomization list will be maintained by and limited to the unblinded Biostatistician and the designated personnel directly responsible for labeling of study materials. The Medical Monitor will not have access to the randomization list, but may determine that unblinding of one or all Patients may be necessary in the case that the safety of study Patient(s) is at risk. In an emergency, the study blind may be broken only if:

- In the opinion of the Medical Monitor and/or the PI, it is in the Patient's best interest to do so.
- Knowledge of the treatment will alter the clinical management of the Patient.

In the case of an emergency that requires unblinding, the Investigator can request to unblind the Patient without prior contact with the Medical Monitor although follow-up between the Investigator and Medical Monitor must occur so that all parties are aware of the unblinding. Although it is recommended that the Investigator contact the Medical Monitor prior to unblinding any Patient, in instances where this is not feasible or advisable, the PI may directly access the Patient's treatment assignment. In all situations, the Interactive Web Response System (IWRS), will be used to obtain treatment assignment information, with limited access to only the

above-designated individuals; and any unblinding will be documented in the source records accordingly.

7. EFFICACY AND SAFETY ENDPOINTS

7.1 Efficacy Endpoints

7.1.1 Primary Efficacy Endpoints

The co-primary efficacy endpoints are as follows:

- Proportion of Patients with an assessment of clear or almost clear and with at least a 2-grade improvement in IGA from Baseline at Week 12.
- Absolute change from Baseline in lesion count on the face at Week 12 (separately for inflammatory and non-inflammatory lesions).

7.1.2 Secondary Efficacy Endpoints

The secondary efficacy endpoints are as follows:

- Percent change from Baseline, in non-inflammatory lesion count at Week 12.
- Percent change from Baseline, in inflammatory lesion count at Week 12.
- Proportion of Patients in the E-BPO/E-ATRA cream arm compared to vehicle control achieving at least a 4-point reduction on Item 1 (pimples) of the PRE-FACE from Baseline to Week 12.
- Proportion of Patients in the E-BPO/E-ATRA Cream arm compared to vehicle control achieving at least a 4-point reduction on Item 5 (embarrassment) of the PRE-FACE from Baseline to Week 12.
- Absolute change from Baseline, in non-inflammatory lesion count at Week 8
- Absolute change from Baseline, in inflammatory lesion count at Week 8.
- Absolute change from Baseline, in non-inflammatory lesion count at Week 4.
- Absolute change from Baseline, in inflammatory lesion count at Week 4.

7.1.3 Supportive Efficacy Endpoints

The supportive efficacy endpoints are as follows:

- Proportion of Patients with an assessment of clear or almost clear and with at least a 2-grade improvement in IGA from Baseline, at Weeks 2, 4 and 8.
- Absolute change from Baseline in inflammatory and non-inflammatory lesion counts from Baseline to Week 2.
- PRE-FACE ASD: Mean absolute change in PRE-FACE ASD scores from Baseline to Weeks 2, 4, and 8.
- PRE-FACE AID: Mean absolute change in PRE-FACE AID scores from Baseline to Weeks 2, 4, and 8.
- Proportion of Patients in treatment relative to control who report at least “minimally improved” as measured by the PGI-C at Week 12.
- Patient Global Impress of Symptom Severity (PGI-S) at Week 12.
- Patient Global Impression of Treatment Satisfaction (PGI-TS) at Week 12.

7.1.4 Exploratory Endpoints

The exploratory endpoint is the mean change in Acne-QoL domain scores from Baseline to Week 12.

7.2 Safety Endpoints

Safety will be assessed through Cutaneous Safety Assessment, Local Tolerability Assessment, AE reporting, physical examination, and vital signs.

8. STATISTICAL AND ANALYTICAL PLANS

8.1 General Methodology

All statistical processing will be performed using SAS® version 9.3 or later unless otherwise stated. Statistical significance will be based on two-tailed tests of the null hypothesis resulting in p-values of 0.05 or less.

The primary method of handling missing efficacy data will be based on estimation using the method of Markov Chain Monte Carlo (MCMC) imputation. The estimation will be done for each treatment group separately so that the pattern of missingness for one group does not influence the estimation of missing data for another group. Groups of complete datasets following the estimation will be concatenated to form analysis datasets for the comparative

analyses and subsequent imputation result inference with SAS PROC MIANALYZE. Descriptive statistics will also be derived from the multiply imputed datasets.

Sensitivity analyses for the primary efficacy endpoints will use 3 methods. For the lesion count endpoint, the first method will use a repeated measures analysis of covariance (ANCOVA), with treatment, analysis center, visit (i.e., Week 2, Week 4 and Week 8), and treatment group by visit interaction as independent factors and a covariate of Baseline. In this analysis, data from all post-baseline visits will be included with no imputation for missing data.

The second sensitivity analyses will use the model based multiple imputation method to impute missing data for the absolute change at Week 12.

The third sensitivity analysis will involve a tipping point analysis.

Similar methods for the dichotomized IGA will involve a repeated measures logistic regression model and a model based multiple imputation and tipping point analysis.

8.1.1 Statistical Analysis

All analyses will be performed by QST using SAS® Version 9.3 or later. All summary tables and data listings will be prepared utilizing SAS® software.

The standard operating procedures (SOPs) of QST will be followed in the creation and quality control of all data displays and analyses.

All data listings will be by subject. Additionally, all listings except the screen failure and randomization listings will be by treatment.

8.1.2 Baseline Definition

Baseline is defined as the last non-missing assessment prior to first application of study drug. If the date of first application is unknown due to the subject being lost to follow-up, the Baseline visit record will be used as Baseline if it is non-missing. Missing results will not be flagged as Baseline.

8.1.3 Visit Windowing

Data will be summarized based on nominal visit indications with the exception of data captured at early termination and unscheduled visits. Data from early termination and unscheduled visits will be summarized based on mapped visit values. The analysis windows for early termination and unscheduled visits are presented in the following table.

Analysis Windows for Efficacy and Safety Assessments

Scheduled Visit	Target Study Day	Window (Days)
Week 2	15	8 to 21
Week 4	29	22 to 42
Week 8	57	43 to 70
Week 12	85	71 to 98

Data collected at early termination and unscheduled visits prior to study day 8 will not be analyzed, with the exception of those identified as Baseline values. Data collected at early termination and unscheduled visits after study day 98 will not be included in analyses.

The definition for the study day included in each study window is defined as below:

Study Day prior to Day 1 = Visit Date – Day 1 Date

Study Day on or after Day 1 = Visit Date – Day 1 Date + 1

If an assessment's mapped visit is a visit at which the subject has data from a scheduled visit present, or if no analyses are planned for the assessment at the mapped visit, the data collected at the early termination or unscheduled visit will not be included in analyses.

In the event of multiple values from unscheduled or early termination assessments within an analysis window, the value closest to the scheduled visit target study day will be used for analyses. If two values tie as closest to the time point (for example, one value is before and the other value is after the time point), then the later value will be selected.

Data collected at all visits will be included in the data listings with visit presented as reported by the site.

8.1.4 Adjustments for Covariates

Baseline lesion count will be a covariate for the primary efficacy endpoint for acne lesion counts. No other covariates are planned to be used in the analyses for this study.

8.1.5 Handling of Dropouts or Missing Data

Missing data for the ITT population will be estimated by multiple imputation and subsequently analyzed. Missing lesion count and IGA data will be derived for the analysis using the method of Markov Chain Monte Carlo (MCMC) multiple imputation. The pattern of missing observations

in each treatment group cannot influence the missing value estimation in the other group because the imputation will be conducted independently for each treatment group.

Last observation carried forward (LOCF) will be used to impute missing data for the efficacy analyses using the Per Protocol (PP) population.

Patients that discontinue from the study due to an AE related to study treatment or documented lack of treatment effect will be included in the PP population. Data for these subjects will not be imputed by multiple imputation or LOCF but rather their data will be imputed with values consistent with their status as treatment failures. For these subjects, values for lesion count and IGA will be imputed such that change from Baseline is zero, meaning the values will be set to the Baseline value. This imputation will be done after the data for all subjects has been through the MI process.

Incomplete start and end dates for medications will be imputed. Other safety data will not be imputed and will be summarized on an observed case basis.

8.1.5.1 Lesion Count Variable Missing Data Imputation

Multiple imputation and subsequent analysis will involve 3 distinct phases with these principal tasks:

1. Create a data set of patients, one for each treatment group, with observed values and those needing estimation by MCMC. The missing lesion count values in each data set will be filled in using the MCMC method 5 times to generate 5 data sets. The resulting data sets for each treatment arm will be combined into one complete data set for each imputation.

Syntax:

```
proc mi data=datain out=dataout seed=&seed. nimpute=5 <options>;  
  where trtpn=(1, or 2);  
  mcmc chain=multiple;  
  var baseline week2 week4 week8 week12;  
run;
```
2. For each complete data set, the variable of interest for Baseline minus the Week 12 value for the week imputed will be computed. Each complete data set will be analyzed as specified for the particular analysis.
3. The results from these analyses will be combined into a single inference using SAS PROC MIANALYZE.

A total of 4 random seeds are needed to impute lesion counts. The following 4 random seeds have been pre-specified by using a random number generator:

- Inflammatory Lesion Counts; S6G5T-3: Seed = 577660451
- Inflammatory Lesion Counts; S6G5T-8 Vehicle: Seed = 1077045427
- Non-inflammatory Lesion Counts; S6G5T-3: Seed = 2132522555
- Non-inflammatory Lesion Counts; S6G5T-8 Vehicle: Seed = 2096664573

8.1.5.2 IGA Missing Data Imputation

A similar procedure will be used for the analyses based on proportion of IGA successes wherein the ANCOVA analysis is replaced with a logistic regression analysis. Specifically, missing IGA values from which the dichotomized IGA is derived will be estimated by MCMC. The pattern of missing observations in each treatment group cannot influence the missing value estimation in the other because the imputation is being conducted independently for each treatment group.

The missing IGA values will be derived for the analysis using the method of MCMC multiple imputation. Multiple imputation and subsequent analysis will involve 3 principal tasks:

1. Create a data set, one for each treatment group, of patients with observed values and those needing estimation by MCMC. The missing IGA values in each data set will be filled in using the MCMC method 5 times to generate 5 data sets. The resulting data sets for each treatment arm will be combined into one complete data set by imputation.

Syntax:

```
proc mi data=datain out=dataout seed=&seed. nimpute=5 <options>;  
  where trtpn=(1, or 2);  
  mcmc chain=multiple;  
  var baseline week2 week4 week8 week12;  
run;
```

2. For each complete data set, the dichotomous success rate (clear or almost clear with a 2-point change from Baseline) will be computed. The estimated global values will be rounded to the nearest integer value prior to evaluating the success rate. Each complete data set will be analyzed with a logistic regression with factors of treatment group and analysis center.
3. The results from these analyses will be combined into a single inference using SAS PROC MIANALYZE.

The following 2 random seeds have been pre-specified by using a random number generator:

- IGA; S6G5T-3: Seed = 1024310713
- IGA; S6G5T-3 Vehicle: Seed = 1659491795

8.1.5.3 PRE-FACE Missing Data Imputation

The same procedure will be used for the analyses based on proportion of PRE-FACE item 1 (pimples) and item 5 (embarrassment) successes as the IGA success. Specifically, missing PRE-FACE items 1 and 5 values from which the dichotomized versions are derived will be estimated by MCMC. The pattern of missing observations in each treatment group cannot influence the missing value estimation in the other because the imputation is being conducted independently for each treatment group.

The missing PRE-FACE items 1 and 5 values will be derived for the analysis using the method of MCMC multiple imputation. Multiple imputation and subsequent analysis will involve 3 principal tasks:

1. Create a data set, one for each treatment group, of patients with observed values and those needing estimation by MCMC. The missing PRE-FACE items 1 and 5 values in each data set will be filled in using the MCMC method 5 times to generate 5 data sets. The resulting data sets for each treatment arm will be combined into one complete data set by imputation.

Syntax:

```
proc mi data=datain out=dataout seed=&seed. nimpute=5 <options>;  
  where trtpn=(1, or 2);  
  mcmc chain=multiple;  
  var baseline week2 week4 week8 week12;  
run;
```

2. For each complete data set, the dichotomous success rate (at least a 4-point reduction from Baseline) will be computed. The estimated global values will be rounded to the nearest integer value prior to evaluating the success rate. Each complete data set will be analyzed with a logistic regression with factors of treatment group and analysis center.
3. The results from these analyses will be combined into a single inference using SAS PROC MIANALYZE.

The following 4 random seeds have been pre-specified by using a random number generator:

- PRE-FACE Pimples Scores; S6G5T-3: Seed = 3965781
- PRE-FACE Pimples Scores; S6G5T-3 Vehicle: Seed = 96876327

- PRE-FACE Embarrassment Scores; S6G5T-3: Seed = 852215120
- PRE-FACE Embarrassment Scores; S6G5T-3 Vehicle: Seed = 1366717274

8.1.5.4 Medication Date Imputation

If the medication start date is incomplete, then it will be imputed as follows for the purpose of determining concomitant use:

- If the start date is completely missing, the start date will be equal to the first dose date. However, if the stop date is not missing and is before the first dose date, then the stop date will be used instead.
- If the start day is missing, the first day of the month will be used.
- If the start day and month are missing, then the first day of the first month (January) will be used.

If the medication stop date is incomplete, then it will be imputed as follows for the purpose of determining concomitant use:

- If the stop date is completely missing and the medication is not ongoing, the stop date will be equal to the last dose date or date of completion/withdrawal, whichever is the latest.
- If the stop day is missing, the last day of the month will be used.

If the stop day and month are missing, then the last day of the last month (December) will be used.

8.1.6 Interim Analyses and Data Monitoring

No interim analysis or data monitoring is planned for this study.

8.1.7 Multicenter Studies

The clinical study will be conducted under a common protocol for each investigational site with the intention of pooling the data for analysis. Every effort will be made to promote consistency in study execution at each investigational site. The study is intended to be conducted in a manner such that a minimum of 15 subjects will be randomized and included in the ITT population (i.e., at least ten subjects in the active treatment arm and five subjects in the vehicle treatment arm) for any investigator. In the event that there are too few subjects in a treatment arm for an

investigational site, then the site's data will be combined with other site's data to achieve the desired sample size minimum per treatment arm. The combining of investigator data will be accomplished by taking the data of the investigator with the smallest enrollment and combining them with the data of the investigator with the largest enrollment, restricted to investigational sites which did not meet minimum enrollment. If there is a further need to combine data, then the data of the investigator with the second smallest enrollment will be combined with the site's data which had the second largest enrollment (restricted to investigational sites which did not meet minimum enrollment), and so on. This process will continue for all investigators who did not have a minimum of 15 subjects enrolled. The process of combining investigator data that have insufficient subjects per treatment arm will result in redefining the groups of investigators for the purposes of statistical analyses. These combined groups will be referred to as "analysis centers" in the statistical analyses.

The consistency of treatment response will be investigated across the analysis centers subsequent to combining the data as described above. Statistical tests will be conducted to identify if there are extreme analysis centers that could affect the interpretation of common statistical and clinical conclusions. An analysis center by treatment interaction will be included in the primary analyses to test for parallel treatment effect at an alpha level of 0.10. Change from Baseline in inflammatory and non-inflammatory lesions will be analyzed with an ANCOVA (unranked or ranked) with factors of treatment group, analysis center and treatment group by analysis center interaction and the respective Baseline lesion count variable as a covariate. For the purpose of testing consistency of treatment response, the dichotomized IGA will be analyzed with a logistic regression with factors of treatment group, analysis center, and the interaction term of treatment group by analysis center. Further examination will follow for any variables that have a significant ANCOVA or logistic regression interaction term.

In the event that the ANCOVA or logistic regression interaction (referred to henceforth as the "appropriate test") p-value is less than or equal to 0.10, a sensitivity analysis that excludes analysis centers with the extreme efficacy result will be performed to determine the robustness of the treatment effect. On the other hand, if all three analyses result in interaction terms with p-values greater than 0.10, then the conclusions from the pooled data will be considered to be free of the impact of extreme analysis centers.

The first step in conducting a sensitivity analysis is to identify the extreme analysis center or centers that contribute to the statistical significance of the appropriate test. The process involves submitting subsets of analysis centers to the appropriate test and observing the appropriate test p-value for the subset. Subsets with p-values greater than 0.10 for the appropriate test are considered homogeneous.

The search for an extreme analysis center begins by analyzing all subsets that can be created by excluding one analysis center. If one or more of the subsets result in an appropriate test p-value greater than or equal to 0.10, then the analysis center excluded from the subset with the largest p-value for the appropriate test is deemed to be the extreme analysis center.

If all appropriate test subset p-values are less than or equal to 0.10, then the process will analyze the appropriate test for all subsets that can be created by excluding two analysis centers. If one or more of these subsets generate appropriate test p-values larger than 0.10, then the analysis centers excluded from the subset with the largest appropriate test p-value are deemed the extreme analysis centers.

Thus, the process of identifying the extreme analysis centers will continue in a stepwise manner by first excluding one, then two, then three, etc., analysis centers until the appropriate test p-value exceeds 0.10.

Once the extreme analysis center or centers have been identified, then the treatment p-values of the remaining analysis centers will be computed. Inferences will be drawn from the treatment p-value, as well as any pertinent observations regarding the extreme analysis center or centers. Additionally, it is noted that this process excludes patients from the analysis in a non-random manner and has an unpredictable impact on the power of the treatment effect test. In the event that the treatment effect of the remaining subset is not statistically significant, due consideration of the post-hoc aspects of the process will be given when the results are interpreted. Conclusions will be presented by the Sponsor as appropriate to the findings of the sensitivity analysis.

Prior to investigating the treatment effect within the analysis centers, the treatment effect within investigational site will be investigated to determine if the site-to-site variability is such that it could mask the analysis center effects. Thus, prior to pooling, change from Baseline in inflammatory and non-inflammatory lesions will be analyzed with an ANCOVA (unranked or ranked) with factors of treatment group, investigational site, and treatment group by investigational site interaction, and the respective Baseline lesion count variable as a covariate. The dichotomized primary endpoint will be analyzed with a logistic regression with factors of treatment group, investigational site, and the interaction term of treatment group by investigational site. If any of the analyses are not computationally feasible due to some investigational sites having very few subjects enrolled, the low-enrolling investigational sites will be excluded from the analysis.

8.1.8 Multiple Comparisons/Multiplicity

The overall Type I error will be controlled by requiring the three co-primary efficacy endpoints to be statistically significant. Specifically, failure of either one of the primary efficacy endpoints will invalidate the statistical significance of the secondary efficacy endpoints.

Evaluation of the secondary efficacy variables will use a gated sequential procedure starting with the comparisons of the first step and proceeding onto the next step and etc.

A stepwise process will be conducted for testing the secondary efficacy endpoints in order to control for multiplicity. These tests will be performed for only the ITT population. The testing process will terminate whenever a statistical test for a step is not significant. All subsequent tests for the remaining steps will be considered not significant. The order of testing is provided below.

Step Number	Secondary Endpoint
1	Percent change from Baseline, in non-inflammatory lesion count at Week 12.
2	Percent change from Baseline, in inflammatory lesion count at Week 12.
3	Proportion of patients in the E-BPO/E-ATRA cream arm compared to vehicle control achieving at least a 4-point reduction on Item 1 (pimples) of the PREFACE from Baseline to Week 12.
4	Proportion of patients in the E-BPO/E-ATRA Cream arm compared to vehicle control achieving at least a 4-point reduction on Item 5 (embarrassment) of the PRE-FACE from Baseline to Week 12.
5	Absolute change from Baseline, in non-inflammatory lesion count at Week 8
6	Absolute change from Baseline, in inflammatory lesion count at Week 8.
7	Absolute change from Baseline, in non-inflammatory lesion count at Week 4..

8.1.9 Use of an Efficacy Subset of Subjects

Subjects randomized to study drug who were dispensed study product and do not have major protocol deviations will form the PP Population. The requirements for the PP Population are outlined in Section 8.4.4. Any additional major protocol deviations will be defined at the time of evaluability evaluation, the time between the database soft lock and hard lock before unblinding.

Excluding subjects who have major protocol deviations will decrease the variability in treatment response and will allow for a better determination of dose-response relationship of S6G5T-3.

8.1.10 Active-Control Studies Intended to Show Equivalence

Not applicable to this study.

8.1.11 Examination of Subgroups

Subset analyses will be conducted for the ITT populations for the subgroups based on at least the following:

- Baseline Global Severity;
 - Categorized as Baseline IGA = 3 (moderate) and Baseline IGA = 4 (severe); due to the inclusion criteria requiring subjects to have either a 3 or 4 IGA score at study entry other IGA response categories will not be presented
- Sex;
 - Male versus female subjects
- Age;
 - Dichotomized to less than the median age of ITT subjects and greater than or equal to the median age of ITT subjects
 - Categories of less than 18, 18 to less than the median age of ITT subjects and greater than or equal to the median age of ITT subjects; if the median age of ITT subjects is 18 or less, the subgroup will be less than 18 and greater than or equal to 18
 - Categories of 9-11 years, 12-17 years, 18-30 years, and 31 years and older
- Ethnicity;
 - Categorized as Hispanic or Latino and Not Hispanic or Latino; ethnicities of Not Reported and Unknown will not be included
- Race
 - Categorized as White and Non-White; subjects indicating more than one race category which includes both white and a non-white race will be summarized under the Non-White subgroup.

Subset analyses will be conducted on the variables absolute change from Baseline in inflammatory lesions at Week 12 as well as the dichotomized global severity score at Week 12. These analyses will contain only descriptive statistics.

8.2 Disposition of Subjects

The number of subjects included in each analysis population (randomized, ITT, Safety, and PP) will be summarized by treatment group and overall. The number of subjects completed and discontinued (including the reasons for discontinuation) will be summarized for each treatment group as well as by overall. The percentages will be calculated based on the number of randomized patients, unless otherwise specified.

8.3 Protocol Deviations

In order to define the PP Population, protocol deviations potentially influencing the evaluation of the primary efficacy endpoint will be defined as major deviations. The protocol deviations that will exclude a subject from PP are given in Section [8.4.4](#).

In case other deviations detected during the study conduct are considered to potentially influence the evaluation of the primary efficacy endpoint, these deviations will be documented prior to the database lock and the patients having these deviations will be excluded from the PP Population.

All protocol deviations will be reported to the sponsor and recorded throughout the study. Protocol deviations will not be entered into the database. SolGel will provide a list of protocol deviations to QST. A tabulation of protocol deviations will be presented in a data listing.

8.4 Data Sets Analyzed

Subjects will be presented/summarized based on the primary reason for exclusion. Below is the order to be used in summaries:

8.4.1 Randomized Population

All subjects who are randomized to study treatment will be included in the randomized population and will be analyzed according to the treatment group they were randomized. Listings will be provided for all randomized subjects.

8.4.2 Intent-to-Treat (ITT) Population

All subjects in the randomized population who are dispensed study product will be included in the ITT population and will be analyzed according to the treatment group they were randomized. All efficacy analyses will be presented using the ITT population.

8.4.3 Safety Population

All subjects in the randomized population who are presumed to have used the study product at least once and who provide at least one post-baseline safety evaluation will be included in the Safety population and will be analyzed according to the treatment they received. Presumed to have used study product will be defined as having at least one confirmed application of study medication. All safety analyses will be performed using the Safety population.

8.4.4 Per-Protocol (PP) Population

All subjects in the ITT population who complete the Week 12 evaluation without any significant protocol violations will be included in the PP population and analyzed according to the treatment group they received. The PP population will include subjects in the ITT population who do not meet any of the following criteria:

- Failed any of the inclusion/exclusion criteria;
- Have taken any interfering concomitant medications;
- Did not attend the Week 12 Visit;
- Missed more than 1 post-baseline study visit prior to Week 12;
- Have not been compliant with the dosing regimen (i.e., Patients may not miss more than five consecutive days of applications and must take 80-120% of expected applications. The number of expected applications will be determined for each Patient based on the length of their participation in the study);
- Out of visit window (+/- 4 days) at the 12-week Visit.

Subjects that discontinue from the study due to an AE related to study treatment or documented lack of treatment effect will be included in the PP population. Data for these subjects will not be imputed by multiple imputation but rather their data will be imputed with values consistent with their status as treatment failures. See Section 8.1.5 for additional detail. Prior to breaking the blind, other additional criteria may be added to the list to accommodate for unforeseen events that may occur during the conduct of the trial and result in noteworthy study protocol violations.

All efficacy analyses performed on the PP population will be according to the treatment they received.

8.5 Demographic and Other Baseline Characteristics

All Baseline summaries will be done on the ITT, PP, and Safety populations by treatment group and overall.

Sex, race, ethnicity, and Baseline IGA will be summarized by counts and percentages. Age, height (cm), weight (kg), body mass index (BMI), and Baseline lesion counts will be summarized with descriptive statistics.

Age, height, weight, BMI, and Baseline lesion counts will be compared among the two treatment groups using a two-way analysis of variance (ANOVA) with factors of treatment group and analysis center. Ethnicity, race, sex, and Baseline IGA will be analyzed with a Cochran-Mantel-Haenszel test stratified by analysis center.

Age will be calculated as the difference in days between the date of birth and the date of informed consent and converted to years by dividing the number of days by 365.25 and using a floor function to drop the decimal portion. In case the exact birth day is missing, day 15 will be used. The BMI will be calculated as weight (kg) divided by squared height (m²).

Medical histories will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) dictionary and presented in a by-subject listing.

The medical history data will be summarized with frequencies and percentages of patients with at least one medical history term reported, and patient frequencies and percentages on the System Organ Class (SOC) and Preferred Term (PT) levels. The number of events will also be summarized. The table will be sorted by overall descending frequency of SOC and then, within a SOC, by overall descending frequency of PT.

8.6 Prior and Concomitant Medications

Concomitant medications will be coded to preferred name and Anatomical Therapeutic Chemical (ATC) classification of ingredients using the World Health Organization (WHO) Drug Global Dictionary, Format B3, Version March 1, 2018.

Medications which start prior to first application will be considered prior medications. Ongoing medications and medications ending after the date of first application will be considered concomitant medications. If the date of first application is unknown and the medication is not

listed as ongoing the interval will be considered “unknown”. If the date of first application is unknown and the medication is listed as ongoing the interval will be considered concomitant.

Incomplete medication start and end dates will be imputed as described in Section 8.1.5.4

A summary of prior and concomitant medications will be provided.

A by-subject listing of all prior and concomitant medications will be presented for the Safety population.

8.7 Analysis of Efficacy

Inflammatory and non-inflammatory lesion counts will be summarized at each evaluation from Baseline through Week 12. Absolute and percent change in lesion counts will be summarized at Weeks 2, 4, 8, and 12. IGA scores will be summarized from Baseline through Week 12 using descriptive statistics. The dichotomized IGA scores will be summarized at Weeks 2, 4, 8, and 12 using descriptive statistics.

Primary, secondary, and supportive efficacy analyses will be conducted on the ITT (primary) population. Primary and secondary efficacy analyses will be conducted on the PP (supportive) population.

All efficacy results will be presented in by-subject listings.

8.7.1 Primary Efficacy Analysis

The primary efficacy analysis will be presented on both the ITT and PP populations.

8.7.1.1 Lesion Counts

Tests of superiority for the absolute change from Baseline in inflammatory and non-inflammatory lesions will be based on either parametric or non-parametric methods consistent with the statistical assumptions required to support the analyses. Specifically, the tests of superiority will be based on an ANCOVA with factors of treatment and analysis center and the respective Baseline lesion count as a covariate or on ranked data submitted to an ANCOVA with factors of treatment and analysis center and the respective Baseline lesion count as a covariate. If the treatment-by-analysis center interaction effect is significant at an alpha less than 0.10, then the effect will be included in the model; otherwise it will be removed.

A skewness test, based on the methods presented by J.H. Zar [4], will be applied to the residuals resulting from an ANCOVA. A two-sided p-value for the skewness test significant at 0.01 will

imply the use of the non-parametric method. If a parametric analysis is indicated, the results of the parametric analysis will be considered the primary analysis. Should a non-parametric analysis be indicated, the absolute or percent changes in lesion counts will be rank transformed prior to submitting them to the ANCOVA. Results of the rank-transformed analyses then will be considered the primary analysis; however, results of the non-ranked transformed analyses will also be presented.

The following steps provide a brief synopsis of the process that will be followed.

1. Missing data will be imputed using multiple imputation. Refer to Section 8.1.5.1.
2. The pooling analysis will be conducted. Refer to Section 8.1.7.
 - a. The treatment-by-analysis center interaction p-values from both parametric and non-parametric (unranked and ranked) analyses will be presented, along with the skewness p-value calculated from the residuals from the unranked ANCOVA. The skewness p-value will determine which analysis results to report:
 - i. Skewness p-value > 0.01 : Report results based on the parametric (unranked) approach.
 - ii. Skewness p-value ≤ 0.01 : Report results based on the non-parametric (ranked) approach.
3. For the primary efficacy analysis
 - a. Results of both parametric and non-parametric (unranked and ranked) analyses will be presented. For each, data will be submitted to an ANCOVA with factors of treatment and analysis center and Baseline lesion count as a covariate (if the treatment-by-analysis center interaction p-value is ≤ 0.10 , the interaction will also be included in the model). The residuals from the unranked analysis will be used to calculate the skewness p-value. The skewness p-value will determine which analysis results to report:
 - i. Skewness p-value > 0.01 : Report results from the parametric (unranked) ANCOVA.
 - ii. Skewness p-value ≤ 0.01 : Report results from the non-parametric (ranked) ANCOVA.
4. If there was a significant treatment by analysis center interaction (as determined in step 1 – the pooling analysis), a sensitivity analysis will be performed as described in

Section 8.1.7 to find the extreme analysis center(s). Then step 3 above will be repeated the extreme analysis center(s) removed, to confirm the treatment response.

8.7.1.2 Investigator Global Assessment (IGA)

The IGA will be dichotomized into “success” and “failure” with a patient considered a success for those visits if the IGA is at least 2 grades less than Baseline and “Clear” or “Almost Clear”. The analysis of the dichotomized IGA will be based on a logistic regression test with factors of treatment group and analysis center.

8.7.2 Sensitivity Efficacy Analysis

8.7.2.1 Sensitivity Analyses for Absolute Change in Lesion Count

8.7.2.1.1 Repeated Measures

The first sensitivity analyses for absolute change in lesion count (both inflammatory and non-inflammatory) will use a repeated measures ANCOVA, with treatment, analysis center, visit (i.e., Week 2, Week 4 and Week 8), and treatment group by visit interaction as independent factors and a covariate of Baseline lesion count. In this analysis, data from all post-baseline visits will be included with no imputation for missing data.

8.7.2.1.2 Model Based Multiple Imputation

The second sensitivity analysis will use the model based multiple imputation method to impute missing data for the absolute change in lesion counts at Week 12. The multiple imputation will involve 3 principal tasks:

1. Missing values will be filled in 5 times to generate 5 complete data sets. The imputation model used will be an ANCOVA with factors of treatment group and analysis center, and a covariate of Baseline lesion count (i.e., the imputation model will be the same as the analysis model).

Syntax:

```
proc mi data=datain out=dataout seed=&seed. nimpute=5 <options>;  
  class trtpn sitegr1;  
  var trtpn baseline sitegr1 week12;  
  monotone logistic (sitegr1=trtpn baseline);  
  monotone reg (week12=trtpn baseline sitegr1);  
run;
```

2. Each complete data set will be analyzed with an ANCOVA with factors of treatment group, and analysis center, and a covariate of Baseline lesion count. Appropriate modifications will be made should the analysis be based on a non-parametric method.
3. Results from these analyses will be combined into a single inference.

Two random seeds will be needed to impute the inflammatory and non-inflammatory lesion counts. The following random seed has been pre-specified by using a random number generator:

Inflammatory Lesion Count Seed= 470857023

Non-inflammatory Lesion Count Seed= 2132132334

8.7.2.1.3 Tipping Point

A tipping point analysis of the primary endpoints will be performed as a sensitivity analysis for the handling of missing data. The multiple imputation datasets used for the primary analyses will be used for the tipping point analyses for lesion counts. To perform the tipping point analysis, the imputed values from the multiple imputation datasets for only the E-BPO/E-ATRA cream arm will be adjusted, by adding a constant (shift value) to the lesion counts. Change from Baseline will then be recalculated with the changed imputed values. The shifted multiple imputed datasets will then be analyzed as described in the primary endpoint section. This will then be repeated by adding the constant again to create another new shifted multiple imputed dataset and that dataset will be analyzed. The resulting point estimates and p-values associated with each shift value will be presented in order to assess the magnitude of the shift value required to “tip” the p-value greater than 0.05.

8.7.2.2 Sensitivity Analyses for IGA

8.7.2.2.1 Repeated Measures

The first sensitivity analysis for the dichotomized IGA success will use a repeated measures logistic regression model (generalized estimating equations), with dichotomized IGA success as the dependent variable and treatment, analysis center, visit (i.e., Week 2, Week 4 and Week 8), and treatment group by visit interaction as independent factors. In this analysis, data from all post-baseline visits will be included with no imputation for missing data.

8.7.2.2.2 Model Based Multiple Imputation

The second sensitivity analysis will use the model based multiple imputation method to impute missing data for the dichotomized IGA data. The multiple imputation will involve 3 principal tasks:

1. Missing values will be filled in 5 times to generate 5 complete data sets. The imputation model used logistic regression with factors of treatment group and analysis center (i.e., the imputation model will be the same as the analysis model).

Syntax:

```
proc mi data=datain out=dataout seed=&seed. nimpute=5 <options>;  
  class trtpn sitegr1 diiga;  
  var trtpn sitegr1 diiga;  
  monotone logistic (sitegr1=trtpn);  
  monotone logistic (diiga=trtpn sitegr1);  
run;
```

2. Each complete data set will be analyzed with a logistic regression a factors of treatment group and analysis center.
3. Results from these analyses will be combined into a single inference.

One random seed will be needed to impute IGA. The following random seed has been pre-specified by using a random number generator:

IGA Seed= 1497605671

8.7.2.2.3 Tipping Point

A tipping point analysis of the primary endpoint will be performed as a sensitivity analysis for the handling of missing data. To perform the tipping point analysis for the dichotomized IGA, all combinations for the number of imputed successes for the nonrespondents in the E-BPO/E-ATRA cream group and the vehicle group will be analyzed to identify the points that would indicate a treatment failure using a p-value greater than 0.05. The resulting points of treatment failure will be plotted with the average number of successes in each treatment group from the primary multiple imputation analysis overlayed. The tipping points of the study will be identified by the points where the particular combinations of imputed successes that change the treatment success to a treatment failure.

8.7.3 Secondary Efficacy Analysis

Appropriate descriptive statistics will be computed for all secondary efficacy parameters.

Additionally, all inferential testing of percent change in lesions will follow the methods for the primary lesion count analyses. Methods corresponding to the analysis of IGA will be used to compare the proportion of patients in the E-BPO/EATRA Cream arm versus vehicle control achieving at least a 4-point reduction in pimples (item1 of the PRE-FACE) or in embarrassment (item5 of the PRE-FACE) scores from Baseline to Week 12.

A stepwise process will be conducted for testing the secondary efficacy endpoints in order to control for multiplicity, refer to Section 8.1.8.

The secondary efficacy analysis will be presented on the ITT and PP populations.

8.7.4 Supportive Efficacy Analysis

Appropriate descriptive statistics will be computed for all supportive efficacy parameters.

Additionally, all inferential testing will follow the methods for the co-primary variables wherein the continuous variables will parallel the lesion count analyses and the discrete dichotomized variables will follow the analysis of the IGA. Inferential testing for PGI-S and PGI-TS at Week 12 will use a cumulative logistic regression with factors of treatment group and analysis center. Missing values will not be imputed.

8.7.5 Exploratory Endpoint Analysis

The mean change in Acne-Qol domain scores from Baseline to Week 12 will be summarized using descriptive statistics.

Domain scores will be calculated as follows:

1. Code each response. Responses are numbered starting with 0 in ascending order.
 - For questions 1-14 and 18-19:
 - Extremely=0, Very Much=1, Quite A Bit=2, A Good Bit=3, Somewhat=4, A Little Bit=5, Not At All=6
 - For questions 15-17:
 - 0=Extensive, 1=A Whole Lot, 2=A Lot, 3=A Moderate Amount, 4=Some, 5=Very Few, 6=None

2. Check for missing values and impute as follows:
 - Within each domain, a minimum number of responses is required in order to score the domain. At least 3 items must be answered within each domain in order to calculate the domain scores. If the minimum number of items have been answered but 1-2 questions have missing responses, calculate the mean value within the domain for the answered items and replace missing values with the mean value.
3. Calculate overall domain scores for each domain by summing the coded responses to each question in the domain.
 - Domains will be calculated as follows:
 - Self-Perception domain calculated from questions 1, 2, 3, 6, and 10.
 - Role-Emotional domain calculated from questions 4, 5, 7, 8, and 9.
 - Role-Social domain calculated from questions 11, 12, 13, and 14.
 - Acne Symptoms domain calculated from questions 15, 16, 17, 18, and 19.

8.8 Safety Evaluation

8.8.1 Extent of Exposure

The extent of exposure to study drug in each treatment group will be summarized by total number of days of exposure, total number of applications, number of missed applications and number and percentage of subjects who are compliant. A subject will be considered compliant with the dosing regimen if the subject applied 80% to 120% of the expected number of applications and did not miss more than 5 consecutive applications while enrolled in the study.

Days of exposure = Date of last study application – Date of first study application + 1

The total number of applications taken is as follows:

(Date of Last Application – Date of First Application + 1) – (Number of Days marked as missed applications on the CRF) + (Number of extra applications marked on the CRF)

If a subject did apply medication on the last day, the total number of applications expected is as follows:

Date Subject End Participation – Date of Baseline +1.

If the total number of applications exceeds 89 then it will be set to 89.

If a subject did not apply medication on the last day, the total number of applications expected is as follows:

Date Subject End Participation - Date of Baseline

If the total number of applications exceeds 88 then it will be set to 88.

Compliance will be calculated as a percentage as 100 times the total number of applications taken from the first application until Week 12 divided by the total number of applications expected from first application until Week 12. Subjects who discontinue study medication before Week 12 will be considered to be 0% compliant for the number of days from discontinuing study medication until Week 12.

Compliance will not be calculated for subjects who are lost to follow-up or subjects who have unknown first or last application dates.

8.8.2 Adverse Events (AEs)

All AEs occurring during the study will be recorded and classified on the basis of MedDRA terminology. Descriptions of AEs will include the date of onset, the date the AE ended, the severity of the AE, the relationship to study product, the action taken regarding study product usage, the action taken to treat the AE, and the outcome. All reported TEAEs will be summarized by the number of patients reporting AEs, system organ class, severity, seriousness, and relationship to study product. TEAEs are those AEs with an onset on or after the date of the first study product application; if the AE is not indicated as prior to first application on the CRF then it will be considered a TEAE.

AEs will be summarized by treatment group and severity. Each patient will be counted only once within a system organ class or a preferred term by using the AEs with the highest severity within each category.

AEs will be summarized by treatment group and relationship to study product. Each patient will be counted only once within a system organ class or a preferred term by using the AEs with the greatest relationship within each category.

If relationship to study drug is reported as definitely, probably, or possible, then this is defined as related. If relationship to study drug is reported as unlikely or not related, then this is defined as unrelated.

Comparisons among treatment groups will be made by tabulating the frequency of patients with one or more AEs (classified into MedDRA terms) during the study. The Fisher's Exact test will

be used to compare the proportion of patients in each treatment group who report any AE at a significance level of 0.05. The specific system organ classes and preferred terms analyzed will be those that are reported by at least one percent of the patients in any treatment group.

All information pertaining to AEs noted during the study will be listed by patient, detailing verbatim given by the investigator, preferred term, system organ class, start date, stop date, severity, actions taken, and drug relatedness. The AE onset will also be shown relative (in number of days) to the day of initial application of the randomized study product.

Serious adverse events (SAEs) will be tabulated by patient within treatment groups.

In addition, a list of patients who discontinued from the study and a list of patients who experienced SAEs will also be provided.

8.8.1 Clinical Laboratory Evaluation

Urine pregnancy test results will be presented in a by-subject listing.

8.8.1 Other Observations Related to Safety

8.8.1.1 Cutaneous Safety Assessments

Descriptive statistics by treatment group and visit will be provided for pigmentation, erythema, dryness, and scaling.

8.8.1.2 Local Tolerability Assessments

Descriptive statistics by treatment group and visit will be provided for itching, burning and stinging.

8.8.1.3 Vital Signs

Vital sign measurements include heart rate (HR), sitting blood pressure (BP) (both systolic and diastolic), body temperature, and weight. The data will be summarized with descriptive statistics by visit and treatment group. In addition, the changes from baseline will be summarized with descriptive statistics.

Furthermore, to identify potentially clinically significant vital signs, the following criteria will be used and tabulated as a shift table by visit:

- Systolic Blood Pressure: <90 mmHg (low), 90-140 mmHg (normal), >140 mmHg (high)

- Diastolic Blood Pressure: <90 mm Hg (low), 90-100 mmHg (normal), >100 mmHg (high)

Heart Rate: <60 beats per minute (low), 60-100 beats per minute (normal), >100 beats per minute (high).

8.8.1.4 Physical Examination

Abnormal physical examination findings will be summarized by body system, visit, and treatment group. In addition to the summary, all physical examination findings will be listed.

9. DETERMINATION OF SAMPLE SIZE

The following power calculations are based on the observed Week 12 results of the Phase 2 study, SGT-65-02. This study was a six-arm trial including S6G5T-3 and Vehicle Cream in the treatment of acne vulgaris. Estimates from the S6G5T-3 arm were used in the power assessments. The anticipated randomization ratio is 2:1 for S6G5T-3 and S6G5T-8 Vehicle Cream, respectively. The computations were performed with nQuery Advisor Version 7.0 using a two-sided test with a statistical significance value of 0.05.

A sample size of 274 in the S6G5T-3 and 137 in the Vehicle Cream group (total of 411) has 99% power to detect a statistically significant difference in inflammatory lesions. The estimated absolute change from Baseline in treatment means were -16.7 and -12.2 for S6G5T-3 and Vehicle Cream, respectively, with a common standard deviation of 10.0.

A sample size of 146 in the S6G5T-3 and 73 in the Vehicle Cream group (total of 219) has 99% power to detect a statistically significant difference in non-inflammatory lesions. The estimated absolute change from Baseline in treatment means were -23.7 and -13.7 for S6G5T-3 and Vehicle Cream, respectively, with a common standard deviation of 19.0.

A sample size of 231 in the S6G5T-3 and 116 in the Vehicle Cream has group (total of 346) has 99% power to detect a statistically significant difference the proportion of Patients who have at least a 2-grade reduction at Week 12 from Baseline in IGA and are Clear or Almost Clear. The estimated percentages with a 2-grade reduction at Week 12 from Baseline in the IGA and Clear or Almost Clear are 33.3% and 12.6% for S6G5T-3 and Vehicle Cream, respectively.

Therefore, a total of 420 Patients has adequate power to demonstrate statistical significance of S6GT5-3 over S6GT5-8 Vehicle Cream for the lesion count endpoints as well as dichotomized IGA.

10. CHANGES IN THE PLANNED ANALYSES

There are no changes in the conduct of the study, but there are minor changes to the planned analyses.

Absolute change from Baseline in inflammatory and non-inflammatory lesion counts from Baseline to weeks 4 and 8 were removed from the supportive efficacy endpoints, as they were also included in the secondary efficacy endpoints.

The pooling analysis described in the protocol is updated in the statistical analysis plan (SAP) to reflect the intended analysis. The protocol discusses pooling sites with five or fewer subjects enrolled in each treatment arm. Taking into consideration the randomization ratio, the SAP requires ten subjects in the active treatment arm and five subjects in the vehicle group.

As part of the pooling analysis, the treatment effect within investigational site must be investigated. The protocol states the site main effect will be examined by using a one-way analysis of variance (for lesion count variables) or a logistic regression analysis (for dichotomized IGA) with a factor of site. The SAP instead explains site will be incorporated into the primary analysis models. Change from Baseline in lesion counts will be analyzed with an ANCOVA (unranked or ranked) with factors of treatment group, investigational site and treatment group by investigational site interaction, and the respective Baseline lesion count variable as a covariate. The dichotomized primary endpoint will be analyzed with a logistic regression with factors of treatment group, investigational site and the interaction term of treatment group by investigational site.

The protocol describes repeated measures sensitivity analyses for the primary efficacy endpoints. Treatment group, analysis center and visit are listed as factors for the repeated measures analyses. In addition to these factors, the SAP includes a factor of treatment group by visit interaction.

The protocol describes imputing only Week 12 data with MCMC imputation, but all missing post-Baseline data will be imputed.

The protocol provided did not provide seeds for the IGA MCMC imputation or for the model based multiple imputation, so those were added in the SAP. All seeds given in the SAP were produced in SAS as seeds given in the 65-05 protocol were identical to the 65-04 study protocol.

Geographic region was removed from the examination of subgroups as all sites in the study are in the United States.

An additional age grouping of 9-11 years, 12-17 years, 18-30 years, and 31 years and older was added to the subgroup summaries.

The secondary efficacy analysis will be presented on the PP population in addition to the ITT population as specified in the protocol.

11. REFERENCES

1. Bhate K, Williams HC. Epidemiology of acne vulgaris. Br J Dermatol. 2013Mar;168(3):474-485.
2. Gollnick H, Cunliffe W Berson D, et al; Global Alliance to Improve Outcomes in Acne. Management of acne: a report form a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49(suppl 1):S1-S37.
3. Leyden J, Kaidbey K, Levy SF. The combination formulation of clindamycin 1% plus benzoyl peroxide 5% versus 3 different formulations of topical clindamycin alone in the reduction of Propionibacterium acnes. Am J Clin Dermatol 2001;2 (4):63-266.
4. Zar, JH. Bio-statistical analysis, 1984 2nd ed. Englewood Cliffs (NJ)Prentice-Hall.

12. INDEX OF PLANNED TABLES

Table 14.0.1: Summary of Subject Completion/Discontinuation (All Randomized Subjects)	44
Table 14.0.2.1: Summary of Subject Enrollment and Evaluability (All Randomized Subjects)..	45
Table 14.0.2.2: Summary of Subject Evaluability by Analysis Center and Investigational Site (All Randomized Subjects)	46
Table 14.1.1.1: Summary of Subject Demographic Characteristics (Intent-to-Treat Population).....	47
Table 14.1.1.2: Summary of Subject Demographics (Per-Protocol Population).....	49
Table 14.1.1.3: Summary of Subject Demographics (Safety Population).....	49
Table 14.1.2.1: Subject Baseline Characteristics (Intent-to-Treat Population).....	50
Table 14.1.2.2: Subject Baseline Characteristics (Per-Protocol Population).....	51
Table 14.1.2.3: Subject Baseline Characteristics (Safety Population).....	51
Table 14.1.3.1: Summary of Medical History by System Organ Class and Preferred Term (Intent-to-Treat Population).....	52
Table 14.1.3.2: Summary of Medical History by System Organ Class and Preferred Term (Per-Protocol Population)	52
Table 14.1.3.3: Summary of Medical History by System Organ Class and Preferred Term (Safety Population)	52
Table 14.1.4.1: Summary of Prior Medications by ATC Level 2 and Preferred Name (Safety Population).....	53
Table 14.1.4.2: Summary of Concomitant Medications by ATC Level 2 and Preferred Name (Safety Population).....	54
Table 14.2.1.1: Pooling Analysis for Primacy Efficacy Endpoints (Intent-to-Treat Population)	55
Table 14.2.1.2: Primary Efficacy Analysis: Absolute Change from Baseline in Lesion Counts and Dichotomized IGA Success at Week 12 (Intent-to-Treat Population).....	56
Table 14.2.1.3: Primary Efficacy Analysis: Absolute Change from Baseline in Lesion Counts and Dichotomized IGA Success at Week 12 (Per-Protocol Population)	57
Table 14.2.2.1.1: Summary of Inflammatory Lesion Counts at Each Evaluation (Intent-to-Treat Population).....	58
Table 14.2.2.1.2: Summary of Inflammatory Lesion Counts at Each Evaluation (Per-Protocol Population)	62

Table 14.2.2.2: Summary of Absolute Change in Inflammatory Lesion Counts at Week 12 by Analysis Center (Intent-to-Treat Population).....	63
Table 14.2.3.1.1: Summary of Non-Inflammatory Lesion Counts at Each Evaluation (Intent-to-Treat Population).....	64
Table 14.2.3.1.2: Summary of Non-Inflammatory Lesion Counts at Each Evaluation (Per-Protocol Population)	68
Table 14.2.3.2: Summary of Absolute Change in Non-Inflammatory Lesion Counts at Week 12 by Analysis Center (Intent-to-Treat Population).....	69
Table 14.2.4.1.1: Summary of Investigator Global Assessment at Each Evaluation (Intent-to-Treat Population).....	70
Table 14.2.4.1.2: Summary of Investigator Global Assessment at Each Evaluation (Per-Protocol Population)	74
Table 14.2.4.2: Summary of Investigator Global Assessment (Two Grade Reduction from Baseline and Clear or Almost Clear) at Week 12 by Analysis Center (Intent-to-Treat Population)	75
Table 14.2.5.1: Subgroup Summaries of Primary Endpoints (Intent-to-Treat Population).....	76
Table 14.2.6.1: Sensitivity Analysis of Primary Endpoints: Absolute Change from Baseline in Lesion Counts and Dichotomized IGA Success at Week 12 (Intent-to-Treat Population).....	84
Table 14.2.7.1: Sensitivity Tipping-Point Analysis of the Primary Endpoint: Lesion Counts at Week 12 (Intent-to-Treat Population).....	86
Table 14.2.8.1: Secondary Efficacy Analyses (Intent-to-Treat Population).....	87
Table 14.2.8.2: Secondary Efficacy Analyses (Per-Protocol Population)	89
Table 14.2.9.1: Summary of Patient-Reported Evaluation of Facial Acne (PRE-FACE) at Each Evaluation (Intent-to-Treat Population).....	90
Table 14.2.9.2: Summary of Patient-Reported Evaluation of Facial Acne (PRE-FACE) at Each Evaluation (Per-Protocol Population)	117
Table 14.2.10.1: Supportive Efficacy Analyses: PGI-TS, PGI-S, and PGI-C at Week 12 (Intent-to-Treat Population)	118
Table 14.2.11.1: Supportive Efficacy Analyses: Lesion Count and IGA.....	119
Table 14.2.12.1: Supportive Efficacy Analyses: PRE-FACE ASD Scores	122
Table 14.2.13.1: Supportive Efficacy Analyses: PRE-FACE AID Scores.....	125
Table 14.2.14.1: Summary of Patient Global Impression of Change (PGI-C) at Each Evaluation (Intent-to-Treat Population).....	128

Table 14.2.15.1: Summary of Patient Global Impression of Symptom Severity (PGI-S) at Each Evaluation (Intent-to-Treat Population).....	130
Table 14.2.16.1: Summary of Patient Global Impression of Treatments Satisfaction (PGI-TS) at Each Evaluation (Intent-to-Treat Population).....	132
Table 14.2.17.1: Summary of Acne-QoL Questionnaire Responses at Baseline and Week 12 (Intent-to-Treat Population)	134
Table 14.3.0.1: Summary of Extent of Exposure (Safety Population)	138
Table 14.3.1.1: Summary of Cutaneous Signs and Local Tolerability at Each Evaluation (Safety Population)	139
Table 14.3.1.2.1: Summary of Treatment-Emergent Adverse Event Characteristics (Safety Population).....	153
Table 14.3.1.2.2: Summary of Treatment-Emergent Adverse Events by MedDRA System Organ Class and Preferred Term (Safety Population).....	155
Table 14.3.1.2.3: Summary of Treatment-Emergent Adverse Events by Severity (Safety Population)	156
Table 14.3.1.2.4: Summary of Treatment-Emergent Adverse Events by Relationship to Study Drug (Safety Population)	157
Table 14.3.1.3.1: Summary of Treatment-Emergent Serious Adverse Event Characteristics (Safety Population).....	158
Table 14.3.1.3.2: Summary of Treatment-Emergent Serious Adverse Events by MedDRA System Organ Class and Preferred Term (Safety Population).....	160
Table 14.3.1.3.3: Summary of Serious Treatment-Emergent Adverse Events by Severity (Safety Population)	161
Table 14.3.1.3.4: Summary of Treatment-Emergent Serious Adverse Events by Relationship to Study Drug (Safety Population)	162
Table 14.3.1.4: Summary of Vital Signs (Safety Population)	163
Table 14.3.1.4.2: Shift Table of Vital Signs (Safety Population).....	168
Table 14.3.1.5: Summary of Abnormal Physical Examination Findings by Visit (Safety Population)	169
Table 14.3.1.6: Summary of Patient Global Impression of Treatment Side-Effects (PGI-SE) at Each Evaluation (Safety Population)	170

Table 14.0.1: Summary of Subject Completion/Discontinuation
(All Randomized Subjects)

	E-BPO/E-ATRA 3%/0.1% Cream (N= xxx)	Vehicle Cream (N=xxx)	Total (N=xxx)
Completed Study			
Yes	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
No	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
Reason for Discontinuation			
Adverse Event	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
Lost to Follow-Up	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
Lack of Efficacy	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
Pregnancy	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
Protocol Violation	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
Withdrawal by Parent/Guardian	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
Withdrawal by Subject	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
Study Terminated by Sponsor	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
Physician Decision	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
Worsening of Condition	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
Other	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.0.2.1: Summary of Subject Enrollment and Evaluability
(All Randomized Subjects)

	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)	Total (N=xxx)
Number of Randomized Subjects	xx	xx	xx
Number of Subjects Included in the ITT Population	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
Number of Subjects Excluded from the ITT Population	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
Reason Excluded from the ITT Population			
Not Dispensed Study Drug	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
Number of Subjects Included in the Safety Population	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
Number of Subjects Excluded from the Safety Population	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
Reasons Excluded from the Safety Population ^a			
No Documented use of Study Drug	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
No Post-Baseline Safety Assessment	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
Number of Subjects Included in the PP Population	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
Number of Subjects Excluded from the PP Population	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
Reasons Excluded from the PP Population ^a			
Not Included in ITT Population	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
Violated Inclusion/Exclusion Criteria	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
Used Interfering Concomitant Medication	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
Did not Attend Week 12/ET Visit	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
Missed More Than 1 Post-Baseline Visit Prior to Week 12	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
Not Compliant with Dosing Regimen ^b	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
Week 12/ET Visit Out of Window (+/-4 days)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
Other	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)

^a Table includes primary reason (assigned in order presented in table) for reason subject was excluded.

^b Subjects lost to follow-up not included. A subject was considered compliant with the dosing regimen if the subject applied 80-120% of the expected number of applications and did not miss more than 5 consecutive applications while enrolled in the study.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.0.2.2: Summary of Subject Evaluability by Analysis Center and Investigational Site
(All Randomized Subjects)
(Page 1 of xx)

Analysis Center	Investigational Site	Number Randomized	E-BPO/E-ATRA 3%/0.1% Cream			Vehicle Cream		
			ITT	PP	Safety	ITT	PP	Safety
xx	xx	xx	xx	xx	xx	xx	xx	xx
xx	xx	xx	xx	xx	xx	xx	xx	xx
	xx	xx	xx	xx	xx	xx	xx	xx
xx	xx	xx	xx	xx	xx	xx	xx	xx
xx	xx	xx	xx	xx	xx	xx	xx	xx
	xx	xx	xx	xx	xx	xx	xx	xx
	xx	xx	xx	xx	xx	xx	xx	xx

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.1.1.1: Summary of Subject Demographic Characteristics
(Intent-to-Treat Population)
(Page 1 of 2)

	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)	Total (N=xxx)	P-Value
Age (years)				
n	xx	xx	xx	x.xxx ^a
Mean	xx.x	xx.x	xx.x	
SD	xx.xx	xx.xx	xx.xx	
Median	xx.x	xx.x	xx.x	
Min. to Max.	xx to xx	xx to xx	xx to xx	
< Median (xx years)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	
≥ Median (xx years)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	
< 18 years	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	
≥ 18 years and < Median (xx years)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	
≥ Median (xx years)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	
9-11 years	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	
12-17 years	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	
18-30 years	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	
≥ 31 years	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	

^a P-value from a two-way analysis of variance with factors of treatment group and analysis center.

^b P-value from a Cochran-Mantel-Haenszel general association test, stratified by analysis center.

^c See Listing 16.2.4.1 for a complete list of other races.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.1.1.1: Summary of Subject Demographics
(Intent-to-Treat Population)
(Page 2 of 2)

	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)	Total (N=xxx)	P-Value
Sex				
n	xx	xx	xx	x.xxx ^b
Male	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	
Female	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	
Ethnicity				
n	xx	xx	xx	x.xxx ^b
Hispanic or Latino	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	
Not Hispanic or Latino	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	
Race				
n	xx	xx	xx	x.xxx ^b
American Indian or Alaska Native	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	
Asian	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	
Black or African American	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	
Native Hawaiian or Other Pacific Islander	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	
White	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	
Multiple/Other ^c	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	

^a P-value from a two-way analysis of variance with factors of treatment group and analysis center.

^b P-value from a Cochran-Mantel-Haenszel general association test, stratified by analysis center.

^c See Listing 16.2.4.1 for a complete list of other races.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Repeat Table 14.1.1.1 for the following tables:

Table 14.1.1.2: Summary of Subject Demographics (Per-Protocol Population)

Table 14.1.1.3: Summary of Subject Demographics (Safety Population)

Table 14.1.2.1: Subject Baseline Characteristics
(Intent-to-Treat Population)
(Page 1 of 2)

	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)	Total (N=xxx)	P-Value
Height (cm)				
n	xx	xx	xx	x.xxx ^a
Mean	xx.x	xx.x	xx.x	
SD	xx.xx	xx.xx	xx.xx	
Median	xx.x	xx.x	xx.x	
Min. to Max.	xx to xx	xx to xx	xx to xx	
Weight (kg)				
n	xx	xx	xx	x.xxx ^a
Mean	xx.x	xx.x	xx.x	
SD	xx.xx	xx.xx	xx.xx	
Median	xx.x	xx.x	xx.x	
Min. to Max.	xx to xx	xx to xx	xx to xx	
BMI (kg/m ²)				
n	xx	xx	xx	x.xxx ^a
Mean	xx.x	xx.x	xx.x	
SD	xx.xx	xx.xx	xx.xx	
Median	xx.x	xx.x	xx.x	
Min. to Max.	xx to xx	xx to xx	xx to xx	

^a P-value from a two-way analysis of variance with factors of treatment group and analysis center.

^b P-value from a Cochran-Mantel-Haenszel general association test, stratified by analysis center.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.1.2.1: Subject Baseline Characteristics
(Intent-to-Treat Population)
(Page 2 of 2)

	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)	Total (N=xxx)	P-Value
Inflammatory Lesion Count				
n	xx	xx	xx	x.xxx ^a
Mean	xx.x	xx.x	xx.x	
SD	xx.xx	xx.xx	xx.xx	
Median	xx.x	xx.x	xx.x	
Min. to Max.	xx to xx	xx to xx	xx to xx	
Non-Inflammatory Lesion Count				
n	xx	xx	xx	x.xxx ^a
Mean	xx.x	xx.x	xx.x	
SD	xx.xx	xx.xx	xx.xx	
Median	xx.x	xx.x	xx.x	
Min. to Max.	xx to xx	xx to xx	xx to xx	
Investigator Global Assessment				
n	xx	xx	xx	x.xxx ^b
0 - Clear	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	
1 – Almost Clear	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	
2 - Mild	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	
3 - Moderate	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	
4 - Severe	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	

^a P-value from a two-way analysis of variance with factors of treatment group and analysis center.

^b P-value from a Cochran-Mantel-Haenszel general association test, stratified by analysis center.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Repeat Table 14.1.2.1 for the following table:

Table 14.1.2.2: Subject Baseline Characteristics (Per-Protocol Population)

Table 14.1.2.3: Subject Baseline Characteristics (Safety Population)

Table 14.1.3.1: Summary of Medical History by System Organ Class and Preferred Term
(Intent-to-Treat Population)
(Page 1 of xx)

System Organ Class Preferred Term	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)		Vehicle Cream (N=xxx)		Total (N=xxx)	
	By Subject ^a	By Event ^b	By Subject ^a	By Event ^b	By Subject ^a	By Event ^b
Number (%) of Subjects Reporting at Least One Medical History Term	xx (xx.x%)		xx (xx.x%)		xx (xx.x%)	
System Organ Class	xx (xx.x%)	xx	xx (xx.x%)	xx	xx (xx.x%)	xx
Preferred Term	xx (xx.x%)	xx	xx (xx.x%)	xx	xx (xx.x%)	xx

^a Counts reflect number of subjects reporting one or more medical history terms that map to MedDRA. At each level of summarization (System Organ Class or Preferred Term) subjects are counted once. Percentages are based on the number of subjects in the safety population.

^b Counts reflect number of medical history terms that map to MedDRA.

Note: MedDRA Version 21.0

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

{NOTE TO PROGRAMMER: The table will be sorted by overall descending frequency of SOC and then, within a SOC, by overall descending frequency of PT}

Repeat Table 14.1.3.1 for the following table:

Table 14.1.3.2: Summary of Medical History by System Organ Class and Preferred Term (Per-Protocol Population)

Table 14.1.3.3: Summary of Medical History by System Organ Class and Preferred Term (Safety Population)

Table 14.1.4.1: Summary of Prior Medications by ATC Level 2 and Preferred Name
(Safety Population)
(Page 1 of xx)

ATC Level 2 Term ^a Preferred Name	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Number (%) of Subjects Reporting at Least One Prior Medication	xx (xx.x%)	xx (xx.x%)
ATC Level 2 Term	xx (xx.x%)	xx (xx.x%)
Preferred Name	xx (xx.x%)	xx (xx.x%)

^a Counts reflect number of subjects reporting one or more medications that map to the WHO term. At each level of summarization (ATC Level 2 Term or Preferred Name) subjects are counted once. Percentages are based on the number of subjects in the safety population.

Note: WHO Drug Global Dictionary, Format B3, Version March 1, 2018
Prior medications are those used before the date of first study drug application.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.1.4.2: Summary of Concomitant Medications by ATC Level 2 and Preferred Name
(Safety Population)
(Page 1 of xx)

ATC Level 2 Term ^a Preferred Name	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Number (%) of Subjects Reporting at Least One Concomitant Medication	xx (xx.x%)	xx (xx.x%)
ATC Level 2 Term	xx (xx.x%)	xx (xx.x%)
Preferred Name	xx (xx.x%)	xx (xx.x%)

^a Counts reflect number of subjects reporting one or more medications that map to the WHO term. At each level of summarization (ATC Level 2 Term or Preferred Name) subjects are counted once. Percentages are based on the number of subjects in the safety population.

Note: WHO Drug Global Dictionary, Format B3, Version March 1, 2018
Concomitant medications are those used on/after the date of first study drug application.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.1.1: Pooling Analysis for Primacy Efficacy Endpoints
(Intent-to-Treat Population)

Endpoint	Investigational Site Pooling Analysis		Analysis Center Pooling Analysis	
	Skewness P-Value	Investigational Site by Treatment Group P-Value	Skewness P-Value	Analysis Center Treatment Group P-Value
Absolute Change from Baseline in Inflammatory Lesion Counts at Week 12	x.xxx ^c		x.xxx ^c	
Ranked Analysis		x.xxx ^a		x.xxx ^e
Unranked Analysis		x.xxx ^b		x.xxx ^f
Absolute Change from Baseline in Non-Inflammatory Lesion Counts at Week 12	x.xxx ^c		x.xxx ^c	
Ranked Analysis		x.xxx ^a		x.xxx ^e
Unranked Analysis		x.xxx ^b		x.xxx ^f
Two Grade Reduction from Baseline in IGA and Achieving Clear or Almost Clear at Week 12	NA	x.xxx ^d	NA	x.xxx ^g

^a P-value for the interaction term from a ranked analysis of covariance with factors of treatment, investigational site, treatment by investigational site interaction and the respective Baseline lesion count as a covariate.

^b P-value for the interaction term from an unranked analysis of covariance with factors of treatment, investigational site, treatment by investigational site interaction and the respective Baseline lesion count as a covariate.

^c Skewness test, based on methods presented by J.H. Zar (1984), assessed for each imputed dataset. The average p-value is presented.

^d P-value for the interaction term from a logistic regression with factors of treatment, investigational site, treatment by investigational site interaction.

^e P-value for the interaction term from a ranked analysis of covariance with factors of treatment, analysis center, treatment by analysis center interaction and the respective Baseline lesion count as a covariate.

^f P-value for the interaction term from an unranked analysis of covariance with factors of treatment, analysis center, treatment by analysis center interaction and the respective Baseline lesion count as a covariate.

^g P-value for the interaction term from a logistic regression with factors of treatment, analysis center, treatment by analysis center interaction.

Note: Multiple imputation (MCMC) used to impute missing values.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

{NOTE TO PROGRAMMER: ADJUST FOOTNOTE “d” AND/OR “g” IF FIRTH’S PENALIZED LIKELIHOOD IS NEEDED}

Table 14.2.1.2: Primary Efficacy Analysis: Absolute Change from Baseline in Lesion Counts and Dichotomized IGA Success at Week 12
(Intent-to-Treat Population)

	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)	Skewness P-Value	Treatment P-Value
Inflammatory Lesion Count – Absolute Change from Baseline				
LSMean ^a	xx.x	xx.x	x.xxx ^b	x.xxx ^a
LSSD ^a	xx.xx	xx.xx		x.xxx ^c
Non-Inflammatory Lesion Count – Absolute Change from Baseline				
LSMean ^a	xx.x	xx.x	x.xxx ^b	x.xxx ^a
LSSD ^a	xx.xx	xx.xx		x.xxx ^c
At Least Two Grade Reduction from Baseline and Achieving Clear or Almost Clear				
Success	xx.x%	xx.x%	N/A	x.xxx ^d
Failure	xx.x%	xx.x%		

^a Least squares means, standard deviations and treatment p-value from an analysis of covariance with factors of treatment group and analysis center and the respective Baseline lesion count as a covariate. Negative least squares means values represent decrease from Baseline.

^b Skewness test, based on methods presented by J.H. Zar (1984), assessed for each imputed dataset. The average p-value is presented.

^c P-value from a ranked analysis of covariance with factors of treatment group and analysis center and the respective Baseline lesion count as a covariate.

^d P-value from a logistic regression with factors of treatment group and analysis center.

Note: Multiple imputation (MCMC) used to impute missing values.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

{NOTE TO PROGRAMMER: ADJUST FOOTNOTE “d” IF FIRTH’S PENALIZED LIKELIHOOD IS NEEDED}

Repeat Table 14.2.1.2 for the following table:

Table 14.2.1.3: Primary Efficacy Analysis: Absolute Change from Baseline in Lesion Counts and Dichotomized IGA Success at Week 12 (Per-Protocol Population)

Update footnote to “Note: Missing values imputed using last observation carried forward.”

Table 14.2.2.1.1: Summary of Inflammatory Lesion Counts at Each Evaluation
(Intent-to-Treat Population)
(Page 1 of 4)

Inflammatory Lesion Counts	E-BPO/E-ATRA 3%/0.1% Cream	Vehicle Cream
	(N=xxx)	(N=xxx)
Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Week 2		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Percent Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx

Note: Multiple imputation (MCMC) used to impute missing values. Summary statistics for Weeks 2, 4, 8, and 12 represent average values, obtained from averaging the summary statistics generated from each imputed dataset.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.2.1.1: Summary of Inflammatory Lesion Counts at Each Evaluation
(Intent-to-Treat Population)
(Page 2 of 4)

Inflammatory Lesion Counts	E-BPO/E-ATRA 3%/0.1% Cream	Vehicle Cream
	(N=xxx)	(N=xxx)
Week 4		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Percent Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx

Note: Multiple imputation (MCMC) used to impute missing values. Summary statistics for Weeks 2, 4, 8, and 12 represent average values, obtained from averaging the summary statistics generated from each imputed dataset.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.2.1.1: Summary of Inflammatory Lesion Counts at Each Evaluation
(Intent-to-Treat Population)
(Page 3 of 4)

Inflammatory Lesion Counts	E-BPO/E-ATRA 3%/0.1% Cream	Vehicle Cream
	(N=xxx)	(N=xxx)
Week 8		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Percent Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx

Note: Multiple imputation (MCMC) used to impute missing values. Summary statistics for Weeks 2, 4, 8, and 12 represent average values, obtained from averaging the summary statistics generated from each imputed dataset.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.2.1.1: Summary of Inflammatory Lesion Counts at Each Evaluation
(Intent-to-Treat Population)
(Page 4 of 4)

Inflammatory Lesion Counts	E-BPO/E-ATRA 3%/0.1% Cream	Vehicle Cream
	(N=xxx)	(N=xxx)
Week 12		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Percent Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx

Note: Multiple imputation (MCMC) used to impute missing values. Summary statistics for Weeks 2, 4, 8, and 12 represent average values, obtained from averaging the summary statistics generated from each imputed dataset. Negative values represent decrease from Baseline.

SOURCE: USERNAME/SPONSOR/PROJECT/JOBNAME (DATE,TIME)

Repeat Table 14.2.2.1.1 for the following table:

Table 14.2.2.1.2: Summary of Inflammatory Lesion Counts at Each Evaluation (Per-Protocol Population)

Change footnote to “Note: Missing values imputed using last observation carried forward. Negative values represent decrease from Baseline.”

Table 14.2.2.2: Summary of Absolute Change in Inflammatory Lesion Counts at Week 12 by Analysis Center
(Intent-to-Treat Population)

Analysis Center (Investigational Sites)	E-BPO/E-ATRA 3%/0.1% Cream			Vehicle Cream		
	(N=xxx)			(N=xxx)		
	n	Mean	SD	n	Mean	SD
xx (y, z)	xx	xx.x	xx.xx	xx	xx.x	xx.xx
xx (y, z)	xx	xx.x	xx.xx	xx	xx.x	xx.xx
xx (y, z)	xx	xx.x	xx.xx	xx	xx.x	xx.xx
xx (y, z)	xx	xx.x	xx.xx	xx	xx.x	xx.xx
xx (y, z)	xx	xx.x	xx.xx	xx	xx.x	xx.xx
xx (y, z)	xx	xx.x	xx.xx	xx	xx.x	xx.xx
xx (y, z)	xx	xx.x	xx.xx	xx	xx.x	xx.xx
xx (y, z)	xx	xx.x	xx.xx	xx	xx.x	xx.xx
xx (y, z)	xx	xx.x	xx.xx	xx	xx.x	xx.xx

Note: Multiple imputation (MCMC) used to impute missing values. Summary statistics represent average values, obtained from averaging the summary statistics generated from each imputed dataset. Negative values represent decrease from Baseline.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Table 14.2.3.1.1: Summary of Non-Inflammatory Lesion Counts at Each Evaluation
(Intent-to-Treat Population)
(Page 1 of 4)

Non-Inflammatory Lesion Counts	E-BPO/E-ATRA 3%/0.1% Cream	Vehicle Cream
	(N=xxx)	(N=xxx)
Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Week 2		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Percent Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx

Note: Multiple imputation (MCMC) used to impute missing values. Summary statistics for Weeks 2, 4, 8, and 12 represent average values, obtained from averaging the summary statistics generated from each imputed dataset.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.3.1.1: Summary of Non-Inflammatory Lesion Counts at Each Evaluation
(Intent-to-Treat Population)
(Page 2 of 4)

Non-Inflammatory Lesion Counts	E-BPO/E-ATRA 3%/0.1% Cream	Vehicle Cream
	(N=xxx)	(N=xxx)
Week 4		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Percent Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx

Note: Multiple imputation (MCMC) used to impute missing values. Summary statistics for Weeks 2, 4, 8, and 12 represent average values, obtained from averaging the summary statistics generated from each imputed dataset.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.3.1.1: Summary of Non-Inflammatory Lesion Counts at Each Evaluation
(Intent-to-Treat Population)
(Page 3 of 4)

Non-Inflammatory Lesion Counts	E-BPO/E-ATRA 3%/0.1% Cream	Vehicle Cream
	(N=xxx)	(N=xxx)
Week 8		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Percent Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx

Note: Multiple imputation (MCMC) used to impute missing values. Summary statistics for Weeks 2, 4, 8, and 12 represent average values, obtained from averaging the summary statistics generated from each imputed dataset.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.3.1.1: Summary of Non-Inflammatory Lesion Counts at Each Evaluation
(Intent-to-Treat Population)
(Page 4 of 4)

Non-Inflammatory Lesion Counts	E-BPO/E-ATRA 3%/0.1% Cream	Vehicle Cream
	(N=xxx)	(N=xxx)
Week 12		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Percent Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx

Note: Multiple imputation (MCMC) used to impute missing values. Summary statistics for Weeks 2, 4, 8, and 12 represent average values, obtained from averaging the summary statistics generated from each imputed dataset. Negative values represent decrease from Baseline.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Repeat Table 14.2.3.1.1 for the following table:

Table 14.2.3.1.2: Summary of Non-Inflammatory Lesion Counts at Each Evaluation (Per-Protocol Population)

Change footnote to “Note: Missing values imputed using last observation carried forward. Negative values represent decrease from Baseline.”

Table 14.2.3.2: Summary of Absolute Change in Non-Inflammatory Lesion Counts at Week 12 by Analysis Center
(Intent-to-Treat Population)

Analysis Center (Investigational Sites)	E-BPO/E-ATRA 3%/0.1% Cream			Vehicle Cream		
	(N=xxx)			(N=xxx)		
	n	Mean	SD	n	Mean	SD
xx (y, z)	xx	xx.x	xx.xx	xx	xx.x	xx.xx
xx (y, z)	xx	xx.x	xx.xx	xx	xx.x	xx.xx
xx (y, z)	xx	xx.x	xx.xx	xx	xx.x	xx.xx
xx (y, z)	xx	xx.x	xx.xx	xx	xx.x	xx.xx
xx (y, z)	xx	xx.x	xx.xx	xx	xx.x	xx.xx
xx (y, z)	xx	xx.x	xx.xx	xx	xx.x	xx.xx
xx (y, z)	xx	xx.x	xx.xx	xx	xx.x	xx.xx
xx (y, z)	xx	xx.x	xx.xx	xx	xx.x	xx.xx
xx (y, z)	xx	xx.x	xx.xx	xx	xx.x	xx.xx

Note: Multiple imputation (MCMC) used to impute missing values. Summary statistics represent average values, obtained from averaging the summary statistics generated from each imputed dataset. Negative values represent decrease from Baseline.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Table 14.2.4.1.1: Summary of Investigator Global Assessment at Each Evaluation
(Intent-to-Treat Population)
(Page 1 of 4)

Investigator Global Assessment	E-BPO/E-ATRA 3%/0.1% Cream	Vehicle Cream
	(N=xxx)	(N=xxx)
Baseline		
0 - Clear	xx.x%	xx.x%
1 - Almost Clear	xx.x%	xx.x%
2 - Mild	xx.x%	xx.x%
3 - Moderate	xx.x%	xx.x%
4 - Severe	xx.x%	xx.x%

Note: Multiple imputation (MCMC) used to impute missing values. Percentages for Weeks 2, 4, 8, and 12 represent average values, obtained from averaging the summary statistics generated from each imputed dataset.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.4.1.1: Summary of Investigator Global Assessment at Each Evaluation
(Intent-to-Treat Population)
(Page 2 of 4)

Investigator Global Assessment	E-BPO/E-ATRA 3%/0.1% Cream	Vehicle Cream
	(N=xxx)	(N=xxx)
Week 4		
0 - Clear	xx.x%	xx.x%
1 - Almost Clear	xx.x%	xx.x%
2 - Mild	xx.x%	xx.x%
3 - Moderate	xx.x%	xx.x%
4 - Severe	xx.x%	xx.x%
Two Grade Reduction from Baseline		
Success	xx.x%	xx.x%
Failure	xx.x%	xx.x%
Two Grade Reduction from Baseline and Achieving Clear or Almost Clear		
Success	xx.x%	xx.x%
Failure	xx.x%	xx.x%

Note: Multiple imputation (MCMC) used to impute missing values. Percentages for Weeks 2, 4, 8, and 12 represent average values, obtained from averaging the summary statistics generated from each imputed dataset.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.4.1.1: Summary of Investigator Global Assessment at Each Evaluation
(Intent-to-Treat Population)
(Page 3 of 4)

Investigator Global Assessment	E-BPO/E-ATRA 3%/0.1% Cream	Vehicle Cream
	(N=xxx)	(N=xxx)
Week 8		
0 - Clear	xx.x%	xx.x%
1 - Almost Clear	xx.x%	xx.x%
2 - Mild	xx.x%	xx.x%
3 - Moderate	xx.x%	xx.x%
4 - Severe	xx.x%	xx.x%
Two Grade Reduction from Baseline		
Success	xx.x%	xx.x%
Failure	xx.x%	xx.x%
Two Grade Reduction from Baseline and Achieving Clear or Almost Clear		
Success	xx.x%	xx.x%
Failure	xx.x%	xx.x%

Note: Multiple imputation (MCMC) used to impute missing values. Percentages for Weeks 2, 4, 8, and 12 represent average values, obtained from averaging the summary statistics generated from each imputed dataset.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.4.1.1: Summary of Investigator Global Assessment at Each Evaluation
(Intent-to-Treat Population)
(Page 4 of 4)

Investigator Global Assessment	E-BPO/E-ATRA 3%/0.1% Cream	Vehicle Cream
	(N=xxx)	(N=xxx)
Week 12		
0 - Clear	xx.x%	xx.x%
1 - Almost Clear	xx.x%	xx.x%
2 - Mild	xx.x%	xx.x%
3 - Moderate	xx.x%	xx.x%
4 - Severe	xx.x%	xx.x%
Two Grade Reduction from Baseline		
Success	xx.x%	xx.x%
Failure	xx.x%	xx.x%
Two Grade Reduction from Baseline and Achieving Clear or Almost Clear		
Success	xx.x%	xx.x%
Failure	xx.x%	xx.x%

Note: Multiple imputation (MCMC) used to impute missing values. Percentages for Weeks 2, 4, 8, and 12 represent average values, obtained from averaging the summary statistics generated from each imputed dataset.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Repeat Table 14.2.4.1.1 for the following table:

Table 14.2.4.1.2: Summary of Investigator Global Assessment at Each Evaluation (Per-Protocol Population)

Change footnote to “Note: Missing values imputed using last observation carried forward.”

Table 14.2.4.2: Summary of Investigator Global Assessment (Two Grade Reduction from Baseline and Clear or Almost Clear)
at Week 12 by Analysis Center
(Intent-to-Treat Population)

Analysis Center (Investigational Sites)	E-BPO/E-ATRA 3%/0.1% Cream	Vehicle Cream
	(N=xxx)	(N=xxx)
	xx.x%	xx.x%
xx (y, z)	xx.x%	xx.x%
xx (y, z)	xx.x%	xx.x%
xx (y, z)	xx.x%	xx.x%
xx (y, z)	xx.x%	xx.x%
xx (y, z)	xx.x%	xx.x%
xx (y, z)	xx.x%	xx.x%
xx (y, z)	xx.x%	xx.x%
xx (y, z)	xx.x%	xx.x%
xx (y, z)	xx.x%	xx.x%

Note: Multiple imputation (MCMC) used to impute missing values. Summary statistics represent average values, obtained from averaging the summary statistics generated from each imputed dataset.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Table 14.2.5.1: Subgroup Summaries of Primary Endpoints
(Intent-to-Treat Population)
(Page 1 of 8)

Age	Age < Median Age (xx)		Age >= Median Age (xx)	
	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Inflammatory Lesion Count – Absolute Change from Baseline				
n	xxx	xxx	xxx	xxx
Mean	xx.x	xx.x	xx.x	xx.x
SD	xx.xx	xx.xx	xx.xx	xx.xx
Median	xx.x	xx.x	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx	xx to xx	xx to xx
Non-Inflammatory Lesion Count – Absolute Change from Baseline				
n	xxx	xxx	xxx	xxx
Mean	xx.x	xx.x	xx.x	xx.x
SD	xx.xx	xx.xx	xx.xx	xx.xx
Median	xx.x	xx.x	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx	xx to xx	xx to xx
Two Grade Reduction from Baseline in IGA and Achieving Clear or Almost Clear				
Success	xx.x%	xx.x%	xx.x%	xx.x%
Failure	xx.x%	xx.x%	xx.x%	xx.x%

^a Ethnicities of Not Reported and Unknown are not included.

Note: Multiple imputation (MCMC) used to impute missing values. Summary statistics represent average values, obtained from averaging the summary statistics generated from each imputed dataset. Negative absolute change values represent decrease from Baseline.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Table 14.2.5.1: Subgroup Summaries of Primary Endpoints
(Intent-to-Treat Population)
(Page 2 of 8)

Age	Age < 18		18 <= Age < Median Age (xx)	
	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Inflammatory Lesion Count – Absolute Change from Baseline				
n	xxx	xxx	xxx	xxx
Mean	xx.x	xx.x	xx.x	xx.x
SD	xx.xx	xx.xx	xx.xx	xx.xx
Median	xx.x	xx.x	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx	xx to xx	xx to xx
Non-Inflammatory Lesion Count – Absolute Change from Baseline				
n	xxx	xxx	xxx	xxx
Mean	xx.x	xx.x	xx.x	xx.x
SD	xx.xx	xx.xx	xx.xx	xx.xx
Median	xx.x	xx.x	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx	xx to xx	xx to xx
Two Grade Reduction from Baseline in IGA and Achieving Clear or Almost Clear				
Success	xx.x%	xx.x%	xx.x%	xx.x%
Failure	xx.x%	xx.x%	xx.x%	xx.x%

^a Ethnicities of Not Reported and Unknown are not included.

Note: Multiple imputation (MCMC) used to impute missing values. Summary statistics represent average values, obtained from averaging the summary statistics generated from each imputed dataset. Negative absolute change values represent decrease from Baseline.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Table 14.2.5.1: Subgroup Summaries of Primary Endpoints
(Intent-to-Treat Population)
(Page 3 of 8)

Age	9-11 years		12-17 years	
	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Inflammatory Lesion Count – Absolute Change from Baseline				
n	xxx	xxx	xxx	xxx
Mean	xx.x	xx.x	xx.x	xx.x
SD	xx.xx	xx.xx	xx.xx	xx.xx
Median	xx.x	xx.x	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx	xx to xx	xx to xx
Non-Inflammatory Lesion Count – Absolute Change from Baseline				
n	xxx	xxx	xxx	xxx
Mean	xx.x	xx.x	xx.x	xx.x
SD	xx.xx	xx.xx	xx.xx	xx.xx
Median	xx.x	xx.x	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx	xx to xx	xx to xx
Two Grade Reduction from Baseline in IGA and Achieving Clear or Almost Clear				
Success	xx.x%	xx.x%	xx.x%	xx.x%
Failure	xx.x%	xx.x%	xx.x%	xx.x%

^a Ethnicities of Not Reported and Unknown are not included.

Note: Multiple imputation (MCMC) used to impute missing values. Summary statistics represent average values, obtained from averaging the summary statistics generated from each imputed dataset. Negative absolute change values represent decrease from Baseline.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Table 14.2.5.1: Subgroup Summaries of Primary Endpoints
(Intent-to-Treat Population)
(Page 4 of 8)

Age	18-30 years		>= 31 years	
	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Inflammatory Lesion Count – Absolute Change from Baseline				
n	xxx	xxx	xxx	xxx
Mean	xx.x	xx.x	xx.x	xx.x
SD	xx.xx	xx.xx	xx.xx	xx.xx
Median	xx.x	xx.x	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx	xx to xx	xx to xx
Non-Inflammatory Lesion Count – Absolute Change from Baseline				
n	xxx	xxx	xxx	xxx
Mean	xx.x	xx.x	xx.x	xx.x
SD	xx.xx	xx.xx	xx.xx	xx.xx
Median	xx.x	xx.x	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx	xx to xx	xx to xx
Two Grade Reduction from Baseline in IGA and Achieving Clear or Almost Clear				
Success	xx.x%	xx.x%	xx.x%	xx.x%
Failure	xx.x%	xx.x%	xx.x%	xx.x%

^a Ethnicities of Not Reported and Unknown are not included.

Note: Multiple imputation (MCMC) used to impute missing values. Summary statistics represent average values, obtained from averaging the summary statistics generated from each imputed dataset. Negative absolute change values represent decrease from Baseline.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Table 14.2.5.1: Subgroup Summaries of Primary Endpoints
(Intent-to-Treat Population)
(Page 5 of 8)

Sex	Male		Female	
	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Inflammatory Lesion Count – Absolute Change from Baseline				
n	xxx	xxx	xxx	xxx
Mean	xx.x	xx.x	xx.x	xx.x
SD	xx.xx	xx.xx	xx.xx	xx.xx
Median	xx.x	xx.x	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx	xx to xx	xx to xx
Non-Inflammatory Lesion Count – Absolute Change from Baseline				
n	xxx	xxx	xxx	xxx
Mean	xx.x	xx.x	xx.x	xx.x
SD	xx.xx	xx.xx	xx.xx	xx.xx
Median	xx.x	xx.x	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx	xx to xx	xx to xx
Two Grade Reduction from Baseline in IGA and Achieving Clear or Almost Clear				
Success	xx.x%	xx.x%	xx.x%	xx.x%
Failure	xx.x%	xx.x%	xx.x%	xx.x%

^a Ethnicities of Not Reported and Unknown are not included.

Note: Multiple imputation (MCMC) used to impute missing values. Summary statistics represent average values, obtained from averaging the summary statistics generated from each imputed dataset. Negative absolute change values represent decrease from Baseline.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Table 14.2.5.1: Subgroup Summaries of Primary Endpoints
(Intent-to-Treat Population)
(Page 6 of 8)

Ethnicity ^a	Hispanic or Latino		Not Hispanic or Latino	
	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Inflammatory Lesion Count – Absolute Change from Baseline				
n	xxx	xxx	xxx	xxx
Mean	xx.x	xx.x	xx.x	xx.x
SD	xx.xx	xx.xx	xx.xx	xx.xx
Median	xx.x	xx.x	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx	xx to xx	xx to xx
Non-Inflammatory Lesion Count – Absolute Change from Baseline				
n	xxx	xxx	xxx	xxx
Mean	xx.x	xx.x	xx.x	xx.x
SD	xx.xx	xx.xx	xx.xx	xx.xx
Median	xx.x	xx.x	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx	xx to xx	xx to xx
Two Grade Reduction from Baseline in IGA and Achieving Clear or Almost Clear				
Success	xx.x%	xx.x%	xx.x%	xx.x%
Failure	xx.x%	xx.x%	xx.x%	xx.x%

^a Ethnicities of Not Reported and Unknown are not included.

Note: Multiple imputation (MCMC) used to impute missing values. Summary statistics represent average values, obtained from averaging the summary statistics generated from each imputed dataset. Negative absolute change values represent decrease from Baseline.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Table 14.2.5.1: Subgroup Summaries of Primary Endpoints
(Intent-to-Treat Population)
(Page 7 of 8)

Race	White		Non-White	
	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Inflammatory Lesion Count – Absolute Change from Baseline				
n	xxx	xxx	xxx	xxx
Mean	xx.x	xx.x	xx.x	xx.x
SD	xx.xx	xx.xx	xx.xx	xx.xx
Median	xx.x	xx.x	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx	xx to xx	xx to xx
Non-Inflammatory Lesion Count – Absolute Change from Baseline				
n	xxx	xxx	xxx	xxx
Mean	xx.x	xx.x	xx.x	xx.x
SD	xx.xx	xx.xx	xx.xx	xx.xx
Median	xx.x	xx.x	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx	xx to xx	xx to xx
Two Grade Reduction from Baseline in IGA and Achieving Clear or Almost Clear				
Success	xx.x%	xx.x%	xx.x%	xx.x%
Failure	xx.x%	xx.x%	xx.x%	xx.x%

^a Ethnicities of Not Reported and Unknown are not included.

Note: Multiple imputation (MCMC) used to impute missing values. Summary statistics represent average values, obtained from averaging the summary statistics generated from each imputed dataset. Negative absolute change values represent decrease from Baseline.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Table 14.2.5.1: Subgroup Summaries of Primary Endpoints
(Intent-to-Treat Population)
(Page 8 of 8)

Baseline IGA	Moderate		Severe	
	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Inflammatory Lesion Count – Absolute Change from Baseline				
n	xxx	xxx	xxx	xxx
Mean	xx.x	xx.x	xx.x	xx.x
SD	xx.xx	xx.xx	xx.xx	xx.xx
Median	xx.x	xx.x	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx	xx to xx	xx to xx
Non-Inflammatory Lesion Count – Absolute Change from Baseline				
n	xxx	xxx	xxx	xxx
Mean	xx.x	xx.x	xx.x	xx.x
SD	xx.xx	xx.xx	xx.xx	xx.xx
Median	xx.x	xx.x	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx	xx to xx	xx to xx
Two Grade Reduction from Baseline in IGA and Achieving Clear or Almost Clear				
Success	xx.x%	xx.x%	xx.x%	xx.x%
Failure	xx.x%	xx.x%	xx.x%	xx.x%

^a Ethnicities of Not Reported and Unknown are not included.

Note: Multiple imputation (MCMC) used to impute missing values. Summary statistics represent average values, obtained from averaging the summary statistics generated from each imputed dataset. Negative absolute change values represent decrease from Baseline.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Table 14.2.6.1: Sensitivity Analysis of Primary Endpoints: Absolute Change from Baseline in Lesion Counts and Dichotomized IGA Success at Week 12
(Intent-to-Treat Population)
(Page 1 of 2)

	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)	Skewness P-Value	Treatment P-Value
Inflammatory Lesion Count – Absolute Change from Baseline				
LSMean ^a	xx.x	xx.x	x.xxx ^b	x.xxx ^a
LSSD ^a	xx.xx	xx.xx		x.xxx ^c
Non-Inflammatory Lesion Count – Absolute Change from Baseline				
LSMean ^a	xx.x	xx.x	x.xxx ^b	x.xxx ^a
LSSD ^a	xx.xx	xx.xx		x.xxx ^c
At Least Two Grade Reduction from Baseline and Achieving Clear or Almost Clear				
Success	xx.x%	xx.x%	N/A	x.xxx ^d
Failure	xx.x%	xx.x%		

^a Least squares means, standard deviations and treatment p-value from a repeated measures analysis of covariance with factors of treatment group, analysis center, visit and treatment group by visit interaction, and the respective Baseline lesion count as a covariate. Negative least squares means values represent decrease from Baseline.

^b Skewness test based on methods presented by J.H. Zar (1984).

^c P-value from a ranked repeated measures analysis of covariance with factors of treatment group, analysis center, visit and treatment group by visit interaction, and the respective Baseline lesion count as a covariate.

^d P-value from a repeated measures logistic regression with factors of treatment group, analysis center, visit and treatment group by visit interaction.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Table 14.2.6.1: Sensitivity Analysis of Primary Endpoints: Absolute Change from Baseline in Lesion Counts and Dichotomized IGA Success at Week 12
(Intent-to-Treat Population)
(Page 2 of 2)

	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)	Skewness P-Value	Treatment P-Value
Inflammatory Lesion Count – Absolute Change from Baseline				
LSMean ^a	xx.x	xx.x	x.xxx ^b	x.xxx ^a
LSSD ^a	xx.xx	xx.xx		x.xxx ^c
Non-Inflammatory Lesion Count – Absolute Change from Baseline				
LSMean ^a	xx.x	xx.x	x.xxx ^b	x.xxx ^a
LSSD ^a	xx.xx	xx.xx		x.xxx ^c
At Least Two Grade Reduction from Baseline and Achieving Clear or Almost Clear				
Success	xx.x%	xx.x%	N/A	x.xxx ^d
Failure	xx.x%	xx.x%		

^a Least squares means, standard deviations and treatment p-value from an analysis of covariance with factors of treatment group and analysis center and the respective Baseline lesion count as a covariate. Negative least squares means values represent decrease from Baseline.

^b Skewness test, based on methods presented by J.H. Zar (1984), assessed for each imputed dataset. The average p-value is presented.

^c P-value from a ranked analysis of covariance with factors of treatment group and analysis center and the respective Baseline lesion count as a covariate.

^d P-value from a logistic regression with factors of treatment group and analysis center.

Note: Multiple imputation (regression model) used to impute missing values.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Table 14.2.7.1: Sensitivity Tipping-Point Analysis of the Primary Endpoint: Lesion Counts at Week 12
(Intent-to-Treat Population)

Inflammatory Lesion Count		Non-Inflammatory Lesion Count	
Shift Value	P-Value ^a	Shift Value	P-Value ^a
X.XX	X.XXX	X.XX	X.XXX
X.XX	X.XXX	X.XX	X.XXX
X.XX	X.XXX	X.XX	X.XXX
X.XX	X.XXX	X.XX	X.XXX
X.XX	X.XXX	X.XX	X.XXX
X.XX	X.XXX	X.XX	X.XXX
X.XX	X.XXX	X.XX	X.XXX
X.XX	X.XXX	X.XX	X.XXX
X.XX	X.XXX	X.XX	X.XXX
X.XX	X.XXX	X.XX	X.XXX
X.XX	X.XXX	X.XX	X.XXX
X.XX	X.XXX	X.XX	X.XXX
X.XX	X.XXX	X.XX	X.XXX
X.XX	X.XXX	X.XX	X.XXX
X.XX	X.XXX	X.XX	X.XXX

^a P-value from an analysis of covariance with factors of treatment group and analysis center and the respective Baseline lesion count as a covariate.

Note: Multiple imputation (MCMC) used to impute missing values, with shift values applied to the imputed lesion count values from E-BPO/E-ATRA 3%/0.1% Cream group. Values have been adjusted for multiple imputation.

SOURCE: USERNAME/SPONSOR/PROJECT/JOBNAME (DATE,TIME)

{NOTE TO PROGRAMMER: ADJUST FOOTNOTE “a” TO THE FOLLOWING IF THE NON-PARAMETRIC ANALYSIS WAS CONSIDERED TO BE THE CORRECT ANALYSIS FOR THE PRIMARY EFFICACY ANALYSIS: “P-value from a ranked analysis of covariance with factors of treatment group and analysis center and the respective Baseline lesion count as a covariate.”}

Table 14.2.8.1: Secondary Efficacy Analyses
(Intent-to-Treat Population)
(Page 1 of 3)

	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)	Skewness P-Value	Treatment P-Value
Inflammatory Lesion Count – Percent Change from Baseline to Week 12				
LSMean ^a	xx.x	xx.x	x.xxx ^b	x.xxx ^a
LSSD ^a	xx.xx	xx.xx		x.xxx ^c
Non-Inflammatory Lesion Count – Percent Change from Baseline to Week 12				
LSMean ^a	xx.x	xx.x	x.xxx ^b	x.xxx ^a
LSSD ^a	xx.xx	xx.xx		x.xxx ^c
At Least 4-Point Reduction on Item 1 (Pimples) of the PRE-FACE from Baseline to Week 12				
Success	xx.x%	xx.x%	N/A	x.xxx ^d
Failure	xx.x%	xx.x%		
At Least 4-Point Reduction on Item 5 (Embarrassment) of the PRE-FACE from Baseline to Week 12				
Success	xx.x%	xx.x%	N/A	x.xxx ^d
Failure	xx.x%	xx.x%		

^a Least squares means, standard deviations and treatment p-value from an analysis of covariance with factors of treatment and analysis center and the respective Baseline lesion count as a covariate. Negative least squares means values represent decrease from Baseline.

^b Skewness test, based on methods presented by J.H. Zar (1984), assessed for each imputed dataset. The average p-value is presented.

^c P-value from a ranked analysis of covariance with factors of treatment and analysis center and the respective Baseline lesion count as a covariate.

^d P-value from a logistic regression with factors of treatment group and analysis center.

Note: Multiple imputation (MCMC) used to impute missing values.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

{NOTE TO PROGRAMMER: ADJUST FOOTNOTE “d” IF FIRTH’S PENALIZED LIKELIHOOD IS NEEDED}

Table 14.2.8.1: Secondary Efficacy Analyses
(Intent-to-Treat Population)
(Page 2 of 3)

	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)	Skewness P-Value	Treatment P-Value
Inflammatory Lesion Count –Absolute Change from Baseline to Week 8				
LSMean ^a	xx.x	xx.x	x.xxx ^b	x.xxx ^a
LSSD ^a	xx.xx	xx.xx		x.xxx ^c
Non-Inflammatory Lesion Count –Absolute Change from Baseline to Week 8				
LSMean ^a	xx.x	xx.x	x.xxx ^b	x.xxx ^a
LSSD ^a	xx.xx	xx.xx		x.xxx ^c

^a Least squares means, standard deviations and treatment p-value from an analysis of covariance with factors of treatment and analysis center and the respective Baseline lesion count as a covariate. Negative least squares means values represent decrease from Baseline.

^b Skewness test, based on methods presented by J.H. Zar (1984), assessed for each imputed dataset. The average p-value is presented.

^c P-value from a ranked analysis of covariance with factors of treatment and analysis center and the respective Baseline lesion count as a covariate.

^d P-value from a logistic regression with factors of treatment group and analysis center.

Note: Multiple imputation (MCMC) used to impute missing values.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Table 14.2.8.1: Secondary Efficacy Analyses
(Intent-to-Treat Population)
(Page 3 of 3)

	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)	Skewness P-Value	Treatment P-Value
Inflammatory Lesion Count – Absolute Change from Baseline to Week 4				
LSMean ^a	xx.x	xx.x	x.xxx ^b	x.xxx ^a
LSSD ^a	xx.xx	xx.xx		x.xxx ^c
Non-Inflammatory Lesion Count – Absolute Change from Baseline to Week 4				
LSMean ^a	xx.x	xx.x	x.xxx ^b	x.xxx ^a
LSSD ^a	xx.xx	xx.xx		x.xxx ^c

^a Least squares means, standard deviations and treatment p-value from an analysis of covariance with factors of treatment and analysis center and the respective Baseline lesion count as a covariate. Negative least squares means values represent decrease from Baseline.

^b Skewness test, based on methods presented by J.H. Zar (1984), assessed for each imputed dataset. The average p-value is presented.

^c P-value from a ranked analysis of covariance with factors of treatment and analysis center and the respective Baseline lesion count as a covariate.

^d P-value from a logistic regression with factors of treatment group and analysis center.

Note: Multiple imputation (MCMC) used to impute missing values.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Repeat Table 14.2.8.1 for the following table:

Table 14.2.8.2: Secondary Efficacy Analyses (Per-Protocol Population)

Change footnote to “Note: Missing values imputed using last observation carried forward.”

Table 14.2.9.1: Summary of Patient-Reported Evaluation of Facial Acne (PRE-FACE) at Each Evaluation
(Intent-to-Treat Population)
(Page 1 of 28)

Rate the pimples on your face today ^a	E-BPO/E-ATRA 3%/0.1% Cream	Vehicle Cream
	(N=xxx)	(N=xxx)
Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Week 2		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
At Least 4-Point Reduction from Baseline		
Success	xx.x%	xx.x%
Failure	xx.x%	xx.x%

^a Multiple imputation used to impute missing values for only item 1 (pimples) and item 5 (embarrassment).

Note: 0 = No pimples, 10 = Pimples as bad as you can imagine

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.9.1: Summary of Patient-Reported Evaluation of Facial Acne (PRE-FACE) at Each Evaluation
(Intent-to-Treat Population)
(Page 2 of 28)

	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Rate the pimples on your face today^a		
Week 4		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
At Least 4-Point Reduction from Baseline		
Success	xx.x%	xx.x%
Failure	xx.x%	xx.x%

^a Multiple imputation used to impute missing values for only item 1 (pimples) and item 5 (embarrassment).

Note: 0 = No pimples, 10 = Pimples as bad as you can imagine

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.9.1: Summary of Patient-Reported Evaluation of Facial Acne (PRE-FACE) at Each Evaluation
(Intent-to-Treat Population)
(Page 3 of 28)

	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Rate the pimples on your face today^a		
Week 8		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
At Least 4-Point Reduction from Baseline		
Success	xx.x%	xx.x%
Failure	xx.x%	xx.x%

^a Multiple imputation used to impute missing values for only item 1 (pimples) and item 5 (embarrassment).

Note: 0 = No pimples, 10 = Pimples as bad as you can imagine

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.9.1: Summary of Patient-Reported Evaluation of Facial Acne (PRE-FACE) at Each Evaluation
(Intent-to-Treat Population)
(Page 4 of 28)

	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Rate the pimples on your face today^a		
Week 12		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
At Least 4-Point Reduction from Baseline		
Success	xx.x%	xx.x%
Failure	xx.x%	xx.x%

^a Multiple imputation used to impute missing values for only item 1 (pimples) and item 5 (embarrassment).

Note: 0 = No pimples, 10 = Pimples as bad as you can imagine

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.9.1 Summary of Patient-Reported Evaluation of Facial Acne (PRE-FACE) at Each Evaluation
(Intent-to-Treat Population)
(Page 5 of 28)

	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Rate the blackheads on your face today		
Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Week 2		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
At Least 4-Point Reduction from Baseline		
Success	xx (xx.x%)	xx (xx.x%)
Failure	xx (xx.x%)	xx (xx.x%)

^a Multiple imputation used to impute missing values for only item 1 (pimples) and item 5 (embarrassment).

Note: 0 = No blackheads, 10 = Blackheads as bad as you can imagine

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.9.1: Summary of Patient-Reported Evaluation of Facial Acne (PRE-FACE) at Each Evaluation
(Intent-to-Treat Population)
(Page 6 of 28)

	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Rate the blackheads on your face today		
Week 4		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
At Least 4-Point Reduction from Baseline		
Success	xx (xx.x%)	xx (xx.x%)
Failure	xx (xx.x%)	xx (xx.x%)

^a Multiple imputation used to impute missing values for only item 1 (pimples) and item 5 (embarrassment).

Note: 0 = No blackheads, 10 = Blackheads as bad as you can imagine

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.9.1: Summary of Patient-Reported Evaluation of Facial Acne (PRE-FACE) at Each Evaluation
(Intent-to-Treat Population)
(Page 7 of 28)

	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Rate the blackheads on your face today		
Week 8		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
At Least 4-Point Reduction from Baseline		
Success	xx (xx.x%)	xx (xx.x%)
Failure	xx (xx.x%)	xx (xx.x%)

^a Multiple imputation used to impute missing values for only item 1 (pimples) and item 5 (embarrassment).

Note: 0 = No blackheads, 10 = Blackheads as bad as you can imagine

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.9.1: Summary of Patient-Reported Evaluation of Facial Acne (PRE-FACE) at Each Evaluation
(Intent-to-Treat Population)
(Page 8 of 28)

	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Rate the blackheads on your face today		
Week 12		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
At Least 4-Point Reduction from Baseline		
Success	xx (xx.x%)	xx (xx.x%)
Failure	xx (xx.x%)	xx (xx.x%)

^a Multiple imputation used to impute missing values for only item 1 (pimples) and item 5 (embarrassment).

Note: 0 = No blackheads, 10 = Blackheads as bad as you can imagine

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.9.1 Summary of Patient-Reported Evaluation of Facial Acne (PRE-FACE) at Each Evaluation
(Intent-to-Treat Population)
(Page 9 of 28)

	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Rate the whiteheads on your face today		
Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Week 2		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
At Least 4-Point Reduction from Baseline		
Success	xx (xx.x%)	xx (xx.x%)
Failure	xx (xx.x%)	xx (xx.x%)

^a Multiple imputation used to impute missing values for only item 1 (pimples) and item 5 (embarrassment).

Note: 0 = No whiteheads, 10 = Whiteheads as bad as you can imagine

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.9.1: Summary of Patient-Reported Evaluation of Facial Acne (PRE-FACE) at Each Evaluation
(Intent-to-Treat Population)
(Page 10 of 28)

	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Rate the whiteheads on your face today		
Week 4		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
At Least 4-Point Reduction from Baseline		
Success	xx (xx.x%)	xx (xx.x%)
Failure	xx (xx.x%)	xx (xx.x%)

^a Multiple imputation used to impute missing values for only item 1 (pimples) and item 5 (embarrassment).

Note: 0 = No whiteheads, 10 = Whiteheads as bad as you can imagine

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.9.1: Summary of Patient-Reported Evaluation of Facial Acne (PRE-FACE) at Each Evaluation
(Intent-to-Treat Population)
(Page 11 of 28)

	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Rate the whiteheads on your face today		
Week 8		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
At Least 4-Point Reduction from Baseline		
Success	xx (xx.x%)	xx (xx.x%)
Failure	xx (xx.x%)	xx (xx.x%)

^a Multiple imputation used to impute missing values for only item 1 (pimples) and item 5 (embarrassment).

Note: 0 = No whiteheads, 10 = Whiteheads as bad as you can imagine

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.9.1: Summary of Patient-Reported Evaluation of Facial Acne (PRE-FACE) at Each Evaluation
(Intent-to-Treat Population)
(Page 12 of 28)

	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Rate the whiteheads on your face today		
Week 12		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
At Least 4-Point Reduction from Baseline		
Success	xx (xx.x%)	xx (xx.x%)
Failure	xx (xx.x%)	xx (xx.x%)

^a Multiple imputation used to impute missing values for only item 1 (pimples) and item 5 (embarrassment).

Note: 0 = No whiteheads, 10 = Whiteheads as bad as you can imagine

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.9.1 Summary of Patient-Reported Evaluation of Facial Acne (PRE-FACE) at Each Evaluation
(Intent-to-Treat Population)
(Page 13 of 28)

	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Rate the redness on your face today		
Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Week 2		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
At Least 4-Point Reduction from Baseline		
Success	xx (xx.x%)	xx (xx.x%)
Failure	xx (xx.x%)	xx (xx.x%)

^a Multiple imputation used to impute missing values for only item 1 (pimples) and item 5 (embarrassment).

Note: 0 = No redness, 10 = Redness as bad as you can imagine

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.9.1: Summary of Patient-Reported Evaluation of Facial Acne (PRE-FACE) at Each Evaluation
(Intent-to-Treat Population)
(Page 14 of 28)

	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Rate the redness on your face today		
Week 4		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
At Least 4-Point Reduction from Baseline		
Success	xx (xx.x%)	xx (xx.x%)
Failure	xx (xx.x%)	xx (xx.x%)

^a Multiple imputation used to impute missing values for only item 1 (pimples) and item 5 (embarrassment).

Note: 0 = No redness, 10 = Redness as bad as you can imagine

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.9.1: Summary of Patient-Reported Evaluation of Facial Acne (PRE-FACE) at Each Evaluation
(Intent-to-Treat Population)
(Page 15 of 28)

	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Rate the redness on your face today		
Week 8		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
At Least 4-Point Reduction from Baseline		
Success	xx (xx.x%)	xx (xx.x%)
Failure	xx (xx.x%)	xx (xx.x%)

^a Multiple imputation used to impute missing values for only item 1 (pimples) and item 5 (embarrassment).

Note: 0 = No redness, 10 = Redness as bad as you can imagine

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.9.1: Summary of Patient-Reported Evaluation of Facial Acne (PRE-FACE) at Each Evaluation
(Intent-to-Treat Population)
(Page 16 of 28)

	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Rate the redness on your face today		
Week 12		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
At Least 4-Point Reduction from Baseline		
Success	xx (xx.x%)	xx (xx.x%)
Failure	xx (xx.x%)	xx (xx.x%)

^a Multiple imputation used to impute missing values for only item 1 (pimples) and item 5 (embarrassment).

Note: 0 = No redness, 10 = Redness as bad as you can imagine

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.9.1 Summary of Patient-Reported Evaluation of Facial Acne (PRE-FACE) at Each Evaluation
(Intent-to-Treat Population)
(Page 17 of 28)

Over the past seven days, rate how embarrassed you felt because of the acne on your face ^a	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Week 2		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
At Least 4-Point Reduction from Baseline		
Success	xx.x%	xx.x%
Failure	xx.x%	xx.x%

^a Multiple imputation used to impute missing values for only item 1 (pimples) and item 5 (embarrassment).

Note: 0 = Not embarrassed at all, 10 = Extremely embarrassed

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.9.1: Summary of Patient-Reported Evaluation of Facial Acne (PRE-FACE) at Each Evaluation
(Intent-to-Treat Population)
(Page 18 of 28)

Over the past seven days, rate how embarrassed you felt because of the acne on your face ^a	E-BPO/E-ATRA 3%/0.1% Cream	Vehicle Cream
	(N=xxx)	(N=xxx)
Week 4		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
At Least 4-Point Reduction from Baseline		
Success	xx.x%	xx.x%
Failure	xx.x%	xx.x%

^a Multiple imputation used to impute missing values for only item 1 (pimples) and item 5 (embarrassment).

Note: 0 = Not embarrassed at all, 10 = Extremely embarrassed

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.9.1: Summary of Patient-Reported Evaluation of Facial Acne (PRE-FACE) at Each Evaluation
(Intent-to-Treat Population)
(Page 19 of 28)

Over the past seven days, rate how embarrassed you felt because of the acne on your face ^a	E-BPO/E-ATRA 3%/0.1% Cream	Vehicle Cream
	(N=xxx)	(N=xxx)
Week 8		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
At Least 4-Point Reduction from Baseline		
Success	xx.x%	xx.x%
Failure	xx.x%	xx.x%

^a Multiple imputation used to impute missing values for only item 1 (pimples) and item 5 (embarrassment).

Note: 0 = Not embarrassed at all, 10 = Extremely embarrassed

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.9.1: Summary of Patient-Reported Evaluation of Facial Acne (PRE-FACE) at Each Evaluation
(Intent-to-Treat Population)
(Page 20 of 28)

Over the past seven days, rate how embarrassed you felt because of the acne on your face ^a	E-BPO/E-ATRA 3%/0.1% Cream	Vehicle Cream
	(N=xxx)	(N=xxx)
Week 12		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
At Least 4-Point Reduction from Baseline		
Success	xx.x%	xx.x%
Failure	xx.x%	xx.x%

^a Multiple imputation used to impute missing values for only item 1 (pimples) and item 5 (embarrassment).

Note: 0 = Not embarrassed at all, 10 = Extremely embarrassed

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.9.1 Summary of Patient-Reported Evaluation of Facial Acne (PRE-FACE) at Each Evaluation
(Intent-to-Treat Population)
(Page 21 of 28)

Over the past seven days, rate how self-conscious you felt because of the acne on your face.	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Week 2		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
At Least 4-Point Reduction from Baseline		
Success	xx (xx.x%)	xx (xx.x%)
Failure	xx (xx.x%)	xx (xx.x%)

^a Multiple imputation used to impute missing values for only item 1 (pimples) and item 5 (embarrassment).

Note: 0 = Not self-conscious at all, 10 = Extremely self-conscious

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.9.1: Summary of Patient-Reported Evaluation of Facial Acne (PRE-FACE) at Each Evaluation
(Intent-to-Treat Population)
(Page 22 of 28)

Over the past seven days, rate how self-conscious you felt because of the acne on your face.	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Week 4		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
At Least 4-Point Reduction from Baseline		
Success	xx (xx.x%)	xx (xx.x%)
Failure	xx (xx.x%)	xx (xx.x%)

^a Multiple imputation used to impute missing values for only item 1 (pimples) and item 5 (embarrassment).

Note: 0 = Not self-conscious at all, 10 = Extremely self-conscious

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.9.1: Summary of Patient-Reported Evaluation of Facial Acne (PRE-FACE) at Each Evaluation
(Intent-to-Treat Population)
(Page 23 of 28)

Over the past seven days, rate how self-conscious you felt because of the acne on your face.	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Week 8		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
At Least 4-Point Reduction from Baseline		
Success	xx (xx.x%)	xx (xx.x%)
Failure	xx (xx.x%)	xx (xx.x%)

^a Multiple imputation used to impute missing values for only item 1 (pimples) and item 5 (embarrassment).

Note: 0 = Not self-conscious at all, 10 = Extremely self-conscious

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.9.1: Summary of Patient-Reported Evaluation of Facial Acne (PRE-FACE) at Each Evaluation
(Intent-to-Treat Population)
(Page 24 of 28)

Over the past seven days, rate how self-conscious you felt because of the acne on your face.	E-BPO/E-ATRA 3%/0.1% Cream	Vehicle Cream
	(N=xxx)	(N=xxx)
Week 12		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
At Least 4-Point Reduction from Baseline		
Success	xx (xx.x%)	xx (xx.x%)
Failure	xx (xx.x%)	xx (xx.x%)

^a Multiple imputation used to impute missing values for only item 1 (pimples) and item 5 (embarrassment).

Note: 0 = Not self-conscious at all, 10 = Extremely self-conscious

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.9.1 Summary of Patient-Reported Evaluation of Facial Acne (PRE-FACE) at Each Evaluation
(Intent-to-Treat Population)
(Page 25 of 28)

Over the past seven days, rate how sad you felt because of the acne on your face.	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Week 2		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
At Least 4-Point Reduction from Baseline		
Success	xx (xx.x%)	xx (xx.x%)
Failure	xx (xx.x%)	xx (xx.x%)

^a Multiple imputation used to impute missing values for only item 1 (pimples) and item 5 (embarrassment).

Note: 0 = Not sad at all, 10 = Extremely sad

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.9.1: Summary of Patient-Reported Evaluation of Facial Acne (PRE-FACE) at Each Evaluation
(Intent-to-Treat Population)
(Page 26 of 28)

Over the past seven days, rate how sad you felt because of the acne on your face.	E-BPO/E-ATRA 3%/0.1% Cream	Vehicle Cream
	(N=xxx)	(N=xxx)
Week 4		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
At Least 4-Point Reduction from Baseline		
Success	xx (xx.x%)	xx (xx.x%)
Failure	xx (xx.x%)	xx (xx.x%)

^a Multiple imputation used to impute missing values for only item 1 (pimples) and item 5 (embarrassment).

Note: 0 = Not sad at all, 10 = Extremely sad

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.9.1: Summary of Patient-Reported Evaluation of Facial Acne (PRE-FACE) at Each Evaluation
(Intent-to-Treat Population)
(Page 27 of 28)

Over the past seven days, rate how sad you felt because of the acne on your face.	E-BPO/E-ATRA 3%/0.1% Cream	Vehicle Cream
	(N=xxx)	(N=xxx)
Week 8		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
At Least 4-Point Reduction from Baseline		
Success	xx (xx.x%)	xx (xx.x%)
Failure	xx (xx.x%)	xx (xx.x%)

^a Multiple imputation used to impute missing values for only item 1 (pimples) and item 5 (embarrassment).

Note: 0 = Not sad at all, 10 = Extremely sad

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.9.1: Summary of Patient-Reported Evaluation of Facial Acne (PRE-FACE) at Each Evaluation
(Intent-to-Treat Population)
(Page 28 of 28)

Over the past seven days, rate how sad you felt because of the acne on your face.	E-BPO/E-ATRA 3%/0.1% Cream	Vehicle Cream
	(N=xxx)	(N=xxx)
Week 12		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
At Least 4-Point Reduction from Baseline		
Success	xx (xx.x%)	xx (xx.x%)
Failure	xx (xx.x%)	xx (xx.x%)

^a Multiple imputation used to impute missing values for only item 1 (pimples) and item 5 (embarrassment).

Note: 0 = Not sad at all, 10 = Extremely sad

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Repeat Table 14.2.9.1 for the following table:

Table 14.2.9.2: Summary of Patient-Reported Evaluation of Facial Acne (PRE-FACE) at Each Evaluation (Per-Protocol Population)

Change footnote to “Last observation carried forward used to impute missing values for only item 1 (pimples) and item 5 (embarrassment).

Table 14.2.10.1: Supportive Efficacy Analyses: PGI-TS, PGI-S, and PGI-C at Week 12
(Intent-to-Treat Population)

	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)	Treatment P-Value
Patient Global Impression of Treatment Satisfaction (PGI-TS) at Week 12			
0 - I am very satisfied	xx (xx.x ⁰ %)	xx (xx.x ⁰ %)	x.xxx ^b
1 - I am satisfied	xx (xx.x ⁰ %)	xx (xx.x ⁰ %)	
2 - I am neither satisfied nor dissatisfied	xx (xx.x ⁰ %)	xx (xx.x ⁰ %)	
3 - I am dissatisfied	xx (xx.x ⁰ %)	xx (xx.x ⁰ %)	
4 - I am very dissatisfied	xx (xx.x ⁰ %)	xx (xx.x ⁰ %)	
Patient Global Impression of Symptom Severity (PGI-S) at Week 12			
0 - None: no pimples, clear skin	xx (xx.x ⁰ %)	xx (xx.x ⁰ %)	x.xxx ^b
1 - Mild: very few pimples, almost clear skin	xx (xx.x ⁰ %)	xx (xx.x ⁰ %)	
2 - Moderate: some pimples	xx (xx.x ⁰ %)	xx (xx.x ⁰ %)	
3 - Severe: many pimples, almost no clear skin	xx (xx.x ⁰ %)	xx (xx.x ⁰ %)	
4 - Very severe: Large amount of pimples, no clear skin	xx (xx.x ⁰ %)	xx (xx.x ⁰ %)	
At Least “Minimally Improved” in PGI-C from Baseline to Week 12			
Success	xx.x ⁰ %	xx.x ⁰ %	x.xxx ^a
Failure	xx.x ⁰ %	xx.x ⁰ %	

^a P-value from a logistic regression with factors of treatment group and analysis center.

^b P-value from a cumulative logistic regression with factors of treatment group and analysis center.

Note: No imputation of missing values.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

{NOTE TO PROGRAMMER: ADJUST FOOTNOTE “d” IF FIRTH’S PENALIZED LIKELIHOOD IS NEEDED}

Table 14.2.11.1: Supportive Efficacy Analyses: Lesion Count and IGA
(Intent-to-Treat Population)
(Page 1 of 3)

	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)	Skewness P-Value	Treatment P-Value
At Least Two Grade Reduction from Baseline and Achieving Clear or Almost Clear at Week 8				
Success	xx.x%	xx.x%	N/A	x.xxx ^d
Failure	xx.x%	xx.x%		

^a Least squares means, standard deviations and treatment p-value from an analysis of covariance with factors of treatment and analysis center and the respective Baseline lesion count as a covariate. Negative least squares means values represent decrease from Baseline.

^b Skewness test, based on methods presented by J.H. Zar (1984), assessed for each imputed dataset.

^c P-value from a ranked analysis of covariance with factors of treatment and analysis center and the respective Baseline lesion count as a covariate.

^d P-value from a logistic regression with factors of treatment group and analysis center.

Note: Multiple imputation (MCMC) used to impute missing values.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Table 14.2.11.1: Supportive Efficacy Analyses: Lesion Count and IGA
(Intent-to-Treat Population)
(Page 2 of 3)

	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)	Skewness P-Value	Treatment P-Value
At Least Two Grade Reduction from Baseline and Achieving Clear or Almost Clear at Week 4				
Success	xx.x%	xx.x%	N/A	x.xxx ^d
Failure	xx.x%	xx.x%		

^a Least squares means, standard deviations and treatment p-value from an analysis of covariance with factors of treatment and analysis center and the respective Baseline lesion count as a covariate. Negative least squares means values represent decrease from Baseline.

^b Skewness test, based on methods presented by J.H. Zar (1984), assessed for each imputed dataset.

^c P-value from a ranked analysis of covariance with factors of treatment and analysis center and the respective Baseline lesion count as a covariate.

^d P-value from a logistic regression with factors of treatment group and analysis center.

Note: Multiple imputation (MCMC) used to impute missing values.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Table 14.2.11.1: Supportive Efficacy Analyses: Lesion Count and IGA
(Intent-to-Treat Population)
(Page 3 of 3)

	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)	Skewness P-Value	Treatment P-Value
Inflammatory Lesion Count –Absolute Change from Baseline to Week 2				
LSMean ^a	xx.x	xx.x	x.xxx ^b	x.xxx ^a
LSSD ^a	xx.xx	xx.xx		x.xxx ^c
Non-Inflammatory Lesion Count –Absolute Change from Baseline to Week 2				
LSMean ^a	xx.x	xx.x	x.xxx ^b	x.xxx ^a
LSSD ^a	xx.xx	xx.xx		x.xxx ^c
At Least Two Grade Reduction from Baseline and Achieving Clear or Almost Clear at Week 2				
Success	xx.x%	xx.x%	N/A	x.xxx ^d
Failure	xx.x%	xx.x%		

^a Least squares means, standard deviations and treatment p-value from an analysis of covariance with factors of treatment and analysis center and the respective Baseline lesion count as a covariate. Negative least squares means values represent decrease from Baseline.

^b Skewness test, based on methods presented by J.H. Zar (1984), assessed for each imputed dataset.

^c P-value from a ranked analysis of covariance with factors of treatment and analysis center and the respective Baseline lesion count as a covariate.

^d P-value from a logistic regression with factors of treatment group and analysis center.

Note: Multiple imputation (MCMC) used to impute missing values.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Table 14.2.12.1: Supportive Efficacy Analyses: PRE-FACE ASD Scores
(Intent-to-Treat Population)
(Page 1 of 3)

	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)	Skewness P-Value	Treatment P-Value
PRE-FACE Item 1 (Pimples) –Absolute Change from Baseline to Week 8 ^d				
LSMean ^a	xx.x	xx.x	x.xxx ^b	x.xxx ^a
LSSD ^a	xx.xx	xx.xx		x.xxx ^c
PRE-FACE Item 2 (Blackheads) –Absolute Change from Baseline to Week 8				
LSMean ^a	xx.x	xx.x	x.xxx ^b	x.xxx ^a
LSSD ^a	xx.xx	xx.xx		x.xxx ^c
PRE-FACE Item 3 (Whiteheads) –Absolute Change from Baseline to Week 8				
LSMean ^a	xx.x	xx.x	x.xxx ^b	x.xxx ^a
LSSD ^a	xx.xx	xx.xx		x.xxx ^c
PRE-FACE Item 4 (Redness) –Absolute Change from Baseline to Week 8				
LSMean ^a	xx.x	xx.x	x.xxx ^b	x.xxx ^a
LSSD ^a	xx.xx	xx.xx		x.xxx ^c

^a Least squares means, standard deviations and treatment p-value from an analysis of covariance with factors of treatment and analysis center and the respective Baseline lesion count as a covariate. Negative least squares means values represent decrease from Baseline.

^b Skewness test, based on methods presented by J.H. Zar (1984), assessed for each imputed dataset.

^c P-value from a ranked analysis of covariance with factors of treatment and analysis center and the respective Baseline lesion count as a covariate.

^d Multiple imputation used to impute missing values for only item 1 (pimples).

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Table 14.2.12.1: Supportive Efficacy Analyses: PRE-FACE ASD Scores
(Intent-to-Treat Population)
(Page 2 of 3)

	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)	Skewness P-Value	Treatment P-Value
PRE-FACE Item 1 (Pimples) –Absolute Change from Baseline to Week 4 ^d				
LSMean ^a	xx.x	xx.x	x.xxx ^b	x.xxx ^a
LSSD ^a	xx.xx	xx.xx		x.xxx ^c
PRE-FACE Item 2 (Blackheads) –Absolute Change from Baseline to Week 4				
LSMean ^a	xx.x	xx.x	x.xxx ^b	x.xxx ^a
LSSD ^a	xx.xx	xx.xx		x.xxx ^c
PRE-FACE Item 3 (Whiteheads) –Absolute Change from Baseline to Week 4				
LSMean ^a	xx.x	xx.x	x.xxx ^b	x.xxx ^a
LSSD ^a	xx.xx	xx.xx		x.xxx ^c
PRE-FACE Item 4 (Redness) –Absolute Change from Baseline to Week 4				
LSMean ^a	xx.x	xx.x	x.xxx ^b	x.xxx ^a
LSSD ^a	xx.xx	xx.xx		x.xxx ^c

^a Least squares means, standard deviations and treatment p-value from an analysis of covariance with factors of treatment and analysis center and the respective Baseline lesion count as a covariate. Negative least squares means values represent decrease from Baseline.

^b Skewness test, based on methods presented by J.H. Zar (1984), assessed for each imputed dataset.

^c P-value from a ranked analysis of covariance with factors of treatment and analysis center and the respective Baseline lesion count as a covariate.

^d Multiple imputation used to impute missing values for only item 1 (pimples).

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Table 14.2.12.1: Supportive Efficacy Analyses: PRE-FACE ASD Scores
(Intent-to-Treat Population)
(Page 3 of 3)

	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)	Skewness P-Value	Treatment P-Value
PRE-FACE Item 1 (Pimples) –Absolute Change from Baseline to Week 2 ^d				
LSMean ^a	xx.x	xx.x	x.xxx ^b	x.xxx ^a
LSSD ^a	xx.xx	xx.xx		x.xxx ^c
PRE-FACE Item 2 (Blackheads) –Absolute Change from Baseline to Week 2				
LSMean ^a	xx.x	xx.x	x.xxx ^b	x.xxx ^a
LSSD ^a	xx.xx	xx.xx		x.xxx ^c
PRE-FACE Item 3 (Whiteheads) –Absolute Change from Baseline to Week 2				
LSMean ^a	xx.x	xx.x	x.xxx ^b	x.xxx ^a
LSSD ^a	xx.xx	xx.xx		x.xxx ^c
PRE-FACE Item 4 (Redness) –Absolute Change from Baseline to Week 2				
LSMean ^a	xx.x	xx.x	x.xxx ^b	x.xxx ^a
LSSD ^a	xx.xx	xx.xx		x.xxx ^c

^a Least squares means, standard deviations and treatment p-value from an analysis of covariance with factors of treatment and analysis center and the respective Baseline lesion count as a covariate. Negative least squares means values represent decrease from Baseline.

^b Skewness test, based on methods presented by J.H. Zar (1984), assessed for each imputed dataset.

^c P-value from a ranked analysis of covariance with factors of treatment and analysis center and the respective Baseline lesion count as a covariate.

^d Multiple imputation used to impute missing values for only item 1 (pimples).

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Table 14.2.13.1: Supportive Efficacy Analyses: PRE-FACE AID Scores
(Intent-to-Treat Population)
(Page 1 of 3)

	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)	Skewness P-Value	Treatment P-Value
PRE-FACE Item 5 (Embarrassed) –Absolute Change from Baseline to Week 8 ^d				
LSMean ^a	xx.x	xx.x	x.xxx ^b	x.xxx ^a
LSSD ^a	xx.xx	xx.xx		x.xxx ^c
PRE-FACE Item 6 (Self-Conscious) –Absolute Change from Baseline to Week 8				
LSMean ^a	xx.x	xx.x	x.xxx ^b	x.xxx ^a
LSSD ^a	xx.xx	xx.xx		x.xxx ^c
PRE-FACE Item 7 (Sad) –Absolute Change from Baseline to Week 8				
LSMean ^a	xx.x	xx.x	x.xxx ^b	x.xxx ^a
LSSD ^a	xx.xx	xx.xx		x.xxx ^c

^a Least squares means, standard deviations and treatment p-value from an analysis of covariance with factors of treatment and analysis center and the respective Baseline lesion count as a covariate. Negative least squares means values represent decrease from Baseline.

^b Skewness test, based on methods presented by J.H. Zar (1984), assessed for each imputed dataset.

^c P-value from a ranked analysis of covariance with factors of treatment and analysis center and the respective Baseline lesion count as a covariate.

^d Multiple imputation used to impute missing values for only item 5 (embarrassed).

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Table 14.2.13.1: Supportive Efficacy Analyses: PRE-FACE AID Scores
(Intent-to-Treat Population)
(Page 2 of 3)

	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)	Skewness P-Value	Treatment P-Value
PRE-FACE Item 5 (Embarrassed) –Absolute Change from Baseline to Week 4 ^d				
LSMean ^a	xx.x	xx.x	x.xxx ^b	x.xxx ^a
LSSD ^a	xx.xx	xx.xx		x.xxx ^c
PRE-FACE Item 6 (Self-Conscious) –Absolute Change from Baseline to Week 4				
LSMean ^a	xx.x	xx.x	x.xxx ^b	x.xxx ^a
LSSD ^a	xx.xx	xx.xx		x.xxx ^c
PRE-FACE Item 7 (Sad) –Absolute Change from Baseline to Week 4				
LSMean ^a	xx.x	xx.x	x.xxx ^b	x.xxx ^a
LSSD ^a	xx.xx	xx.xx		x.xxx ^c

^a Least squares means, standard deviations and treatment p-value from an analysis of covariance with factors of treatment and analysis center and the respective Baseline lesion count as a covariate. Negative least squares means values represent decrease from Baseline.

^b Skewness test, based on methods presented by J.H. Zar (1984), assessed for each imputed dataset.

^c P-value from a ranked analysis of covariance with factors of treatment and analysis center and the respective Baseline lesion count as a covariate.

^d Multiple imputation used to impute missing values for only item 5 (embarrassed).

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Table 14.2.13.1: Supportive Efficacy Analyses: PRE-FACE AID Scores
(Intent-to-Treat Population)
(Page 3 of 3)

	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)	Skewness P-Value	Treatment P-Value
PRE-FACE Item 5 (Embarrassed) –Absolute Change from Baseline to Week 2 ^d				
LSMean ^a	xx.x	xx.x	x.xxx ^b	x.xxx ^a
LSSD ^a	xx.xx	xx.xx		x.xxx ^c
PRE-FACE Item 6 (Self-Conscious) –Absolute Change				
LSMean ^a	xx.x	xx.x	x.xxx ^b	x.xxx ^a
LSSD ^a	xx.xx	xx.xx		x.xxx ^c
PRE-FACE Item 7 (Sad) –Absolute Change from Baseline to Week 2				
LSMean ^a	xx.x	xx.x	x.xxx ^b	x.xxx ^a
LSSD ^a	xx.xx	xx.xx		x.xxx ^c

^a Least squares means, standard deviations and treatment p-value from an analysis of covariance with factors of treatment and analysis center and the respective Baseline lesion count as a covariate. Negative least squares means values represent decrease from Baseline.

^b Skewness test, based on methods presented by J.H. Zar (1984), assessed for each imputed dataset.

^c P-value from a ranked analysis of covariance with factors of treatment and analysis center and the respective Baseline lesion count as a covariate.

^d Multiple imputation used to impute missing values for only item 5 (embarrassed).

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Table 14.2.14.1: Summary of Patient Global Impression of Change (PGI-C) at Each Evaluation
(Intent-to-Treat Population)
(Page 1 of 2)

Since the start of the study, how have your acne symptoms changed?	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Week 2		
n	xx	xx
0 - Very much improved	xx (xx.x%)	xx (xx.x%)
1 - Much improved	xx (xx.x%)	xx (xx.x%)
2 - Minimally improved	xx (xx.x%)	xx (xx.x%)
3 - No Change	xx (xx.x%)	xx (xx.x%)
4 - Minimally worse	xx (xx.x%)	xx (xx.x%)
5 - Much worse	xx (xx.x%)	xx (xx.x%)
6 - Very much worse	xx (xx.x%)	xx (xx.x%)
At least minimally improved	xx (xx.x%)	xx (xx.x%)
Week 4		
n	xx	xx
0 - Very much improved	xx (xx.x%)	xx (xx.x%)
1 - Much improved	xx (xx.x%)	xx (xx.x%)
2 - Minimally improved	xx (xx.x%)	xx (xx.x%)
3 - No Change	xx (xx.x%)	xx (xx.x%)
4 - Minimally worse	xx (xx.x%)	xx (xx.x%)
5 - Much worse	xx (xx.x%)	xx (xx.x%)
6 - Very much worse	xx (xx.x%)	xx (xx.x%)
At least minimally improved	xx (xx.x%)	xx (xx.x%)

Note: No imputation of missing values. At least minimally improved defined as “very much improved”, “much improved”, or “minimally improved”.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.14.1: Summary of Patient Global Impression of Change (PGI-C) at Each Evaluation
(Intent-to-Treat Population)
(Page 2 of 2)

Since the start of the study, how have your acne symptoms changed?	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Week 8		
n	xx	xx
0 - Very much improved	xx (xx.x%)	xx (xx.x%)
1 - Much improved	xx (xx.x%)	xx (xx.x%)
2 - Minimally improved	xx (xx.x%)	xx (xx.x%)
3 - No Change	xx (xx.x%)	xx (xx.x%)
4 - Minimally worse	xx (xx.x%)	xx (xx.x%)
5 - Much worse	xx (xx.x%)	xx (xx.x%)
6 - Very much worse	xx (xx.x%)	xx (xx.x%)
At least minimally improved	xx (xx.x%)	xx (xx.x%)
Week 12		
n	xx	xx
0 - Very much improved	xx (xx.x%)	xx (xx.x%)
1 - Much improved	xx (xx.x%)	xx (xx.x%)
2 - Minimally improved	xx (xx.x%)	xx (xx.x%)
3 - No Change	xx (xx.x%)	xx (xx.x%)
4 - Minimally worse	xx (xx.x%)	xx (xx.x%)
5 - Much worse	xx (xx.x%)	xx (xx.x%)
6 - Very much worse	xx (xx.x%)	xx (xx.x%)
At least minimally improved	xx (xx.x%)	xx (xx.x%)

Note: No imputation of missing values. At least minimally improved defined as “very much improved”, “much improved”, or “minimally improved”.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.15.1: Summary of Patient Global Impression of Symptom Severity (PGI-S) at Each Evaluation
(Intent-to-Treat Population)
(Page 1 of 2)

Right now, my acne symptoms are:	E-BPO/E-ATRA 3%/0.1% Cream	Vehicle Cream
	(N=xxx)	(N=xxx)
Baseline		
n	xx	xx
0 - None: no pimples, clear skin	xx (xx.x%)	xx (xx.x%)
1 – Mild: very few pimples, almost clear skin	xx (xx.x%)	xx (xx.x%)
2 – Moderate: some pimples	xx (xx.x%)	xx (xx.x%)
3 – Severe: many pimples, almost no clear skin	xx (xx.x%)	xx (xx.x%)
4 – Very severe: Large amount of pimples, no clear skin	xx (xx.x%)	xx (xx.x%)
Week 2		
n	xx	xx
0 - None: no pimples, clear skin	xx (xx.x%)	xx (xx.x%)
1 – Mild: very few pimples, almost clear skin	xx (xx.x%)	xx (xx.x%)
2 – Moderate: some pimples	xx (xx.x%)	xx (xx.x%)
3 – Severe: many pimples, almost no clear skin	xx (xx.x%)	xx (xx.x%)
4 – Very severe: Large amount of pimples, no clear skin	xx (xx.x%)	xx (xx.x%)
Week 4		
n	xx	xx
0 - None: no pimples, clear skin	xx (xx.x%)	xx (xx.x%)
1 – Mild: very few pimples, almost clear skin	xx (xx.x%)	xx (xx.x%)
2 – Moderate: some pimples	xx (xx.x%)	xx (xx.x%)
3 – Severe: many pimples, almost no clear skin	xx (xx.x%)	xx (xx.x%)
4 – Very severe: Large amount of pimples, no clear skin	xx (xx.x%)	xx (xx.x%)

Note: No imputation of missing values.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.15.1: Summary of Patient Global Impression of Symptom Severity (PGI-S) at Each Evaluation
(Intent-to-Treat Population)
(Page 2 of 2)

Right now, my acne symptoms are:	E-BPO/E-ATRA 3%/0.1% Cream	Vehicle Cream
	(N=xxx)	(N=xxx)
Week 8		
n	xx	xx
0 - None: no pimples, clear skin	xx (xx.x%)	xx (xx.x%)
1 - Mild: very few pimples, almost clear skin	xx (xx.x%)	xx (xx.x%)
2 - Moderate: some pimples	xx (xx.x%)	xx (xx.x%)
3 - Severe: many pimples, almost no clear skin	xx (xx.x%)	xx (xx.x%)
4 - Very severe: Large amount of pimples, no clear skin	xx (xx.x%)	xx (xx.x%)
Week 12		
n	xx	xx
0 - None: no pimples, clear skin	xx (xx.x%)	xx (xx.x%)
1 - Mild: very few pimples, almost clear skin	xx (xx.x%)	xx (xx.x%)
2 - Moderate: some pimples	xx (xx.x%)	xx (xx.x%)
3 - Severe: many pimples, almost no clear skin	xx (xx.x%)	xx (xx.x%)
4 - Very severe: Large amount of pimples, no clear skin	xx (xx.x%)	xx (xx.x%)

Note: No imputation of missing values.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.16.1: Summary of Patient Global Impression of Treatments Satisfaction (PGI-TS) at Each Evaluation
(Intent-to-Treat Population)
(Page 1 of 2)

Right now, how satisfied are you with your acne treatment:	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Week 2		
n	xx	xx
0 – I am very satisfied	xx (xx.x%)	xx (xx.x%)
1 – I am satisfied	xx (xx.x%)	xx (xx.x%)
2 – I am neither satisfied not dissatisfied	xx (xx.x%)	xx (xx.x%)
3 – I am dissatisfied	xx (xx.x%)	xx (xx.x%)
4 – I am very dissatisfied	xx (xx.x%)	xx (xx.x%)
Week 4		
n	xx	xx
0 – I am very satisfied	xx (xx.x%)	xx (xx.x%)
1 – I am satisfied	xx (xx.x%)	xx (xx.x%)
2 – I am neither satisfied not dissatisfied	xx (xx.x%)	xx (xx.x%)
3 – I am dissatisfied	xx (xx.x%)	xx (xx.x%)
4 – I am very dissatisfied	xx (xx.x%)	xx (xx.x%)

Note: No imputation of missing values.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.16.1: Summary of Patient Global Impression of Treatments Satisfaction (PGI-TS) at Each Evaluation
(Intent-to-Treat Population)
(Page 2 of 2)

Right now, how satisfied are you with your acne treatment:	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Week 8		
n	xx	xx
0 – I am very satisfied	xx (xx.x%)	xx (xx.x%)
1 – I am satisfied	xx (xx.x%)	xx (xx.x%)
2 – I am neither satisfied not dissatisfied	xx (xx.x%)	xx (xx.x%)
3 – I am dissatisfied	xx (xx.x%)	xx (xx.x%)
4 – I am very dissatisfied	xx (xx.x%)	xx (xx.x%)
Week 12		
n	xx	xx
0 – I am very satisfied	xx (xx.x%)	xx (xx.x%)
1 – I am satisfied	xx (xx.x%)	xx (xx.x%)
2 – I am neither satisfied not dissatisfied	xx (xx.x%)	xx (xx.x%)
3 – I am dissatisfied	xx (xx.x%)	xx (xx.x%)
4 – I am very dissatisfied	xx (xx.x%)	xx (xx.x%)

Note: No imputation of missing values.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.17.1: Summary of Acne-QoL Questionnaire Responses at Baseline and Week 12
(Intent-to-Treat Population)
(Page 1 of 4)

Self-Perception Domain	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Week 12		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Absolute Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx

Note: No imputation of missing values. Change calculated as Week 12 – Baseline. Negative values represent decrease from Baseline.

Self-Perception domain calculated from the questions 1, 2, 3, 6, and 10.

Role-Emotional domain calculated from questions 4, 5, 7, 8, and 9.

Role-Social domain calculated from questions 11, 12, 13, and 14.

Acne Symptoms domain calculated from questions 15, 16, 17, 18, and 19.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.17.1: Summary of Acne-QoL Questionnaire Responses at Baseline and Week 12
(Intent-to-Treat Population)
(Page 2 of 4)

Role-Emotional Domain	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Week 12		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Absolute Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx

Note: No imputation of missing values. Change calculated as Week 12 – Baseline. Negative values represent decrease from Baseline.

Self-Perception domain calculated from the questions 1, 2, 3, 6, and 10.

Role-Emotional domain calculated from questions 4, 5, 7, 8, and 9.

Role-Social domain calculated from questions 11, 12, 13, and 14.

Acne Symptoms domain calculated from questions 15, 16, 17, 18, and 19.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.17.1: Summary of Acne-QoL Questionnaire Responses at Baseline and Week 12
(Intent-to-Treat Population)
(Page 3 of 4)

Role-Social Domain	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Week 12		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Absolute Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx

Note: No imputation of missing values. Change calculated as Week 12 – Baseline. Negative values represent decrease from Baseline.
 Self-Perception domain calculated from the questions 1, 2, 3, 6, and 10.
 Role-Emotional domain calculated from questions 4, 5, 7, 8, and 9.
 Role-Social domain calculated from questions 11, 12, 13, and 14.
 Acne Symptoms domain calculated from questions 15, 16, 17, 18, and 19.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.2.17.1: Summary of Acne-QoL Questionnaire Responses at Baseline and Week 12
(Intent-to-Treat Population)
(Page 4 of 4)

Acne Symptoms Domain	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Week 12		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Absolute Change from Baseline		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx

Note: No imputation of missing values. Change calculated as Week 12 – Baseline. Negative values represent decrease from Baseline.

Self-Perception domain calculated from the questions 1, 2, 3, 6, and 10.

Role-Emotional domain calculated from questions 4, 5, 7, 8, and 9.

Role-Social domain calculated from questions 11, 12, 13, and 14.

Acne Symptoms domain calculated from questions 15, 16, 17, 18, and 19.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.3.0.1: Summary of Extent of Exposure
(Safety Population)

	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Total Number of Days of Exposure		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Total Number of Applications		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Total Number of Missed Applications		
n	xx	xx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Compliant ^a		
n	xx	xx
Yes	xx (xx.x%)	xx (xx.x%)
No	xx (xx.x%)	xx (xx.x%)

^a A subject was considered compliant with the dosing regimen if the subject applied 80-120% of the expected number of applications and did not miss more than 5 consecutive applications while enrolled in the study.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.3.1.1: Summary of Cutaneous Signs and Local Tolerability at Each Evaluation
(Safety Population)
(Page 1 of 14)

Erythema	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)		Vehicle Cream (N=xxx)	
Baseline				
n	xx		xx	
0 – None	xx (xx.x%)		xx (xx.x%)	
1 – Mild	xx (xx.x%)		xx (xx.x%)	
2 – Moderate	xx (xx.x%)		xx (xx.x%)	
3 – Severe	xx (xx.x%)		xx (xx.x%)	
Week 2				
n	xx		xx	
0 – None	xx (xx.x%)		xx (xx.x%)	
1 – Mild	xx (xx.x%)		xx (xx.x%)	
2 – Moderate	xx (xx.x%)		xx (xx.x%)	
3 – Severe	xx (xx.x%)		xx (xx.x%)	
Week 4				
n	xx		xx	
0 – None	xx (xx.x%)		xx (xx.x%)	
1 – Mild	xx (xx.x%)		xx (xx.x%)	
2 – Moderate	xx (xx.x%)		xx (xx.x%)	
3 – Severe	xx (xx.x%)		xx (xx.x%)	

Note: No imputation of missing data.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.3.1.1: Summary of Cutaneous Signs and Local Tolerability at Each Evaluation
(Safety Population)
(Page 2 of 14)

Erythema	E-BPO/E-ATRA 3%/0.1% Cream	Vehicle Cream
	(N=xxx)	(N=xxx)
Week 8		
n	xx	xx
0 – None	xx (xx.x%)	xx (xx.x%)
1 – Mild	xx (xx.x%)	xx (xx.x%)
2 – Moderate	xx (xx.x%)	xx (xx.x%)
3 – Severe	xx (xx.x%)	xx (xx.x%)
Week 12		
n	xx	xx
0 – None	xx (xx.x%)	xx (xx.x%)
1 – Mild	xx (xx.x%)	xx (xx.x%)
2 – Moderate	xx (xx.x%)	xx (xx.x%)
3 – Severe	xx (xx.x%)	xx (xx.x%)

Note: No imputation of missing data.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.3.1.1: Summary of Cutaneous Signs and Local Tolerability at Each Evaluation
(Safety Population)
(Page 3 of 14)

Scaling	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Baseline		
n	xx	xx
0 – None	xx (xx.x%)	xx (xx.x%)
1 – Mild	xx (xx.x%)	xx (xx.x%)
2 – Moderate	xx (xx.x%)	xx (xx.x%)
3 – Severe	xx (xx.x%)	xx (xx.x%)
Week 2		
n	xx	xx
0 – None	xx (xx.x%)	xx (xx.x%)
1 – Mild	xx (xx.x%)	xx (xx.x%)
2 – Moderate	xx (xx.x%)	xx (xx.x%)
3 – Severe	xx (xx.x%)	xx (xx.x%)
Week 4		
n	xx	xx
0 – None	xx (xx.x%)	xx (xx.x%)
1 – Mild	xx (xx.x%)	xx (xx.x%)
2 – Moderate	xx (xx.x%)	xx (xx.x%)
3 – Severe	xx (xx.x%)	xx (xx.x%)

Note: No imputation of missing data.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.3.1.1: Summary of Cutaneous Signs and Local Tolerability at Each Evaluation
(Safety Population)
(Page 4 of 14)

Scaling	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Week 8		
n	xx	xx
0 – None	xx (xx.x%)	xx (xx.x%)
1 – Mild	xx (xx.x%)	xx (xx.x%)
2 – Moderate	xx (xx.x%)	xx (xx.x%)
3 – Severe	xx (xx.x%)	xx (xx.x%)
Week 12		
n	xx	xx
0 – None	xx (xx.x%)	xx (xx.x%)
1 – Mild	xx (xx.x%)	xx (xx.x%)
2 – Moderate	xx (xx.x%)	xx (xx.x%)
3 – Severe	xx (xx.x%)	xx (xx.x%)

Note: No imputation of missing data.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.3.1.1: Summary of Cutaneous Signs and Local Tolerability at Each Evaluation
(Safety Population)
(Page 5 of 14)

Pigmentation	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)		Vehicle Cream (N=xxx)	
Baseline				
n	xx		xx	
0 – None	xx (xx.x%)		xx (xx.x%)	
1 – Mild	xx (xx.x%)		xx (xx.x%)	
2 – Moderate	xx (xx.x%)		xx (xx.x%)	
3 – Severe	xx (xx.x%)		xx (xx.x%)	
Week 2				
n	xx		xx	
0 – None	xx (xx.x%)		xx (xx.x%)	
1 – Mild	xx (xx.x%)		xx (xx.x%)	
2 – Moderate	xx (xx.x%)		xx (xx.x%)	
3 – Severe	xx (xx.x%)		xx (xx.x%)	
Week 4				
n	xx		xx	
0 – None	xx (xx.x%)		xx (xx.x%)	
1 – Mild	xx (xx.x%)		xx (xx.x%)	
2 – Moderate	xx (xx.x%)		xx (xx.x%)	
3 – Severe	xx (xx.x%)		xx (xx.x%)	

Note: No imputation of missing data.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.3.1.1: Summary of Cutaneous Signs and Local Tolerability at Each Evaluation
(Safety Population)
(Page 6 of 14)

Pigmentation	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Week 8		
n	xx	xx
0 – None	xx (xx.x%)	xx (xx.x%)
1 – Mild	xx (xx.x%)	xx (xx.x%)
2 – Moderate	xx (xx.x%)	xx (xx.x%)
3 – Severe	xx (xx.x%)	xx (xx.x%)
Week 12		
n	xx	xx
0 – None	xx (xx.x%)	xx (xx.x%)
1 – Mild	xx (xx.x%)	xx (xx.x%)
2 – Moderate	xx (xx.x%)	xx (xx.x%)
3 – Severe	xx (xx.x%)	xx (xx.x%)

Note: No imputation of missing data.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.3.1.1: Summary of Cutaneous Signs and Local Tolerability at Each Evaluation
(Safety Population)
(Page 7 of 14)

Dryness	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)		Vehicle Cream (N=xxx)	
Baseline				
n	xx		xx	
0 – None	xx (xx.x%)		xx (xx.x%)	
1 – Mild	xx (xx.x%)		xx (xx.x%)	
2 – Moderate	xx (xx.x%)		xx (xx.x%)	
3 – Severe	xx (xx.x%)		xx (xx.x%)	
Week 2				
n	xx		xx	
0 – None	xx (xx.x%)		xx (xx.x%)	
1 – Mild	xx (xx.x%)		xx (xx.x%)	
2 – Moderate	xx (xx.x%)		xx (xx.x%)	
3 – Severe	xx (xx.x%)		xx (xx.x%)	
Week 4				
n	xx		xx	
0 – None	xx (xx.x%)		xx (xx.x%)	
1 – Mild	xx (xx.x%)		xx (xx.x%)	
2 – Moderate	xx (xx.x%)		xx (xx.x%)	
3 – Severe	xx (xx.x%)		xx (xx.x%)	

Note: No imputation of missing data.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.3.1.1: Summary of Cutaneous Signs and Local Tolerability at Each Evaluation
(Safety Population)
(Page 8 of 14)

Dryness	E-BPO/E-ATRA 3%/0.1% Cream		Vehicle Cream	
	(N=xxx)		(N=xxx)	
Week 8				
n	xx		xx	
0 – None	xx (xx.x%)		xx (xx.x%)	
1 – Mild	xx (xx.x%)		xx (xx.x%)	
2 – Moderate	xx (xx.x%)		xx (xx.x%)	
3 – Severe	xx (xx.x%)		xx (xx.x%)	
Week 12				
n	xx		xx	
0 – None	xx (xx.x%)		xx (xx.x%)	
1 – Mild	xx (xx.x%)		xx (xx.x%)	
2 – Moderate	xx (xx.x%)		xx (xx.x%)	
3 – Severe	xx (xx.x%)		xx (xx.x%)	

Note: No imputation of missing data.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.3.1.1: Summary of Cutaneous Signs and Local Tolerability at Each Evaluation
(Safety Population)
(Page 9 of 14)

Itching	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)		Vehicle Cream (N=xxx)	
Baseline				
n	xx		xx	
0 – None	xx (xx.x%)		xx (xx.x%)	
1 – Mild	xx (xx.x%)		xx (xx.x%)	
2 – Moderate	xx (xx.x%)		xx (xx.x%)	
3 – Severe	xx (xx.x%)		xx (xx.x%)	
Week 2				
n	xx		xx	
0 – None	xx (xx.x%)		xx (xx.x%)	
1 – Mild	xx (xx.x%)		xx (xx.x%)	
2 – Moderate	xx (xx.x%)		xx (xx.x%)	
3 – Severe	xx (xx.x%)		xx (xx.x%)	
Week 4				
n	xx		xx	
0 – None	xx (xx.x%)		xx (xx.x%)	
1 – Mild	xx (xx.x%)		xx (xx.x%)	
2 – Moderate	xx (xx.x%)		xx (xx.x%)	
3 – Severe	xx (xx.x%)		xx (xx.x%)	

Note: No imputation of missing data.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.3.1.1: Summary of Cutaneous Signs and Local Tolerability at Each Evaluation
(Safety Population)
(Page 10 of 14)

Itching	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Week 8		
n	xx	xx
0 – None	xx (xx.x%)	xx (xx.x%)
1 – Mild	xx (xx.x%)	xx (xx.x%)
2 – Moderate	xx (xx.x%)	xx (xx.x%)
3 – Severe	xx (xx.x%)	xx (xx.x%)
Week 12		
n	xx	xx
0 – None	xx (xx.x%)	xx (xx.x%)
1 – Mild	xx (xx.x%)	xx (xx.x%)
2 – Moderate	xx (xx.x%)	xx (xx.x%)
3 – Severe	xx (xx.x%)	xx (xx.x%)

Note: No imputation of missing data.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.3.1.1: Summary of Cutaneous Signs and Local Tolerability at Each Evaluation
(Safety Population)
(Page 11 of 14)

	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Burning		
Baseline		
n	xx	xx
0 – None	xx (xx.x%)	xx (xx.x%)
1 – Mild	xx (xx.x%)	xx (xx.x%)
2 – Moderate	xx (xx.x%)	xx (xx.x%)
3 – Severe	xx (xx.x%)	xx (xx.x%)
Week 2		
n	xx	xx
0 – None	xx (xx.x%)	xx (xx.x%)
1 – Mild	xx (xx.x%)	xx (xx.x%)
2 – Moderate	xx (xx.x%)	xx (xx.x%)
3 – Severe	xx (xx.x%)	xx (xx.x%)
Week 4		
n	xx	xx
0 – None	xx (xx.x%)	xx (xx.x%)
1 – Mild	xx (xx.x%)	xx (xx.x%)
2 – Moderate	xx (xx.x%)	xx (xx.x%)
3 – Severe	xx (xx.x%)	xx (xx.x%)

Note: No imputation of missing data.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.3.1.1: Summary of Cutaneous Signs and Local Tolerability at Each Evaluation
(Safety Population)
(Page 12 of 14)

Burning	E-BPO/E-ATRA 3%/0.1% Cream	Vehicle Cream
	(N=xxx)	(N=xxx)
Week 8		
n	xx	xx
0 – None	xx (xx.x%)	xx (xx.x%)
1 – Mild	xx (xx.x%)	xx (xx.x%)
2 – Moderate	xx (xx.x%)	xx (xx.x%)
3 – Severe	xx (xx.x%)	xx (xx.x%)
Week 12		
n	xx	xx
0 – None	xx (xx.x%)	xx (xx.x%)
1 – Mild	xx (xx.x%)	xx (xx.x%)
2 – Moderate	xx (xx.x%)	xx (xx.x%)
3 – Severe	xx (xx.x%)	xx (xx.x%)

Note: No imputation of missing data.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.3.1.1: Summary of Cutaneous Signs and Local Tolerability at Each Evaluation
(Safety Population)
(Page 13 of 14)

Stinging	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)		Vehicle Cream (N=xxx)	
Baseline				
n	xx		xx	
0 – None	xx (xx.x%)		xx (xx.x%)	
1 – Mild	xx (xx.x%)		xx (xx.x%)	
2 – Moderate	xx (xx.x%)		xx (xx.x%)	
3 – Severe	xx (xx.x%)		xx (xx.x%)	
Week 2				
n	xx		xx	
0 – None	xx (xx.x%)		xx (xx.x%)	
1 – Mild	xx (xx.x%)		xx (xx.x%)	
2 – Moderate	xx (xx.x%)		xx (xx.x%)	
3 – Severe	xx (xx.x%)		xx (xx.x%)	
Week 4				
n	xx		xx	
0 – None	xx (xx.x%)		xx (xx.x%)	
1 – Mild	xx (xx.x%)		xx (xx.x%)	
2 – Moderate	xx (xx.x%)		xx (xx.x%)	
3 – Severe	xx (xx.x%)		xx (xx.x%)	

Note: No imputation of missing data.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.3.1.1: Summary of Cutaneous Signs and Local Tolerability at Each Evaluation
(Safety Population)
(Page 14 of 14)

Stinging	E-BPO/E-ATRA 3%/0.1% Cream		Vehicle Cream	
	(N=xxx)		(N=xxx)	
Week 8				
n	xx		xx	
0 – None	xx (xx.x%)		xx (xx.x%)	
1 – Mild	xx (xx.x%)		xx (xx.x%)	
2 – Moderate	xx (xx.x%)		xx (xx.x%)	
3 – Severe	xx (xx.x%)		xx (xx.x%)	
Week 12				
n	xx		xx	
0 – None	xx (xx.x%)		xx (xx.x%)	
1 – Mild	xx (xx.x%)		xx (xx.x%)	
2 – Moderate	xx (xx.x%)		xx (xx.x%)	
3 – Severe	xx (xx.x%)		xx (xx.x%)	

Note: No imputation of missing data.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.3.1.2.1: Summary of Treatment-Emergent Adverse Event Characteristics
(Safety Population)
(Page 1 of 2)

	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Subjects Reporting Any Treatment-Emergent Adverse Event	xx (xx.x%)	xx (xx.x%)
Number of Treatment-Emergent Adverse Events	xx	xx
Subjects Reporting Any Serious Treatment-Emergent Adverse Event	xx (xx.x%)	xx (xx.x%)
Number of Serious Treatment-Emergent Adverse Events	xx	xx
Subjects Reporting Treatment-Emergent Adverse Event with Outcome of Fatal	xx (xx.x%)	xx (xx.x%)
Number of Treatment-Emergent Adverse Events with Outcome of Fatal	xx	xx
Subjects Who Discontinued Study Drug Due to a Treatment-Emergent Adverse Event	xx (xx.x%)	xx (xx.x%)
Number of Treatment-Emergent Adverse Events Leading to Discontinuation of Study Drug	xx	xx
Subjects Who Discontinued from the Study Due to a Treatment-Emergent Adverse Event	xx (xx.x%)	xx (xx.x%)
Number of Treatment-Emergent Adverse Events Leading to Discontinuation of Study	xx	xx

Note: Treatment-emergent adverse events are those events that were not indicated as occurring prior to first application.
Related defined as “Definitely”, “Probably”, or “Possible”. Not Related defined as “Unlikely” or “Not related”.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Table 14.3.1.2.1: Summary of Treatment-Emergent Adverse Event Characteristics
(Safety Population)
(Page 2 of 2)

	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
By Maximum Severity		
Severe	xx (xx.x%)	xx (xx.x%)
Moderate	xx (xx.x%)	xx (xx.x%)
Mild	xx (xx.x%)	xx (xx.x%)
By Strongest Relationship to Study Drug		
Related	xx (xx.x%)	xx (xx.x%)
Not Related	xx (xx.x%)	xx (xx.x%)
Maximum Severity within Relationship to Study Drug		
Related		
Severe	xx (xx.x%)	xx (xx.x%)
Moderate	xx (xx.x%)	xx (xx.x%)
Mild	xx (xx.x%)	xx (xx.x%)
Not Related		
Severe	xx (xx.x%)	xx (xx.x%)
Moderate	xx (xx.x%)	xx (xx.x%)
Mild	xx (xx.x%)	xx (xx.x%)

Note: Treatment-emergent adverse events are those events that were not indicated as occurring prior to first application.
Related defined as “Definitely”, “Probably”, or “Possible”. Not Related defined as “Unlikely” or “Not related”.

SOURCE: USERNAME/SPONSOR/PROJECT/JOBNAME (DATE, TIME)

Table 14.3.1.2.2: Summary of Treatment-Emergent Adverse Events by MedDRA System Organ Class and Preferred Term
(Safety Population)
(Page 1 of x)

System Organ Class ^a Preferred Term	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)	P-Value ^b
XXXXXXXXXXXXXXXXXXXXXXXXXXXXX	xx (xx.x%)	xx (xx.x%)	x.xxx
XXXXXXXXXXXXXXXXXXXXXXXXXXXXX	xx (xx.x%)	xx (xx.x%)	x.xxx

^a Counts reflect numbers of subjects reporting one or more adverse events that map to MedDRA. At each level of summarization (System Organ Class or Preferred Term) subjects are counted once.

^b P-value for the difference between treatment groups from a Fisher's Exact test. The specific system organ classes and preferred terms analyzed will be those that are reported by at least one percent of the patients in any treatment group.

Note: MedDRA Version 21.0

Treatment-emergent adverse events are those events that were not indicated as occurring prior to first application.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Table 14.3.1.2.3: Summary of Treatment-Emergent Adverse Events by Severity
(Safety Population)
(Page 1 of x)

System Organ Class ^a Preferred Term	Severity	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
XXXXXXXXXXXXXXXXXXXXXXXXXXXX	Severe	xx (xx.x%)	xx (xx.x%)
	Moderate	xx (xx.x%)	xx (xx.x%)
	Mild	xx (xx.x%)	xx (xx.x%)
XXXXXXXXXXXXXXXXXXXXXXXXXXXX	Severe	xx (xx.x%)	xx (xx.x%)
	Moderate	xx (xx.x%)	xx (xx.x%)
	Mild	xx (xx.x%)	xx (xx.x%)

^a Counts reflect numbers of subjects reporting one or more adverse events that map to MedDRA. At each level of summarization (System Organ Class or Preferred Term) subjects are counted once under the greatest reported severity.

Note: MedDRA Version 21.0.

Treatment-emergent adverse events are those events that were not indicated as occurring prior to first application.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Table 14.3.1.2.4: Summary of Treatment-Emergent Adverse Events by Relationship to Study Drug
(Safety Population)
(Page 1 of xx)

System Organ Class ^a Preferred Term	Relationship	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx	Related	xx (xx.x%)	xx (xx.x%)
	Not Related	xx (xx.x%)	xx (xx.x%)
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx	Related	xx (xx.x%)	xx (xx.x%)
	Not Related	xx (xx.x%)	xx (xx.x%)

^a Counts reflect numbers of subjects reporting one or more adverse events that map to MedDRA. At each level of summarization (System Organ Class or Preferred Term) subjects are counted once under the greatest reported relationship.

Note: MedDRA Version 21.0.

Treatment-emergent adverse events are those events that were not indicated as occurring prior to first application.

Related defined as “Definitely”, “Probably”, or “Possible”. Not Related defined as “Unlikely” or “Not related”.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Table 14.3.1.3.1: Summary of Treatment-Emergent Serious Adverse Event Characteristics
(Safety Population)
(Page 1 of 2)

	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Subjects Reporting Any Serious Treatment-Emergent Adverse Event	xx (xx.x%)	xx (xx.x%)
Number of Serious Treatment-Emergent Adverse Events	xx	xx
Subjects Reporting Serious Treatment-Emergent Adverse Event with Outcome of Fatal	xx (xx.x%)	xx (xx.x%)
Number of Serious Treatment-Emergent Adverse Events with Outcome of Fatal	xx	xx
Subjects Who Discontinued Study Drug Due to a Serious Treatment-Emergent Adverse Event	xx (xx.x%)	xx (xx.x%)
Number of Serious Treatment-Emergent Adverse Events Leading to Discontinuation of Study Drug	xx	xx
Subjects Who Discontinued from the Study Due to a Serious Treatment-Emergent Adverse Event	xx (xx.x%)	xx (xx.x%)
Number of Serious Treatment-Emergent Adverse Events Leading to Discontinuation of Study	xx	xx

Note: Treatment-emergent adverse events are those events that were not indicated as occurring prior to first application.
Related defined as “Definitely”, “Probably”, or “Possible”. Not Related defined as “Unlikely” or “Not related”.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Table 14.3.1.3.1: Summary of Treatment-Emergent Serious Adverse Event Characteristics
(Safety Population)
(Page 2 of 2)

	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
By Maximum Severity		
Severe	xx (xx.x%)	xx (xx.x%)
Moderate	xx (xx.x%)	xx (xx.x%)
Mild	xx (xx.x%)	xx (xx.x%)
By Strongest Relationship to Study Drug		
Related	xx (xx.x%)	xx (xx.x%)
Not Related	xx (xx.x%)	xx (xx.x%)
Maximum Severity within Relationship to Study Drug		
Related		
Severe	xx (xx.x%)	xx (xx.x%)
Moderate	xx (xx.x%)	xx (xx.x%)
Mild	xx (xx.x%)	xx (xx.x%)
Not Related		
Severe	xx (xx.x%)	xx (xx.x%)
Moderate	xx (xx.x%)	xx (xx.x%)
Mild	xx (xx.x%)	xx (xx.x%)

Note: Treatment-emergent adverse events are those events that were not indicated as occurring prior to first application.
Related defined as “Definitely”, “Probably”, or “Possible”. Not Related defined as “Unlikely” or “Not related”.

SOURCE: USERNAME/SPONSOR/PROJECT/JOBNAME (DATE, TIME)

Table 14.3.1.3.2: Summary of Treatment-Emergent Serious Adverse Events by MedDRA System Organ Class and Preferred Term
(Safety Population)
(Page 1 of x)

System Organ Class ^a Preferred Term	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)	P-Value ^b
XXXXXXXXXXXXXXXXXXXXXXXXXXXX	xx (xx.x%)	xx (xx.x%)	x.xxx
XXXXXXXXXXXXXXXXXXXXXXXXXXXX	xx (xx.x%)	xx (xx.x%)	x.xxx

^a Counts reflect numbers of subjects reporting one or more adverse events that map to MedDRA. At each level of summarization (System Organ Class or Preferred Term) subjects are counted once.

^b P-value for the difference between treatment groups from a Fisher's Exact test. The specific system organ classes and preferred terms analyzed will be those that are reported by at least one percent of the patients in any treatment group.

Note: MedDRA Version 21.0

Treatment-emergent adverse events are those events that were not indicated as occurring prior to first application.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Table 14.3.1.3.3: Summary of Serious Treatment-Emergent Adverse Events by Severity
(Safety Population)
(Page 1 of x)

System Organ Class ^a Preferred Term	Severity	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
XXXXXXXXXXXXXXXXXXXXXXXXXXXX	Severe	xx (xx.x%)	xx (xx.x%)
	Moderate	xx (xx.x%)	xx (xx.x%)
	Mild	xx (xx.x%)	xx (xx.x%)
XXXXXXXXXXXXXXXXXXXXXXXXXXXX	Severe	xx (xx.x%)	xx (xx.x%)
	Moderate	xx (xx.x%)	xx (xx.x%)
	Mild	xx (xx.x%)	xx (xx.x%)

^a Counts reflect numbers of subjects reporting one or more serious adverse events that map to MedDRA. At each level of summarization (System Organ Class or Preferred Term) subjects are counted once under the greatest reported severity.

Note: MedDRA Version 21.0.

Treatment-emergent adverse events are those events that were not indicated as occurring prior to first application.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Table 14.3.1.3.4: Summary of Treatment-Emergent Serious Adverse Events by Relationship to Study Drug
(Safety Population)
(Page 1 of xx)

System Organ Class ^a Preferred Term	Relationship	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx	Related	xx (xx.x%)	xx (xx.x%)
	Not Related	xx (xx.x%)	xx (xx.x%)
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx	Related	xx (xx.x%)	xx (xx.x%)
	Not Related	xx (xx.x%)	xx (xx.x%)

^a Counts reflect numbers of subjects reporting one or more serious adverse events that map to MedDRA. At each level of summarization (System Organ Class or Preferred Term) subjects are counted once under the greatest reported relationship.

Note: MedDRA Version 21.0.

Treatment-emergent adverse events are those events that were not indicated as occurring prior to first application.

Related defined as “Definitely”, “Probably”, or “Possible”. Not Related defined as “Unlikely” or “Not related”.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Table 14.3.1.4: Summary of Vital Signs
(Safety Population)
(Page 1 of 5)

Temperature (°C)	E-BPO/E-ATRA 3%/0.1% Cream	Vehicle Cream
	(N=xxx)	(N=xxx)
Baseline		
n	xxx	xxx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Week 12		
n	xxx	xxx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Change from Baseline		
n	xxx	xxx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx

Note: No imputation of missing values. Negative change values represent decrease from Baseline.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Table 14.3.1.4: Summary of Vital Signs
(Safety Population)
(Page 2 of 5)

Respiratory Rate (breaths/min)	E-BPO/E-ATRA 3%/0.1% Cream	Vehicle Cream
	(N=xxx)	(N=xxx)
Baseline		
n	xxx	xxx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Week 12		
n	xxx	xxx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Change from Baseline		
n	xxx	xxx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx

Note: No imputation of missing values. Negative change values represent decrease from Baseline.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Table 14.3.1.4: Summary of Vital Signs
(Safety Population)
(Page 3 of 5)

Systolic Blood Pressure (mmHg)	E-BPO/E-ATRA 3%/0.1% Cream	Vehicle Cream
	(N=xxx)	(N=xxx)
Baseline		
n	xxx	xxx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Week 12		
n	xxx	xxx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Change from Baseline		
n	xxx	xxx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx

Note: No imputation of missing values. Negative change values represent decrease from Baseline.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Table 14.3.1.4: Summary of Vital Signs
(Safety Population)
(Page 4 of 5)

Diastolic Blood Pressure (mmHg)	E-BPO/E-ATRA 3%/0.1% Cream	Vehicle Cream
	(N=xxx)	(N=xxx)
Baseline		
n	xxx	xxx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Week 12		
n	xxx	xxx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Change from Baseline		
n	xxx	xxx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx

Note: No imputation of missing values. Negative change values represent decrease from Baseline.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Table 14.3.1.4: Summary of Vital Signs
(Safety Population)
(Page 5 of 5)

	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Heart Rate (beats/min)		
Baseline		
n	xxx	xxx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Week 12		
n	xxx	xxx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx
Change from Baseline		
n	xxx	xxx
Mean	xx.x	xx.x
SD	xx.xx	xx.xx
Median	xx.x	xx.x
Min. to Max.	xx to xx	xx to xx

Note: No imputation of missing values. Negative change values represent decrease from Baseline.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Table 14.3.1.4.2: Shift Table of Vital Signs
(Safety Population)

		E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)			Vehicle Cream (N=xxx)		
		Week 12			Week 12		
Systolic Blood Pressure (mmHg)		<90 mmHg	90-140 mmHg	>140 mmHg	<90 mmHg	90-140 mmHg	>140 mmHg
Baseline		xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
<90 mmHg		xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
90-140 mmHg		xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
>140 mmHg		xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
Diastolic Blood Pressure (mmHg)		Week 12			Week 12		
Baseline		<90 mmHg	90-100 mmHg	>100 mmHg	<90 mmHg	90-100 mmHg	>100 mmHg
<90 mmHg		xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
90-100 mmHg		xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
>100 mmHg		xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
Heart Rate (beats/min)		Week 12			Week 12		
Baseline		<60 bpm	60-100 bpm	>100 bpm	<60 bpm	60-100 bpm	>100 bpm
<60 mmHg		xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
60-100 mmHg		xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
>100 mmHg		xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)

Note: No imputation of missing values.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Table 14.3.1.5: Summary of Abnormal Physical Examination Findings by Visit
(Safety Population)

	E-BPO 3% Cream (N=xxx)	Vehicle Cream (N=xxx)
Heart		
Baseline		
n	xx	xx
Abnormal	xx (xx.x%)	xx (xx.x%)
Week 12		
n	xx	xx
Abnormal	xx (xx.x%)	xx (xx.x%)
Lung		
Baseline		
n	xx	xx
Abnormal	xx (xx.x%)	xx (xx.x%)
Week 12		
n	xx	xx
Abnormal	xx (xx.x%)	xx (xx.x%)
Abdomen		
Baseline		
n	xx	xx
Abnormal	xx (xx.x%)	xx (xx.x%)
Week 12		
n	xx	xx
Abnormal	xx (xx.x%)	xx (xx.x%)

Note: No imputation of missing values.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Table 14.3.1.6: Summary of Patient Global Impression of Treatment Side-Effects (PGI-SE) at Each Evaluation
(Safety Population)
(Page 1 of 2)

Right now, how bothered are you by the side effects of your acne treatment:	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Week 2		
n	xx	xx
0 - I am not bothered	xx (xx.x%)	xx (xx.x%)
1 - I am somewhat bothered	xx (xx.x%)	xx (xx.x%)
2 - I am moderately bothered	xx (xx.x%)	xx (xx.x%)
3 - I am very bothered	xx (xx.x%)	xx (xx.x%)
4 - I am extremely bothered	xx (xx.x%)	xx (xx.x%)
Week 4		
n	xx	xx
0 - I am not bothered	xx (xx.x%)	xx (xx.x%)
1 - I am somewhat bothered	xx (xx.x%)	xx (xx.x%)
2 - I am moderately bothered	xx (xx.x%)	xx (xx.x%)
3 - I am very bothered	xx (xx.x%)	xx (xx.x%)
4 - I am extremely bothered	xx (xx.x%)	xx (xx.x%)
Week 8		
n	xx	xx
0 - I am not bothered	xx (xx.x%)	xx (xx.x%)
1 - I am somewhat bothered	xx (xx.x%)	xx (xx.x%)
2 - I am moderately bothered	xx (xx.x%)	xx (xx.x%)
3 - I am very bothered	xx (xx.x%)	xx (xx.x%)
4 - I am extremely bothered	xx (xx.x%)	xx (xx.x%)

Note: No imputation of missing values.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

Table 14.3.1.6: Summary of Patient Global Impression of Treatment Side-Effects (PGI-SE) at Each Evaluation
(Safety Population)
(Page 2 of 2)

Right now, how bothered are you by the side effects of your acne treatment:	E-BPO/E-ATRA 3%/0.1% Cream (N=xxx)	Vehicle Cream (N=xxx)
Week 12		
n	xx	xx
0 - I am not bothered	xx (xx.x%)	xx (xx.x%)
1 - I am somewhat bothered	xx (xx.x%)	xx (xx.x%)
2 - I am moderately bothered	xx (xx.x%)	xx (xx.x%)
3 - I am very bothered	xx (xx.x%)	xx (xx.x%)
4 - I am extremely bothered	xx (xx.x%)	xx (xx.x%)


Note: No imputation of missing values.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

13. INDEX OF PLANNED FIGURES

Figure 14.2.7.2: Sensitivity Tipping-Point Analysis of the Primary Endpoint: Treatment Success in IGA at Week 12 (Intent-to-Treat Population).....	173
---	-----

Figure 14.2.7.2: Sensitivity Tipping-Point Analysis of the Primary Endpoint: Treatment Success in IGA at Week 12
(Intent-to-Treat Population)



Note: The horizontal and vertical axes indicate the number of successes that can potentially be observed among nonrespondents in the each treatment group. Each plotted point indicates the number of imputed successes in each treatment group that would alter the study's conclusion with the staircase region indicating the tipping points of the study. The red lines represent average number of imputed successes from the primary analysis using multiple imputation (MCMC) to impute missing values.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME)

14. INDEX OF PLANNED LISTINGS

Listing 16.1.7: Randomization Scheme	176
Listing 16.2.1.1: End of Study Information	177
Listing 16.2.2.1: Inclusion/Exclusion Criteria	178
Listing 16.2.2.2: Screen Failure	179
Listing 16.2.2.3: Protocol Deviations	180
Listing 16.2.3: Analysis Populations	181
Listing 16.2.4.1: Subject Demographic Information	182
Listing 16.2.4.2.1: Unique Medical/Surgical History Coded to MedDRA System Organ Classes and Preferred Terms	183
Listing 16.2.4.2.2: Medical/Surgical History	184
Listing 16.2.4.3.1: Unique Medication Names Coded to WHO Drug Global Dictionary ATC Level 2 Terms and Preferred Names	185
Listing 16.2.4.3.2: Prior and Concomitant Medications	186
Listing 16.2.4.4.1: Unique Procedure/Therapy Names Coded to MedDRA System Organ Classes and Preferred Terms	187
Listing 16.2.4.4.2: Prior and Concomitant Procedures/Therapies	188
Listing 16.2.5.1: Study Visit Compliance	189
Listing 16.2.5.2: Subject Dosing Compliance	190
Listing 16.2.5.3: Subject Dosing Deviations	191
Listing 16.2.5.4: Study Medication Accountability Log	192
Listing 16.2.5.5: Photography	193
Listing 16.2.6.1: Investigator Global Assessment	194
Listing 16.2.6.2: Lesion Counts	195
Listing 16.2.6.3.1: Acne-QoL Descriptions	196
Listing 16.2.6.3.2: Acne-QoL	198
Listing 16.2.6.3.3: Acne-QoL Domain Scores	199
Listing 16.2.6.4: PRO - Patient Reported Evaluation of Facial Acne (PRE-FACE)	200
Listing 16.2.6.5: PRO - Patient Reported Impression of Symptom Severity (PGI-S)	201
Listing 16.2.6.6: PRO – Patient Global Impression of Change (PGI-C), Patient Global Impression of Treatment Satisfaction (PGI-TS), Patient Global Impression of Treatment Side-Effects (PGI-SE)	202

Listing 16.2.7.1: Cutaneous Signs and Local Tolerability.....	203
Listing 16.2.7.2.1: Unique Adverse Events Coded to MedDRA System Organ Classes and Preferred Terms.....	204
Listing 16.2.7.2.2: Pre-Treatment Adverse Events.....	205
Listing 16.2.7.2.3: Treatment-Emergent Adverse Events.....	206
Listing 16.2.7.2.4: Serious Adverse Events.....	207
Listing 16.2.7.2.5: Subjects Who Prematurely Discontinued Study and/or Discontinued Study Drug Due to Adverse Events.....	208
Listing 16.2.8.1: Urine Pregnancy Tests.....	209
Listing 16.2.8.2: Physical Examination	210
Listing 16.2.8.3: Vital Signs	211

Listing 16.1.7: Randomization Scheme
(Page xx of yy)

Subject	Age/Sex	Eval	Randomization Date	Kit Number	Assigned Arm
xxxxxx	xxxx	xxxxxxxxxx	xxxxxxxxxxxxxxxxxx	xxxx	xxxxx xx xxxxx
xxxxxx	xxxx	xxxxxxxxxx	xxxxxxxxxxxxxxxxxx	xxxx	xxxxxxxx xxxxx
xxxxxx	xxxx	xxxxxxxxxx	xxxxxxxxxxxxxxxxxx	xxxx	xxxxx xx xxxxx
xxxxxx	xxxx	xxxxxxxxxx	xxxxxxxxxxxxxxxxxx	xxxx	xxxxx xx xxxxx
xxxxxx	xxxx	xxxxxxxxxx	xxxxxxxxxxxxxxxxxx	xxxx	xxxxx xx xxxxx
xxxxxx	xxxx	xxxxxxxxxx	xxxxxxxxxxxxxxxxxx	xxxx	xxxxxxxx xxxxx
xxxxxx	xxxx	xxxxxxxxxx	xxxxxxxxxxxxxxxxxx	xxxx	xxxxx xx xxxxx
xxxxxx	xxxx	xxxxxxxxxx	xxxxxxxxxxxxxxxxxx	xxxx	xxxxxxxx xxxxx

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Listing sorted by Subject.

Listing 16.2.1.1: End of Study Information
Treatment Arm
(Page xx of yy)

Subject	Age/Sex	Eval	Date of First Application	Date of Last Application	Date of Study Completion/ Discontinuation (Day) ¹	Did Subject Complete the Study	Primary Reason for Study Discontinuation	Continue to the the Long Term Safety Study
xxxxxx	xxxx	xxxxxxxx	xxxxxxxxxx	xxxxxxxxxx	xxxxxxxxxxxxxxxx	xxx		xxx x xxx xxxxxxxx xxxx xxxxxxxx
xxxxxx	xxxx	xxxxxxxx	xxxxxxxxxx	xxxxxxxxxx	xxxxxxxxxxxxxxxx	xx	xxxxxxx xxxxx	xx x xxx xxxxxxxx xxxx xxx xxxxxxxx
xxxxxx	xxxx	xxxxxxxx	xxxxxxxxxx	xxxxxxxxxx	xxxxxxxxxxxxxxxx	xx	xxxx xx xxxxxxxxxxxx xxxxxxxx xx xxxx xx xxxxxxxxxxxx xxxxx xxxxx xxxxx xxx xxxx	xx x xxx xxxxxxxx xxxx xxx xxxxxxxx

¹ Day is calculated as date - date of first application for dates prior to first application. Otherwise, day is calculated as date - date of first application + 1 for dates on or after first application.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Listing sorted by Subject.

If Primary Reason for Study Discontinuation is Lost to Follow-Up, Protocol Violation, Withdrawal by Subject, or Other, the reason specification will be included following a colon (for example, WITHDRAWAL BY SUBJECT: xxxxx)

If subject will not continue to the LTS, the reason specification will be included in the final column following a colon.

Listing 16.2.2.1: Inclusion/Exclusion Criteria
Treatment Group
(Page xx of yy)

Subject	Age/Sex	Eval	Criterion Failed	Description
xxxxxx	xxxx	xxxxxxxxxx	xxxxxx	xxxxx xxx xx xxxxxxxx xxxx xxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx
xxxxxx	xxxx	xxxxxxxxxx	xxxxxx	xxxxx xxx xx xxxxxxxx xxxx xxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx
xxxxxx	xxxx	xxxxxxxxxx	xxxxxx	xxxxx xxx xx xxxxxxxx xxxx xxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx
			xxxxxx	xxxxx xxx xx xxxxxxxx xxxx xxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx
			xxxxxx	xxxxx xxx xx xxxxxxxx xxxx xxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxx x xxxxxxxxxxxxxxxxxxx xxx

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Listing sorted by Subject and Criterion Failed.

Listing 16.2.2.2: Screen Failure
(Page xx of yy)

Subject	Age/Sex	Eval	Date of Screen Failure	Reason for Screen Failure
xxxxxx	xxxx	xxxxxxxxxx	xxxxxxxxxx	xxxxx xxx xx xxxxxxxx xxxx xxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx
xxxxxx	xxxx	xxxxxxxxxx	xxxxxxxxxx	xxxxx xxx xx xxxxxxxx xxxx xxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx
xxxxxx	xxxx	xxxxxxxxxx	xxxxxxxxxx	xxxxx xxx xx xxxxxxxx xxxx xxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx
			xxxxxxxxxx	xxxxx xxx xx xxxxxxxx xxxx xxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx
			xxxxxxxxxx	xxxxx xxx xx xxxxxxxx xxxx xxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxxxxxxx xxxxxxxxx x xxxxxxxxxxxxxxxxxxxxxxx xxx

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Listing sorted by Subject.

Listing 16.2.2.3: Protocol Deviations
Treatment Group
(Page xx of yy)

Subject	Age/Sex	Eval	Deviation	Date (Day ¹)
xxxxxx	xxxx	xxxxxxxxxx	xxxxxx x xxxxxxxx xxx xx xxxxxx xxxxxx xxx xxx xx xxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxx
			xxxxxx xxx xx xxxxxx xxxxxx xxx xxx xx	xxxxxxxxxxxxxxxxxx
			xxxxxx x xxxxxxxx	
xxxxxx	xxxx	xxxxxxxxxx	xxxxxx xxx xx xxxxxx xxxxxx xxx xxx xx	xxxxxxxxxxxxxxxxxx
xxxxxx	xxxx	xxxxxxxxxx	xxxxxx xxx xx xxxxxx xxxxxx xxx xxx xx	xxxxxxxxxxxxxxxxxx

¹ Day is calculated as date - Baseline date for dates prior to Baseline visit. Otherwise, day is calculated as date - Baseline date + 1 for dates on or after Baseline visit.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Listing sorted by Subject and Date.

Listing 16.2.3: Analysis Populations
Treatment Group
(Page xx of yy)

Subject	Age/Sex	Population	Included	Reason(s)	Excluded	Exception(s)
xxxxxx	xxxx	Intent-to-Treat Safety Per-Protocol	xxx xxx xx		xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx	
xxxxxx	xxxx	Intent-to-Treat Safety Per-Protocol	xxx xxx xxx		xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx	xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx
xxxxxx	xxxx	Intent-to-Treat Safety Per-Protocol	xxx xx xx		xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx	

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Listing sorted by Subject and Population (as ordered above).

Listing 16.2.4.1: Subject Demographic Information
Treatment Arm
(Page xx of yy)

Subject	Eval	B: Date of Birth A: Age S: Sex	R: Race E: Ethnicity	C: Childbearing Potential M: Method of Birth Control	I: Informed Consent Date P: Photography Consent Signed
xxxxxx	xxxxxxxxxx	B: xxxx-xx-xx A: xx S: xxxxxx	R: xxxxxx xxxxxxxx xx xxxxx xxxxxxxx xxxxxxxx xxxxxxxxxxxx E: xxx xxxxxxxx xx xxxxxx	C: xxx M: xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxxxxx xxxx x xxxxxxxxxxx xx xxxxxxxx xxxxxxxxxxx xxxx xxxxxxx	I: xxxx-xx-xx P: xxx
xxxxxx	xxxxxxxxxx	B: xxxx-xx-xx A: xx S: xxx	R: xxxxx E: xxxxxxxx xx xxxxxx	C: xx M:	I: xxxx-xx-xx P: xx
xxxxxx	xxxxxxxxxx	B: xxxx-xx-xx A: xx S: xxxxxx	R: xxxxx E: xxxxxxxx xx xxxxxx	C: xxx M: xxxxxxxx xxxxxxxxxxxxxxx	I: xxxx-xx-xx P: xx xxxx x xxxxxxxxxxx xxxxx

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Listing sorted by Subject.

Listing 16.2.4.2.1: Unique Medical/Surgical History Coded to MedDRA System Organ Classes and Preferred Terms
(Page xx of yy)

MedDRA System Organ Class	MedDRA Preferred Term	Medical/Surgical History Verbatim Term
xxxx xxx xxxxxxxxxxx xxxxxx xxxxxxxxxxx	xxxxxxx	xxxxxx
	xxxx xxxxxxxxxxx xxxxxxxx	xxxx xxxxxxxxxxx xxxxxx
xxxxxxxxxxx xxx xxxxxxxxxxxxxx	xxxxxxxxxxx	xxxxxxxxxxx
	xxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxx x xxxx xxx xxx
		xxxxxxxxxxxxxxxx xx xxxxx xx xxxx xxxxx xxx

Note: System Organ Class and Preferred Term map to MedDRA (Version 21.0).

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Listing sorted by System Organ Class, Preferred Term, and Verbatim Term.

Listing 16.2.4.2.2: Medical/Surgical History
Treatment Arm
(Page xx of yy)

Subject	Age/Sex	Eval	Medical/Surgical History Verbatim Term	S: MedDRA System Organ Class P: MedDRA Preferred Term	S: Onset Date E: End Date
xxxxxx	xxxx	xxxxxxxx	xxxxxx	S: xxxx xxx xxxxxxxxxxxxxx xxxxxx xxxxxxxxxxxx P: xxxxxxxx	S: xxxx E:
			xxxxxxxx xx xxxxxxxxxxxxxx xxxxxxxxxxxx	S: xxxxxx xxxxxx xxxxxxxxxxxx P: xxxxxxxxxxx xxxxxx xxxxxxxx	S: xxxx E: xxxxxxxx
xxxxxx	xxxx	xxxxxxxx	xxxxxx	S: xxxx xxx xxxxxxxxxxxxxx xxxxxx xxxxxxxxxxxx P: xxxxxxxx	S: xxxx E:
xxxxxx	xxxx	xxxxxxxx	xxxxxx	S: xxxx xxx xxxxxxxxxxxxxx xxxxxx xxxxxxxxxxxx P: xxxxxxxx	S: xxxx E:
xxxxxx	xxxx	xxxxxxxx	xxxxxx	S: xxxx xxx xxxxxxxxxxxxxx xxxxxx xxxxxxxxxxxx P: xxxxxxxx	S: xxxx E:
			xxxxxxxxxxxxxxxxxxxx	S: xxxxxx xxxxxx xxxxx P: xxxx xxxxxxxxxxxxxx	S: xxxxxxxxxxxx E: xxxxxxxx

Note: System Organ Class and Preferred Term map to MedDRA (Version 21.0).

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Listing sorted by Subject, Acne Diagnosis (all Acne MH will appear first), Onset Date, End Date, Verbatim Term

Listing 16.2.4.3.1: Unique Medication Names Coded to WHO Drug Global Dictionary ATC Level 2 Terms and Preferred Names
(Page xx of yy)

WHO ATC Level 2 Term	WHO Preferred Name	Medication Verbatim Term	I: Indication T: Route
xxxxxxxxxxxxxx	xxxxxxxxxxxxxx	xxxxxxx	I: xxxxxxxxxx R: xxxxxxxxxx
		xxxxxxx	I: xxxxxxxxxx R: xxxxxxxxxx
xxxxxxxxxxxxxx	xxxxxxxxxxxxxx	xxxxxxx	I: xxxxxxxxxx R: xxxxxxxxxx
		xxxxxxx	I: xxxxxxxxxx R: xxxxxxxxxx

Note: ATC Level 2 Term and Preferred Name map to WHO Drug Global Dictionary, Format B3, Version March 1, 2018

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Listing sorted by ATC Level 2 Term, Preferred Name, Medication Verbatim Term, Indication, and Route.

Listing 16.2.4.3.2: Prior and Concomitant Medications
Treatment Arm
(Page xx of yy)

S: Subject	A: ATC Level 2 Term	S: Start Date (Day) ¹	I: Indication	F: Frequency
A: Age/Sex	P: Preferred Name	E: End Date (Day) ¹	D: Dose	T: Route
E: Eval	M: Medication Name	P: Prior/Concomitant	U: Units	
S: xxxxxx	A: xxxxxxxxxxx xxx xxxxxxxxxxx	S: xxxxxxxxxxxxxxxxx	I: xxxxxxxx	F: xxx
A: xxxx	P: xxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxx xxxxxxx xxx	E: xxxxxxxxxxxxxxxxx	D: xx	T: xxxxxxxxxxxxxxxxx
E: xxxxxxxxxxx	M: xxxxxx xxxxx xxxxxxxxxxx	P: xxxxxxxxxxxxxxxxxxxxx	U: xxxxxxxxxxx	
	A: xxxxxxxx xx xxxxxxxx	S: xxxxxxxxxxxxxxxxx	I: xxxxxxxx	F: xx
	P: xxxxxxxxxxx xxxxxxx xxx	E: xxxxxxxxxxxxxxxxx	D: xx	T: xxxxx
	M: xxxxxx xxxxxxxx	P: xxxxx	U: xxxxxxxx	
S: xxxxxx	A: xxxxxxxxxxx xxx xxxxxxxxxxx	S: xxxxxxxxxxxxxxxxx	I: xxxxxxxx	F: xxx
A: xxxx	P: xxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxx xxxxxxx xxx	E: xxxxxxxxxxxxxxxxx	D: xx	T: xxxxxxxxxxxxxxxxx
E: xxxxxxxxxxx	M: xxxxxx xxxxx xxxxxxxxxxx	P: xxxxxxxxxxxxxxxxxxxxx	U: xxxxxxxxxxx	
	A: xxxxxxxx xx xxxxxxxx	S: xxxxxxxxxxxxxxxxx	I: xxxxxxxx	F: xx
	P: xxxxxxxxxxx xxxxxxx xxx	E: xxxxxxxxxxxxxxxxx	D: xx	T: xxxxx
	M: xxxxxx xxxxxxxx	P: xxxxx	U: xxxxxxxx	

¹ Day is calculated as date - date of first application for dates prior to first application. Otherwise, day is calculated as date - date of first application + 1 for dates on or after first application.

Note: ATC Level 2 Term and Preferred Name map to WHO Drug Global Dictionary, Format B3, Version March 1, 2018

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Listing sorted by Subject, Start Date, End Date, Medication Name, Indication, Route, Frequency. If the Route is Topical, then the area treated is presented within parenthesis (T: Topical (specify area)).

Listing 16.2.4.4.1: Unique Procedure/Therapy Names Coded to MedDRA System Organ Classes and Preferred Terms
(Page xx of yy)

MedDRA System Organ Class	MedDRA Preferred Term	Procedure/Therapy Verbatim Term	Indication
xxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxx	xxxxxxxx xx xxxxx	xxxxxxxxxxxx
		xxxxxxxxxx	xxxxx xx xxxxx
xxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxx	xxxxxxxxxx	xxxxxxxxxx
			xxxxxxxxxxxx
		xxxxxxxxxx	xxxxxxxxxxxx
xxxxxx xxx xx xxxxxxx	xxxxxxx xxxxxxx xxxxx	xxxxxxx xxxxxxx	xxxxxxx xxxxxxxxx xx xx xxxxx

Note: System Organ Class and Preferred Term map to MedDRA (Version 21.0).

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Listing sorted by System Organ Class, Preferred Term, Verbatim Term, and Indication.

Listing 16.2.4.4.2: Prior and Concomitant Procedures/Therapies
Treatment Arm
(Page xx of yy)

Subject	Age/Sex	Eval	S: MedDRA System Organ Class P: MedDRA Preferred Term M: Procedure/Therapy Name	S: Start Date (Day) ¹ E: End Date (Day) ¹ P: Prior/Concomitant	I: Indication A: Anatomical Area Treated
xxxxxx	xxxx	xxxxxxxx	S: xxxxxxxx xxx xxxxxxxx xxxxxxxx P: xxxxxxxxxxxx xxxxxxxxxxxx xxxxxxxx M: xxxxxxxx xxxxx xxxxxxxx xxxxxxxx	S: xxxxxxxxxxxxxxxxxxxx E: xxxxxxxxxxxxxxxxxxxx P: xxxxxxxxxxxxxxxxxxxx	I: xxxxx xxxxxxxx A:
xxxxxx	xxxx	xxxxxxxx	S: xxxxxxxx xxx xxxxxxxx xxxxxxxx P: xxxxxxxxxxxx xxxxxxxxxxxx xxxxxxxx M: xxxxxxxx xxxxx xxxxxxxx xxxxxxxx	S: xxxxxxxxxxxxxxxxxxxx E: xxxxxxxxxxxxxxxxxxxx P: xxxxxxxxxxxxxxxxxxxx	I: xxxxx xxxxxxxx A:
xxxxxx	xxxx	xxxxxxxx	S: xxxxxxxx xxx xxxxxxxx xxxxxxxx P: xxxxxxxxxxxx xxxxxxxxxxxx xxxxxxxx M: xxxxxxxx xxxxx xxxxxxxx xxxxxxxx	S: xxxxxxxxxxxxxxxxxxxx E: xxxxxxxxxxxxxxxxxxxx P: xxxxxxxxxxxxxxxxxxxx	I: xxxxx xxxxxxxx A:
			S: xxxxxxxx xxxxxxxx xxxxx P: xxx xxxxxxxxxxxx xxxxxxxx M: xxxxxxxx xxxxxxxx	S: xxxxxxxxxxxxxxxxxxxx E: xxxxxxxxxxxxxxxxxxxx P: xxxxxxxxxxxxxxxxxxxx	I: xxxxxxxx xxxxx xx xx A: xxxxxxxx
			S: xxxxxxxx xxxxxxxx xxxxx P: xxx xxxxxxxxxxxx xxxxxxxx M: xxxxxxxx xxxxxxxx	S: xxxxxxxxxxxxxxxxxxxx E: xxxxxxxxxxxxxxxxxxxx P: xxxxxxxxxxxxxxxxxxxx	I: xxxxxxxx xxxxx xx xx A: xxxxxxxx

¹ Day is calculated as date - date of first application for dates prior to first application. Otherwise, day is calculated as date - date of first application + 1 for dates on or after first application.

Note: System Organ Class and Preferred Term map to MedDRA (Version 21.0).

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Listing sorted by Subject, Start Date, End Date, Procedure/Therapy Name, and Indication.

Listing 16.2.5.1: Study Visit Compliance
Treatment Arm
(Page xx of yy)

Subject	Age/Sex	Eval	Visit	Visit Date	Study Day ¹	Within Visit Window ²	Reason Screening And Baseline Occurred on Different Days	Reason for Unscheduled Visit
xxxxxx	xxxx	xxxxxxxx	xxxxxxxx xxxxxxxx	xxxxxxxx xxxxxxxx	xx xx	xxx xxx	xxxxxx xxx xx xxxxxxxx	
			xxxx x xxxx x xxxx x xxxx xxxxx	xxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx	xx xx xx xx	xxx xxx xxx xxx		
xxxxxx	xxxx	xxxxxxxx	xxxxxxxx xxxxxxxx xxxx x xxxx x xxxxxxxxxxx xxxxx xxx xxxx x xxxx xxxxx	xxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx	xx xx xx xx xx xx	xxx xxx xxx xxx xxx xxx		xxxxxxxxxxxxxx
xxxxxx	xxxx	xxxxxxxx	xxxxxxxx xxxxxxxx xxxx x xxxx x xxxx x xxxx xxxxx	xxxxxxxx xxxxxxxx xxx xxx xxx xxx xxxxxxxx xxxxxxxx	xx xx xx xx xx xx	xxx xxx xxx xxx xxx xxx		xxx xxx xxx xxx

¹ Day is calculated as date - Baseline date for dates prior to Baseline visit. Otherwise, day is calculated as date - Baseline date + 1 for dates on or after Baseline visit.

² Determined by protocol-specified visit window for scheduled visits after Baseline.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Listing sorted by Subject and Visit Number.

Listing 16.2.5.2: Subject Dosing Compliance
Treatment Arm
(Page xx of yy)

Subject	Age/Sex	Eval	Date of First Application	Date of Last Application	Number of Days of Exposure	Calculated ¹ Number of Applications	Amount of Study Drug Used (g)	Maximum Number of Consecutive Missed Applications	Percent Compliant	Compliant ²
xxxxxx	xxxx	xxxxxxxx	xxxxxxxxxx	xxxxxxxxxx	xx	xx	xxxx	xx	xxxxx	xxx
xxxxxx	xxxx	xxxxxxxx	xxxxxxxxxx	xxxxxxxxxx	xx	xx	xxxx	xx	xxxxx	xxx
xxxxxx	xxxx	xxxxxxxx	xxxxxxxxxx	xxxxxxxxxx	xx	xx	xxxx	xx	xxxxx	xxx
xxxxxx	xxxx	xxxxxxxx	xxxxxxxxxx	xxxxxxxxxx	xx	xx	xxxx	xx	xxxxx	xxx
xxxxxx	xxxx	xxxxxxxx	xxxxxxxxxx	xxxxxxxxxx	xx	xx	xxxx	xx	xxxxx	xxx

¹ The total number of applications was calculated using the date of first application, date of last application, and number of applied applications at a deviation.

² A subject was considered compliant with the dosing regimen if the subject did not miss more than 5 consecutive days applying and applied 80-120% of expected applications based on the length of their participation in the study.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Listing sorted by Subject.

Listing 16.2.5.3: Subject Dosing Deviations
Treatment Arm
(Page xx of yy)

Subject	Age/Sex	Eval	Date of Dosing Deviation (Day) ¹	Number of Applications Applied
xxxxxx	xxxx	xxxxxxx	xxxxxxxxxxxxx xxxxxxxxxxxxx	x x
xxxxxx	xxxx	xxxxxxx	xxxxxxxxxxxxx	x
xxxxxx	xxxx	xxxxxxx	xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx	x x x x x x x
xxxxxx	xxxx	xxxxxxx	xxxxxxxxxxxxx xxxxxxxxxxxxx	x x
xxxxxx	xxxx	xxxxxxx	xxxxxxxxxxxxx	x

¹ Day is calculated as date - date of first application for dates prior to first application. Otherwise, day is calculated as date - date of first application + 1 for dates on or after first application.

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Listing sorted by Subject and Date of Dosing Deviation.

Listing 16.2.5.4: Study Medication Accountability Log
Treatment Arm
(Page xx of yy)

Subject	Age/Sex	Eval	Kit Number	Kit Contents	Pump Identifier	Dispensing		Return		Amount Used (g)
						Date	Weight (g)	Date	Weight (g)	
xxxxxx	xxxx	xxxxxxxx	xxxx	xxxx	x	xxxxxxxxxx	xxxx	xxxxxxxxxx	xxxx	xxxx
				xxxx	x	xxxxxxxxxx	xxxx	xxxxxxxxxx	xxxx	xxxx
				xxxx	x	xxxxxxxxxx	xxxx	xxxxxxxxxx	xxxx	xxxx
				xxxx	x	xxxxxxxxxx	xxxx	xxxxxxxxxx	xxxx	xxxx
			xxxx	xxxx	x	xxxxxxxxxx	xxxx	xxxxxxxxxx	xxxx	xxxx
				xxxx	x	xxxxxxxxxx	xxxx	xxx xxxx		
				xxxx	x	xxxxxxxxxx	xxxx	xxxxxxxxxx	xxxx	xxxx
				xxxx	x	xxxxxxxxxx	xxxx	xxxxxxxxxx	xxxx	xxxx
xxxxxx	xxxx	xxxxxxxx	xxxx	xxxx	x	xxxxxxxxxx	xxxx	xxxxxxxxxx	xxxx	xxxx
				xxxx	x	xxx xxxx				
				xxxx	x	xxxxxxxxxx	xxxx	xxxxxxxxxx	xxxx	xxxx
				xxxx	x	xxxxxxxxxx	xxx xxxx	xxxxxxxxxx	xxxx	
xxxxxx	xxxx	xxxxxxxx	xxxx	xxxx	x	xxxxxxxxxx	xxxx	xxxxxxxxxx	xxxx	xxxx
				xxxx	x	xxxxxxxxxx	xxxx	xxxxxxxxxx	xxxx	xxxx
				xxxx	x	xxxxxxxxxx	xxxx	xxxxxxxxxx	xxx xxxx	
				xxxx	x	xxxxxxxxxx	xxxx	xxxxxxxxxx	xxxx	xxxx

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Note to programmers: Kit Contents is the treatment the kit contained.

Listing 16.2.5.5: Photography
Treatment Arm
(Page xx of yy)

Subject	Age/Sex	Eval	Visit	Were Photographs Taken	Date Taken
xxxxxx	xxxx	xxxxxxxx	xxxxxxxx xxxx x xxxx x xxxx x xxxx xxxxx	xxx xxx xx xxx xxx	xxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx
xxxxxx	xxxx	xxxxxxxx	xxxxxxxx xxxx x xxxx x xxxx x xxxxxxxxxxxx xxxxx xxx xxxx xxxxx	xxx xxx xxx xxx xxx xx	xxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx
xxxxxx	xxxx	xxxxxxxx	xxxxxxxx xxxx x xxxx x xxxx x xxxx xxxxx	xxx xxx xxx xxx xxx	xxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Listing sorted by Subject and Visit Number

Listing 16.2.6.1: Investigator Global Assessment
Treatment Arm
(Page xx of yy)

Subject	Age/Sex	Eval	Visit	Date of Assessment	Evaluator Initials	Result
xxxxxx	xxxx	xxxxxxxx	xxxxxxxx xxxx x xxxx x xxxx x xxxx xxxx	xxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx	xxx xxx xxx xxx xxx	xxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx
xxxxxx	xxxx	xxxxxxxx	xxxxxxxx xxxx x xxxx x xxxx x xxxx xxxx	xxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx	xxx xxx xxx xxx xxx	xxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx
xxxxxx	xxxx	xxxxxxxx	xxxxxxxx xxxx x xxxx x xxxx x xxxx xxxx	xxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx	xxx xxx xxx xxx xxx	xxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Listing sorted by Subject and Visit Number

Listing 16.2.6.2: Lesion Counts
Treatment Arm
(Page xx of yy)

Subject	Age/Sex	Eval	Visit	Date of Assessment	Evaluator Initials	Total Inflammatory Lesion Count	Nodules/Cysts	Total Non-Inflammatory Lesion Count
xxxxxx	xxxx	xxxxxxxx	xxxxxxxx	xxxxxxxx	xxx	xx	xx	xx
			xxxx x	xxxxxxxx	xxx	xx	xx	xx
			xxxx x	xxxxxxxx	xxx	xx	xx	xx
			xxxx x	xxxxxxxx	xxx	xx	xx	xx
			xxxx xxxxx	xxxxxxxx	xxx	xx	xx	xx
xxxxxx	xxxx	xxxxxxxx	xxxxxxxx	xxxxxxxx	xxx	xx	xx	xx
			xxxx x	xxxxxxxx	xxx	xx	xx	xx
			xxxx x	xxxxxxxx	xxx	xx	xx	xx
			xxxx x	xxxxxxxx	xxx	xx	xx	xx
			xxxx xxxxx	xxxxxxxx	xxx	xx	xx	xx
xxxxxx	xxxx	xxxxxxxx	xxxxxxxx	xxxxxxxx	xxx	xx	xx	xx
			xxxx x	xxxxxxxx	xxx	xx	xx	xx
			xxxx x	xxxxxxxx	xxx	xx	xx	xx
			xxxx x	xxxxxxxx	xxx	xx	xx	xx
			xxxx xxxxx	xxxxxxxx	xxx	xx	xx	xx
xxxxxx	xxxx	xxxxxxxx	xxxxxxxx	xxxxxxxx	xxx	xx	xx	xx
			xxxx x	xxxxxxxx	xxx	xx	xx	xx
			xxxx x	xxxxxxxx	xxx	xx	xx	xx
			xxxx xxxxx	xxxxxxxx	xxx	xx	xx	xx

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Listing sorted by Subject and Visit Number

Listing 16.2.6.3.1: Acne-QoL Descriptions
(Page 1 of 2)

Number	Acne-QoL Question
<hr/>	
1	In the past WEEK, how unattractive did you feel because of your facial acne?
2	In the past WEEK, how embarrassed did you feel because of your facial acne?
3	In the past WEEK, how self-conscious (uneasy about oneself) did you feel about your facial acne?
4	In the past WEEK, how upset were you about having facial acne?
5	In the past WEEK, how annoyed did you feel at having to spend time every day cleaning and treating your face because of your facial acne?
6	In the past WEEK, how dissatisfied with your self-appearance did you feel because of your facial acne?
7	In the past WEEK, how concerned or worried were you about not looking your best because of your facial acne?
8	In the past WEEK, how concerned or worried were you that your acne medication/products were working fast enough in clearing up the acne on your face?
9	In the past WEEK, how bothered did you feel about the need to always have medication or cover-up available for the acne on your face?
10	In the past WEEK, how much was your self-confidence (sure of yourself) negatively affected because of your facial acne?
11	In the past WEEK, how concerned or worried were you about meeting new people because of your facial acne?
12	In the past WEEK, how concerned or worried were you about going out in public because of your facial acne?
13	In the past WEEK, how much was socializing with people a problem for you because of your facial acne?
14	In the past WEEK, how much was interacting with the opposite sex (or same sex if gay or lesbian) a problem for you because of your facial acne?
15	In the past WEEK, how many bumps did you have on your face?
16	In the past WEEK, how many bumps full of pus did you have on your face?
<hr/>	
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)	

Listing 16.2.6.3.1: Acne-QoL Descriptions
(Page 1 of 2)

Number	Acne-QoL Question
--------	-------------------

17	In the past WEEK, how much scabbing from your facial acne did you have?
18	In the past WEEK, how concerned or worried were you about scarring from your facial acne?
19	In the past WEEK, how oily was your facial skin?

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Listing 16.2.6.3.2: Acne-QoL
Treatment Arm
(Page xx of yy)

Subject	Age/Sex	Eval	Visit	Date of Assessment	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
xxxxxx	xxxxx	xxxxxxxx	xxxxxxxxxx xxxxxxxxxx	xxxxxxxxxx xxxxxxxxxx	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
xxxxxx	xxxxx	xxxxxxxx	xxxxxxxxxx xxxxxxxxxx	xxxxxxxxxx xxxxxxxxxx	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
xxxxxx	xxxxx	xxxxxxxx	xxxxxxxxxx xxxxxxxxxx	xxxxxxxxxx xxxxxxxxxx	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
xxxxxx	xxxxx	xxxxxxxx	xxxxxxxxxx xxxxxxxxxx	xxxxxxxxxx xxxxxxxxxx	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
xxxxxx	xxxxx	xxxxxxxx	xxxxxxxxxx xxxxxxxxxx	xxxxxxxxxx xxxxxxxxxx	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
xxxxxx	xxxxx	xxxxxxxx	xxxxxxxxxx xxxxxxxxxx	xxxxxxxxxx xxxxxxxxxx	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x

Note: Questions 1-14, 18-19: 0=Extremely, 1=Very Much, 2=Quite A Bit, 3=A Good Bit, 4=Somewhat, 5=A Little Bit, 6=Not At All.
Questions 15-17: 0=Extensive, 1=A Whole Lot, 2=A Lot, 3=A Moderate Amount, 4=Some, 5=Very Few, 6=None.
ND = NOT DONE

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Listing sorted by Subject and Visit Number

Listing 16.2.6.3.3: Acne-QoL Domain Scores
Treatment Arm
(Page xx of yy)

Subject	Age/Sex	Eval	Visit	Date of Assessment	Self Perception	Role-social	Role-emotional	Acne Symptoms
xxxxxx	xxxxx	xxxxxxxx	xxxxxxxxxx	xxxxxxxxxx	xx	xx	xx	xx
			xxxxxxxxxx	xxxxxxxxxx	xx	xx	xx	xx
xxxxxx	xxxxx	xxxxxxxx	xxxxxxxxxx	xxxxxxxxxx	xx	xx	xx	xx
			xxxxxxxxxx	xxxxxxxxxx	xx	xx	xx	xx
xxxxxx	xxxxx	xxxxxxxx	xxxxxxxxxx	xxxxxxxxxx	xx	xx	xx	xx
			xxxxxxxxxx	xxxxxxxxxx	xx	xx	xx	xx
xxxxxx	xxxxx	xxxxxxxx	xxxxxxxxxx	xxxxxxxxxx	xx	xx	xx	xx
			xxxxxxxxxx	xxxxxxxxxx	xx	xx	xx	xx
xxxxxx	xxxxx	xxxxxxxx	xxxxxxxxxx	xxxxxxxxxx	xx	xx	xx	xx
			xxxxxxxxxx	xxxxxxxxxx	xx	xx	xx	xx
xxxxxx	xxxxx	xxxxxxxx	xxxxxxxxxx	xxxxxxxxxx	xx	xx	xx	xx
			xxxxxxxxxx	xxxxxxxxxx	xx	xx	xx	xx
xxxxxx	xxxxx	xxxxxxxx	xxxxxxxxxx	xxxxxxxxxx	xx	xx	xx	xx
			xxxxxxxxxx	xxxxxxxxxx	xx	xx	xx	xx
xxxxxx	xxxxx	xxxxxxxx	xxxxxxxxxx	xxxxxxxxxx	xx	xx	xx	xx
			xxxxxxxxxx	xxxxxxxxxx	xx	xx	xx	xx

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Listing sorted by Subject and Visit Number

Listing 16.2.6.4: PRO - Patient Reported Evaluation of Facial Acne (PRE-FACE)
Treatment Arm
(Page xx of yy)

Subject	Age/Sex	Eval	Visit	Date of Assessment	Category	Assessment	Result
xxxxxx	xxxx	xxxxxxxx	xxxxxxxx	xxxxxxxx	Signs/Symptoms	Rate the pimples on your face today	x
						Rate the blackheads on your face today	x
						Rate the whiteheads on your face today	x
						Rate the redness on your face today	x
					Impacts	Over the past seven days, rate how embarrassed you felt because of the acne on your face	x
						Over the past seven days, rate how sad you felt because of the acne on your face.	x
					Signs/Symptoms	Rate the pimples on your face today	x
						Rate the blackheads on your face today	x
						Rate the whiteheads on your face today	x
						Rate the redness on your face today	x
					Impacts	Over the past seven days, rate how embarrassed you felt because of the acne on your face	x
						Over the past seven days, rate how sad you felt because of the acne on your face.	x

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Listing sorted by Subject and Visit Number, Category (in order presented on eCRF), and Assessment (in order presented on eCRF).

Listing 16.2.6.5: PRO - Patient Reported Impression of Symptom Severity (PGI-S)
Treatment Arm
(Page xx of yy)

Subject	Age/Sex	Eval	Visit	Date of Assessment	Assessment	Result
xxxxxx	xxxx	xxxxxxxx	xxxxxxxx	xxxxxxxx	Right now, my acne symptoms are	xxxxxxxx xx xxxxxx xxxx xxx
			xxxx x	xxxxxxxx	Right now, my acne symptoms are	xxxxxxxx xx xxxxxx xxxx xxx
			xxxx x	xxxxxxxx	Right now, my acne symptoms are	xxxxxxxx xx xxxxxx xxxx xxx
			xxxx x	xxxxxxxx	Right now, my acne symptoms are	xxxxxxxx xx xxxxxx xxxx xxx
			xxxx xx	xxxxxxxx	Right now, my acne symptoms are	xxxxxxxx xx xxxxxx xxxx xxx
xxxxxx	xxxx	xxxxxxxx	xxxxxxxx	xxxxxxxx	Right now, my acne symptoms are	xxxxxxxx xx xxxxxx xxxx xxx
			xxxx x	xxxxxxxx	Right now, my acne symptoms are	xxxxxxxx xx xxxxxx xxxx xxx
			xxxx x	xxxxxxxx	Right now, my acne symptoms are	xxxxxxxx xx xxxxxx xxxx xxx
			xxxx x	xxxxxxxx	Right now, my acne symptoms are	xxxxxxxx xx xxxxxx xxxx xxx
			xxxx xx	xxxxxxxx	Right now, my acne symptoms are	xxxxxxxx xx xxxxxx xxxx xxx
xxxxxx	xxxx	xxxxxxxx	xxxxxxxx	xxxxxxxx	Right now, my acne symptoms are	xxxxxxxx xx xxxxxx xxxx xxx
			xxxx x	xxxxxxxx	Right now, my acne symptoms are	xxxxxxxx xx xxxxxx xxxx xxx
			xxxx x	xxxxxxxx	Right now, my acne symptoms are	xxxxxxxx xx xxxxxx xxxx xxx
			xxxx x	xxxxxxxx	Right now, my acne symptoms are	xxxxxxxx xx xxxxxx xxxx xxx
			xxxx xx	xxxxxxxx	Right now, my acne symptoms are	xxxxxxxx xx xxxxxx xxxx xxx

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Listing sorted by Subject and Visit Number.

Listing 16.2.6.6: PRO - Patient Global Impression of Change (PGI-C), Patient Global Impression of Treatment Satisfaction (PGI-TS), Patient Global Impression of Treatment Side-Effects (PGI-SE)
Treatment Arm
(Page xx of yy)

Subject	Age/Sex	Eval	Visit	Date of Assessment	PRO Category	Object of Assessment	Result
xxxxxx	xxxx	xxxxxxxx	xxxxxxxx	xxxxxxxx	PGI-C	CHANGE	xxxxxxxxxxxxxxxx
					PGI-TS	SATISFACTION	xxxxxx xxx xxxx
					PGI-SE	SIDE-EFFECTS	xxxxxxxxxxxxxxxx
			xxxxxxxx	xxxxxxxx	PGI-C	CHANGE	xxxxxxxxxxxxxxxx
					PGI-TS	SATISFACTION	xxxxxx xxx xxxx
					PGI-SE	SIDE-EFFECTS	xxxxxxxxxxxxxxxx
			xxxxxxxx	xxxxxxxx	PGI-C	CHANGE	xxxxxxxxxxxxxxxx
					PGI-TS	SATISFACTION	xxxxxx xxx xxxx
					PGI-SE	SIDE-EFFECTS	xxxxxxxxxxxxxxxx
			xxxxxxxx	xxxxxxxx	PGI-C	CHANGE	xxxxxxxxxxxxxxxx
					PGI-TS	SATISFACTION	xxxxxx xxx xxxx
					PGI-SE	SIDE-EFFECTS	xxxxxxxxxxxxxxxx
xxxxxx	xxxx	xxxxxx	xxxxxxxx	xxxxxxxx	PGI-C	CHANGE	xxxxxxxxxxxxxxxx
					PGI-TS	SATISFACTION	xxxxxx xxx xxxx
					PGI-SE	SIDE-EFFECTS	xxxxxxxxxxxxxxxx
			xxxxxxxx	xxxxxxxx	PGI-C	CHANGE	xxxxxxxxxxxxxxxx
					PGI-TS	SATISFACTION	xxxxxx xxx xxxx
					PGI-SE	SIDE-EFFECTS	xxxxxxxxxxxxxxxx

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Listing sorted by Subject, Visit Number, and PRO Assessment (in order presented on eCRF).

Listing 16.2.7.1: Cutaneous Signs and Local Tolerability
Treatment Arm
(Page xx of yy)

Subject	Age/Sex	Eval	Visit	Date of Assessment	Evaluator Initials	Test	Result
xxxxxx	xxxx	xxxxxxxx	xxxxxxxx	xxxxxxxx	xxx	Erythema Scaling Pigmentation Dryness Itching Burning Stinging	xxxxxx xxx xxx xxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx
			xxxx x	xxxxxxxx	xxx	Erythema Scaling Pigmentation Dryness Itching Burning Stinging	xxxxxx xxx xxx xxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx
			xxxx x	xxxxxxxx	xxx	Erythema Scaling Pigmentation Dryness Itching Burning Stinging	xxxxxx xxx xxx xxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Listing sorted by Subject, Visit Number, and Test (in order presented on eCRF).

Listing 16.2.7.2.1: Unique Adverse Events Coded to MedDRA System Organ Classes and Preferred Terms
Treatment Arm
(Page xx of yy)

MedDRA System Organ Class	MedDRA Preferred Term	Application Area	Adverse Event
xxxxxxx xxxxxxxxxx xxx xxxxxxxxxxxxxxxx	xxxxxxxxxxx xxx xxxxxxxxxxxxxxxxxx	xxx	xxxxxxxxxxxxx xxxxxxxx xx xx xxxxxx
		xx	xxxxxxxxx
		xx	xxxxx xxxxxxxx
	xxxxxxxxx	xx	xxxxxxxxx
xxxxxxx xxxxxx xxxxxxxxxx	xxxxxxxxx	xx	xxxxxxxxx
xxxx xxx xxxxxxxxxxxxxx xxxxxx xxxxxxxxxx	xxxxxxxxx	xxx	xxxxxxxxxxx xx xxxxxxxx
	xxxx xxxxxxxxxxxxxx	xx	xxxxxxxx xxx xxxxxxxxxxx xxx

Note: System Organ Class and Preferred Term map to MedDRA (Version 21.0).

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Listing sorted by System Organ Class, Preferred Term, Adverse Event.

Listing 16.2.7.2.2: Pre-Treatment Adverse Events
Treatment Arm
(Page xx of yy)

S: Subject	S: MedDRA System Organ Class	A: In the Application Area	A: Action Taken with Study Drug	S: Start Date (Day) ¹
A: Age/Sex	P: MedDRA Preferred Term	G: Severity	T: Action Taken to Treat Event	E: End Date (Day) ¹
E: Eval	A: Adverse Event	R: Relationship to Study Drug	O: Outcome	
		S: Serious Event		
S: xxxxxx	S: xxxxx xxx xxxxxxxxxxxxxxx xxxxxx	A: xx	A: xxx xx xxxxxxxx	S: xxxxxxxxxxxxxxxx
A: xxxxx	P: xxxxxxxxxxxxxxx	G: xxxxx	T: xxxxx	E: xxxxxxxxxxxxxxxx
E: xxxxxxxx	A: xxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxx	R: xxx xxxxxxxx	O: xxxxxxxxxxxxxxxx	
		S: xx		
	S: xxxxxxxx xxxxxxxxxxxxxxx xxx xxxxxxxxxxxxxxx	A: xxx	A: xxx xxxxxxxxxxxxxxx	S: xxxxxxxxxxxxxxxx
	P: xxxxxxxxxxxxxxx	G: xxxxx	T: xxxxxxxxxxxxxxx xxxxxxxxxxxxxxx	E: xxxxxxxxxxxxxxxx
	A: xxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxx	R: xxx xxxxxxxx	O: xxxxxxxxxxxxxxxx	
		S: xx		
S: xxxxxx	S: xxxxx xxxxxxxxxxxxxxx xxxxxx	A: xx	A: xxx xx xxxxxxxx	S: xxxxxxxxxxxxxxxx
A: xxxxx	P: xxxxxxxxxxxxxxx	G: xxxxxxxx	T: xxxxx	E: xxxxxxxxxxxxxxxx
E: xxxxxxxx	A: xxxxxxxxxxxxxxx xxxxx	R: xxx xxxxxxxx	O: xxxxxxxxxxxxxxxx	
		S: xx		
S: xxxxxx	S: xxxxx xxxxxxxxxxxxxxx xxxxxx	A: xx	A: xxx xx xxxxxxxx	S: xxxxxxxxxxxxxxxx
A: xxxxx	P: xxxxxxxxxxxxxxx	G: xxxxxxxx	T: xxxxx	E: xxxxxxxxxxxxxxxx
E: xxxxxxxx	A: xxxxxxxxxxxxxxx xxxxx	R: xxxxxxxx	O: xxxxxxxxxxxxxxxx	
		S: xxx		
	S: xxxxxxxx xxxxxxxxxxxxxxx xxx xxxxxxxxxxxxxxx	A: xxx	A: xxx xxxxxxxxxxxxxxx	S: xxxxxxxxxxxxxxxx
	P: xxxxxxxxxxxxxxx	G: xxxxx	T: xxxxxxxxxxxxxxx xxxxxxxxxxxxxxx	E: xxxxxxxxxxxxxxxx
	A: xxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxx	R: xxx xxxxxxxx	O: xxxxxxxxxxxxxxxx	
		S: xx		

¹ Day is calculated as date - date of first application for dates prior to first application. Otherwise, day is calculated as date - date of first application + 1 for dates on or after first application.

Note: System Organ Class and Preferred Term map to MedDRA (Version 21.0).

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Listing sorted by Subject, Start Date, End Date, Adverse Event.

Listing 16.2.7.2.3: Treatment-Emergent Adverse Events
Treatment Arm
(Page xx of yy)

S: Subject	S: MedDRA System Organ Class	A: In the Application Area	A: Action Taken with Study Drug	S: Start Date (Day) ¹
A: Age/Sex	P: MedDRA Preferred Term	G: Severity	T: Action Taken to Treat Event	E: End Date (Day) ¹
E: Eval	A: Adverse Event	R: Relationship to Study Drug	O: Outcome	
		S: Serious Event		
S: xxxxxx	S: xxxxx xxx xxxxxxxxxxxxxxx xxxxxx	A: xx	A: xxx xx xxxxxxxx	S: xxxxxxxxxxxxxxxx
A: xxxxx	P: xxxxxxxxxxxxxxx	G: xxxxx	T: xxxxx	E: xxxxxxxxxxxxxxxx
E: xxxxxxxx	A: xxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxx	R: xxx xxxxxxxx	O: xxxxxxxxxxxxxxxx	
		S: xx		
	S: xxxxxxxx xxxxxxxxxxxxxxx xxx xxxxxxxxxxxxxxx	A: xxx	A: xxx xxxxxxxxxxxxxxx	S: xxxxxxxxxxxxxxxx
	P: xxxxxxxxxxxxxxx	G: xxxxx	T: xxxxxxxxxxxxxxx xxxxxxxxxxxxxxx	E: xxxxxxxxxxxxxxxx
	A: xxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxx	R: xxx xxxxxxxx	O: xxxxxxxxxxxxxxxx	
		S: xx		
S: xxxxxx	S: xxxxx xxxxxxxxxxxxxxx xxxxxx	A: xx	A: xxx xx xxxxxxxx	S: xxxxxxxxxxxxxxxx
A: xxxxx	P: xxxxxxxxxxxxxxx	G: xxxxxxxxxxx	T: xxxxx	E: xxxxxxxxxxxxxxxx
E: xxxxxxxx	A: xxxxxxxxxxxxxxx xxxxx	R: xxx xxxxxxxx	O: xxxxxxxxxxxxxxxx	
		S: xxx		
S: xxxxxx	S: xxxxx xxxxxxxxxxxxxxx xxxxxx	A: xx	A: xxx xx xxxxxxxx	S: xxxxxxxxxxxxxxxx
A: xxxxx	P: xxxxxxxxxxxxxxx	G: xxxxxxxxxxx	T: xxxxx	E: xxxxxxxxxxxxxxxx
E: xxxxxxxx	A: xxxxxxxxxxxxxxx xxxxx	R: xxx xxxxxxxx	O: xxxxxxxxxxxxxxxx	
		S: xxx		
	S: xxxxxxxx xxxxxxxxxxxxxxx xxx xxxxxxxxxxxxxxx	A: xxx	A: xxx xxxxxxxxxxxxxxx	S: xxxxxxxxxxxxxxxx
	P: xxxxxxxxxxxxxxx	G: xxxxx	T: xxxxxxxxxxxxxxx xxxxxxxxxxxxxxx	E: xxxxxxxxxxxxxxxx
	A: xxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxx	R: xxxxxxxx	O: xxxxxxxxxxxxxxxx	
		S: xx		

¹ Day is calculated as date - date of first application for dates prior to first application. Otherwise, day is calculated as date - date of first application + 1 for dates on or after first application.

Note: System Organ Class and Preferred Term map to MedDRA (Version 21.0).

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Listing sorted by Subject, Start Date, End Date, Adverse Event.

Listing 16.2.7.2.4: Serious Adverse Events
Treatment Arm
(Page xx of yy)

S: Subject	A: Age/Sex	E: Eval	S: MedDRA System Organ Class P: MedDRA Preferred Term O: Occurred Prior to First Application	A: Adverse Event	A: In the Application Area G: Severity R: Relationship to Study Drug S: Serious Event	A: Action Taken with Study Drug T: Action Taken to Treat Event O: Outcome	S: Start Date (Day) ¹ E: End Date (Day) ¹
S: xxxxxx	A: xxx	E: xxxxxxxx	S: xxxx xxx xxxxxxxxxxxxxxx xxxxxx	P: xxx xxxxxxxxxxxxxx	A: xx	A: xxx xx xxxxxxxx	S: xxxxxxxxxxxxxxxx
			A: xxxxxxxx xxx xxxxxxxxxxx xxxxx	O: xx	G: xxx	T: xxx	E: xxxxxxxxxxxxxxxx
					R: xxx xxxxxxx	O: xxxxxxxxxxxxxxxxx	
					S: xxx		
			S: xxxxxxx xxxxxxxxxxx xxx xxxxxxxx	P: xxxxxxxxxxxxxx	A: xxx	A: xxx xxxxxxxxxxx	S: xxxxxxxxxxxxxxxx
			A: xxxxxxx xxxxx xxxxxxx xxx	O: xx	G: xxx	T: xxxxxxxxxxx xxxxxxxxxxx	E: xxxxxxxxxxxxxxxx
					R: xxx xxxxxxx	O: xxxxxxxxxxxxxxxxx	
					S: xxx		
S: xxxxxx	A: xxx	E: xxxxxxxx	S: xxxx xxxxxxxxxxx xxxxxx	P: xxxxxxxxxxxxxx	A: xx	A: xxx xx xxxxxxxx	S: xxxxxxxxxxxxxxxx
			A: xxxxxxx xxxxx	O: xx	G: xxxxxxx	T: xxx	E: xxxxxxxxxxxxxxxx
					R: xxxxxxx	O: xxxxxxxxxxxxxxxxx	
					S: xxx		

¹ Day is calculated as date - date of first application for dates prior to first application. Otherwise, day is calculated as date - date of first application + 1 for dates on or after first application.

Note: System Organ Class and Preferred Term map to MedDRA (Version 21.0).

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Listing sorted by Subject, Start Date, End Date, Adverse Event.

Listing 16.2.7.2.5: Subjects Who Prematurely Discontinued Study and/or Discontinued Study Drug Due to Adverse Events
Treatment Arm
(Page xx of yy)

S: Subject		S: MedDRA System Organ Class	A: In the Application Area	A: Action Taken with Study Drug	S: Start Date (Day) ¹
A: Age/Sex		P: MedDRA Preferred Term	G: Severity	T: Action Taken to Treat Event	E: End Date (Day) ¹
E: Eval		O: Occurred Prior to First Application	R: Relationship to Study Drug	O: Outcome	
		S: Serious Event			
S: xxxxxx	S: xxxxx xxx xxxxxxxxxxxxxxx xxxxxx	A: xx	A: xxx xx xxxxxxxx	S: xxxxxxxxxxxxxxxx	
A: xxxxx	P: xxx xxxxxxxxxxxxxxx	G: xxxxx	T: xxxxx	E: xxxxxxxxxxxxxxxx	
E: xxxxxxxx	A: xxxxxxxx xxxxx xxxxxxxxxxx xxxxx	R: xxx xxxxxxxx	O: xxxxxxxxxxxxxxxx		
	O: xx	S: xxx			
	S: xxxxxxxx xxxxxxxxxxx xxx xxxxxxxxxxx	A: xxx	A: xxx xxxxxxxxxxx	S: xxxxxxxxxxxxxxxx	
	P: xxxxxxxxxxx	G: xxxxx	T: xxxxxxxxxxx xxxxxxxxxxx	E: xxxxxxxxxxxxxxxx	
	A: xxxxxxxx xxxxx xxxxxxxxxxx xxxxx	R: xxx xxxxxxxx	O: xxxxxxxxxxxxxxxx		
	O: xx	S: xxx			
S: xxxxxx	S: xxxxx xxxxxxxxxxx xxxxxx	A: xx	A: xxx xx xxxxxxxx	S: xxxxxxxxxxxxxxxx	
A: xxxxx	P: xxxxxxxxxxx	G: xxxxxxxx	T: xxxxx	E: xxxxxxxxxxxxxxxx	
E: xxxxxxxx	A: xxxxxxxxxxx xxxxx	R: xxxxxxxx	O: xxxxxxxxxxxxxxxx		
	O: xx	S: xxx			

¹ Day is calculated as date - date of first application for dates prior to first application. Otherwise, day is calculated as date - date of first application + 1 for dates on or after first application.

Note: System Organ Class and Preferred Term map to MedDRA (Version 21.0).

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Listing sorted by Subject, Start Date, End Date, Adverse Event.

Listing 16.2.8.1: Urine Pregnancy Tests
Treatment Arm
(Page xx of yy)

Subject	Age/Sex	Eval	Visit	Date of Assessment	Results	Reason Test Not Done
xxxxxx	xxxx	xxxxxxxx	xxxxxxxx xxxxxxxx xxxx x xxxx x xxxx x	xxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx	xxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx	xxx xxx
xxx	xxxx	xxxxxxxx	xxxxxxxx xxxxxxxx xxxx x xxxx x xxxx x	xxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx	xxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx	
xxx	xxxx	xxxxxxxx	xxxxxxxx xxxxxxxx xxxx x xxxx x xxxx x			xxx xxxxxxxx xxx xxxxxxxx xxx xxxxxxxx xxx xxxxxxxx xxx xxxxxxxx

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Listing sorted by Subject and Visit Number.

Listing 16.2.8.2: Physical Examination
Treatment Arm
(Page xx of yy)

Subject	Age/Sex	Eval	Visit	Date of Assessment	Body System	Exam Finding	Reason Exam Not Done
xxxxxx	xxxx	xxxxxxxx	xxxxxx	xxxxxxxxxx	xxxxx xxxx xxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxx	xxxxxx xxxxxx xxxxxx xxxxxxxxxx xxxxxxxxx xxxx xxxxxx xxxxx xxxx xxx xxxxxxxxxx xx xxxxx xxxxxxx	
			xxxx xxxxx	xxxxxxxxxx	xxxxx xxxx xxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxxx	xxx xxxx xxx xxxx xxx xxxx	xxx xxxxxxxxx xxx xxxxxxxxx xxx xxxxxxxxx
xxxxxx	xxxx	xxxxxxxx	xxxxxx	xxxxxxxxxx	xxxxx xxxx xxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxx	xxxxxx xxxxxx xxxxxx xxxxxxxxxx xxxxxxxxx xxx xxxxxx xxxxx xxxx xxx xxxxxxxxxx xx xxxxx xxxxxxx	
			xxxx xxxxx	xxxxxxxxxx	xxxxx xxxx xxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxxx	xxx xxxx xxx xxxx xxx xxxx	xxx xxxxxxxxx xxx xxxxxxxxx xxx xxxxxxxxx

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Listing sorted by Subject, Visit Number, and Body System (in order presented on eCRF).

Listing 16.2.8.3: Vital Signs
Treatment Arm
(Page xx of yy)

Subject	Age/Sex	Eval	Visit	Date of Assessment	Vital Sign	Result	Units
xxxxxx	xxxx	xxxxxxxx	xxxxxxxx	xxxxxxxxxx	xxxxxxxxxx xxxxx xxxxxxxxx xxxxxx xxxxx xxxxxx xxxxxxxxxxxxxx xxxxx xxxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxxx	xx xx xxxxx xx xxx xxxx xxx	xxxx xxxxxxxxxx xx xxxxxxxxxxxxxx xxxx x xx
			xxxx xxxxx	xxxxxxxxxx	xxxxxxxxxx xxxxx xxxxxxxxx xxxxxx xxxxx xxxxxxxxxxxxxx xxxxx xxxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxxxxxxx	xx xxx xxxxx xxx xxx xx	xxxx xxxxxxxxxxxxxx xxxx x
xxxxxx	xxxx	xxxxxxxx	xxxxxxxx	xxxxxxxxxx	xxxxxxxxxx xxxxx xxxxxxxxx xxxxxx xxxxx xxxxxx xxxxxxxxxxxxxx xxxxx xxxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxxx	xx xx xxx xx xx xx xxx	xxxx xxxxxxxxxx xx xxxxxxxxxxxxxx xxxx x xx
			xxxx xxxxx	xxxxxxxxxx	xxxxxxxxxx xxxxx xxxxxxxxx xxxxxx xxxxx xxxxxxxxxxxxxx xxxxx xxxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxxxxxxx	xxx xxxxx xxx xxxxx xxx xxxxx xxx xxxxx xxx xxxxx	

SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)

Listing sorted by Subject, Visit Number, and Vital Sign (in alphabetical order).